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Amido-oligopyrroles/imidazoles and dimeric benzimidazoles are heterocyclic 
compounds which are nucleic acid minor groove binding agents. The targets for this 
project were symmetrical and unsymmetrical amide-linked di- and tri- and tetrameric 
benzimidazoles to evaluate as potential DNA binding agents. Syntheses involved 
linkage between C2 and C5 positions of 2-carboxy, 5-carboxy or 2,5-dicarboxy and 
2-amino, 5-amino or 2,5-diamino-bearing benzimidazoles. This matrix of substrates 
could be coupled directly C2-C5 by amide linkage, or these same precursors could 
also be dimerized symmetrically using small bifunctional linkers (diamine or diacid), 
affording symmetrical C2-C2 or C5-C5 dimer types of orientation, such as head-to-
head, and tail-to tail systems. 
 
Monomeric building block benzimidazoles were prepared by condensation of o-
phenylene diamines with either aldehydes or carboxylic acids affording the 
corresponding C2 or C5 amino and C5 carboxybenzimidazoles. 2-
Carboxybenzimidazoles were however prepared by condensation of o-phenylene 
diamines with trichloroacetimidate followed by hydrolysis. New different novel 
symmetrical and unsymmetrical-bis(benzimidazole) libraries (C2-C2, C5-C5 and C5-
C2 orientation) were prepared via coupling of different aminobenzimidazoles with 
different carboxybenzimidazoles from the matrix of available monomers. 
 
Novel tris(benzimidazoles) with differently linked orientations were prepared either 
by coupling one equivalent of 2,5-dicarboxybenzimidazole with two equivalents of 
aminobenzimidazole or coupling one equivalent of 2,5-diaminobenzimidazole with 
two equivalents of carboxybenzimidazole. A second set of novel 
tris(benzimidazoles) was prepared via reduction of a nitro- to amino bearing dimer 
followed by coupling with another carboxybenzimidazole monomer. 
 
Novel symmetrical tetra(benzimidazoles) (C2-C2-C2-C2 and C5-C2-C2-C5 
orientation) were synthesized via either coupling one equivalent 2-dicarboxy dimeric 
benzimidazole with two equivalents of 2 or 5-aminobenzimidazole or via coupling 
one equivalent of 2-diaminobis(benzimidazole) with two equivalents of 2 or 5-
carboxybenzimidazoles.  
 
Novel symmetrical bis(benzimidazoles) piperidine  derivatives  were synthesized via 
coupling one equivalent of 2-dicarboxy dimericbenzimidazole with two equivalents 
of piperidine derivatives. 
 
Forty oligomeric benzimidazoles were evaluated using Surface Plasmon Resonance 
(SPR) for binding to a series of three oligonucleotides containing A2T2, or A3T3 or 
A4T4 sequences.  
Data are presented showing the identification of four optimum ligands from a screen 
of 40, primarily 2L2552L2 tetramers but also several 2L5 dimers and dimeric 5,5-units 
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AcOH              Acetic acid 
Bi    Benzimidazole 
br   Broad 
bs                                Broad singlet 
CDCl3              Chloroform-d 
CDI   N,N-Carbonyldiimidazole 
COSY              Correlated spectroscopy 
d   Doublet 
dd   Boublet of doublets  
DCM    Dichloromethane 
DEPT              Distortionless enhancement by polarisation transfer 
DMF    N,N-Dimethylformamide 
DMSO Dimethylslfoxide 
DNA    Deoxyribonucleic acid 
dq   Doublet of quartets 
EDC    1-Ethyl-3-[3-(dimethylamino)propyl] carbodiimide 
HMQC Heteronuclear Multiple Quantum Coherence  
HOBt                 1-Hydroxybenzotriazole 
HRMS                High resolution mass spectrometry 
IR   Infrared 
LRMS Low resolution mass spectrometry 
m      multiplet 
mp                    Melting point 
ms      Mass spectroscopy 
NMR      Nuclear magnetic resonance 
PBS                             Phosphate buffered saline 
ppm   Parts per million 
q   Quartet 
qd Quartet of doublets  
RNA   Ribonucleic acid 
rt    Room temperature 
 19
s   Singlet 
SPR                             Surface plasmon resonance 
t   triplet 
TFO                             Triplex forming oligonucleotide 
THF              Tetrahydrofuran 
TLC   Thin layer chromatography 
tt              Triplet of triplets 








































1.1 Heterocycles, medicinal chemistry and synthetic  





/,5/;&/'(65/26&! &%)/1,>6%0<! :/,)/! %1-3+%! 60! &(! 3%&&%'! 617%'0&-17! &/%! 3,(+(5,)-+!
2'()%00%0!-17!0655%0&!1%:!&-'5%&0!-17!&%)/1,>6%0!4('!&/%!7,-51(0,0!-17!&'%-&.%1&!(4!
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$%&'()*+! ,-! .,'',/! 0*1*2,.3.)4.! (0&2'&.,(0,2*+! 4/.)56*! 104&7,)*+8! 4'46&7,)*+8!
(32464/*+8! 954/,)4/*+8! 954/&7,)4/*+8! 4'46&7,:;8<=>?(32464/*+8! 4/6,)*+8!!
>*/74'46&7,)*+8!&/6!2*)&1*6!+3+1*'+!&+!+0,@/!4/!!Table 1A"!!
!
1.2  Benzimidazoles: biological occurrence and medicinal         
chemistry 
!
B',/C+1! 0*1*2,.3.)4.! (0&2'&.,(0,2*+8! 10*! >*/74'46&7,)*! 24/C! +3+1*'! 4+! 9541*!
.,'',/A! D0*+*! +5>+125.152*+! &2*! ,-1*/! .&))*6! ǥ(24E4)*C*6F! 65*! 1,! 10*42! @46*!
2*.522*/.*!4/!>4,&.14E*!.,'(,5/6+A!B)10,5C0!10*2*!4+!C2*&1!4/1*2*+1!4/!>*/74'46&7,)*!
)4C&/6+!&/6!+125.152&)!.0*'4+1238!10*!'&4/!4/1*2*+1!!4+!4/!10*42!>4,),C4.&)!&.14E414*+A!!
D0*! *&2)3! GH<I+! @&+! &/! 4'(,21&/1! (*24,6! 2*C&264/C! 64+.,E*23! ,-! 10*! >4,),C4.&)!
+4C/4-4.&/.*! ,-! >*/74'46&7,)*=.,/1&4/4/C! +125.152*+! &/6! 10*! .),+*)3=2*)&1*6! (524/*+ 

















































vitamin B 12 !








).14&(! '?! $%,0<*0<! (%.! <)'461! '0! (%.! $').! 1()4$(4)./! ,1! 1%'>0! *0!Figure 27! @%.1.!
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Figure 2 Some benzimidazole containing drugs  
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1.3  Tautomerism and amphoteric character!!"#  of   
       N-H benzimidazoles   







Figure 3 Imidazole and benzimidazole structures 
 










Figure 4 Tautomerism in N-H benzimidazole. 
 
$1*!40*&8(:%/,8,/!/1%+%/'*+!(@!7*.-,),8%-(3*! G7H!%.8! ,'0!8*+,5%',5*0! ,0! +*@3*/'*8! ,.!
'1*!%7,3,'=!(@!0&/1!/()4(&.80!'(!@(+)!)*'%33,/!0%3'0<!0&/1!%0!0(8,&)!0%3'!G9H< 61,/1!
@(+)0! 61*.! 0(8,&)! %),8* ,0! %88*8! '(! %! 0(3&',(.! (@! 7*.-,),8%-(3*! ,.! %))(.,%!
GScheme 1H9!
 
Scheme 1 Acidic and basic behaviour of benzimidazole 
 
I3*/'+(.*2%',5*!2+(&40!(.!'1*!7*.-,),8%-(3*!+,.2!,./+*%0*!,'0!%/,8,/!.%'&+*<!%33(6,.2!






?.! +! /%.3-7! ,9! 74%! 1,&@36+7(,&! 0%7<%%&! 74%! ()(*+',-%! +&*! 0%&'%&%! /(&6A!
0%&'()(*+',-%!:2B0!,9!C=D "C ;!(.!+!<%+E%/!0+.%!74+&!()(*+',-%!2E0!,9!:#=FC!"C ;=!>4(.!
1,&@36+7(,&! (&1/%+.%.! 74%! &3)0%/! ,9! 1,&7/(037(&6! /%.,&+&1% .7/3173/%.A! 743.!
(&1/%+.(&6! 74%! 14%)(1+-! .7+0(-(78! ,9! 74%!),-%13-%=! ?7! 74%! .+)%! 7()%A! 08! /%),5(&6!
%-%17/,&.!9/,)!74%!&(7/,6%&A!(7!*%1/%+.%.!(7.!2/,7,&!+99(&(78=!
!
1.4 Synthesis of N-H benzimidazoles 
!
>4%! 9(/.7!0%&'()(*+',-%!<+.!2/%2+/%*! (&!GHI"!08!J,%0/%1E%/A"#  <4,!,07+(&%*!"ACK









1.4.1 Condensation reactions of o-phenylene diamines 
?-),.7! +--! .8&74%.%.! ,9! 0%&'()(*+',-%.! .7+/7! <(74! 0%&'%&%! *%/(5+7(5%.! 2,..%..(&6!
&(7/,6%&K1,&7+(&(&6!93&17(,&.!,/74,!7,!%+14!,74%/!:14;L!,9!74%!782%!(&!Figure 5=!
!
Figure 5 ortho di nitrogen compounds  
  
  

















14a28 X= NO2 R= CH2OH




Scheme 3 Condensation of o-phenylenediamine and carboxylic acid !
!
$%)! 1)3,(&+-! +0! (%)! 3221+21&3()! &*&/3()! )'()1! :(1&,%8+1+3,)(&*&/3();! :17;! 4&(%! o<
2%)-.8)-)/&3*&-)! :14;! +1! &('! '38(! 5&=)'! (%)! "<(1&,%8+1+*)(%.8! 6)-7&*&/37+8)! :18;!
:Scheme 4;! +-8.! 3(! 1++*! ()*2)13(>1)?! 3-/! (%&'! &'! 3-! &*2+1(3-(! 21),>1'+1! 0+1! "<
,316+@.8&,!6)-7&*&/37+8)'9AB!
!
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Scheme 5 Synthesis of benzimidazole via condensation of aldehydes and phenylenediamine in 
different oxidizing reagents, Na2S2O5, and PhNO2 
      
C! ->*6)1! +0! 6&':6)-7&*&/37+8)';! %3=)! '.-(%)'&7)/! 6.! >'&-5! /&00)1)-(! *)(%+/'9!
E+4-! et al AA! %3=)! 1)2+1()/! 3! '.-(%)'&'! +0! -+=)8! 6&'6)-7&*&/37+8)! :30;! 6.!
,+-/)-'3(&+-! +0! F<)'()1<o<31.8)-)/&3*&-)! :24;! 3-/! 6)-738/)%./)! :25;! /)1&=3(&=)'?!
! "#
$%&'()*! +,!-,),-%.(/!0%)1(-('&1,$%!0%&.()*!%2+%.! 3264 +5&+!6&2! +5%)! /,)7%.+%'! +,!





Scheme 6  Lown’s route for bisbenzimidazole synthesis AA 
!
B%$$8C!et al A>!5&7%!.%=,.+%'!+5%!28)+5%2(2!,@!0(20%)1(-('&1,$%!3364!08!/,)'%)2&+(,)!















































Scheme 7 Kelly’s route for bisbenzimidazole synthesis $% 
!
 
1.4.2 Base-induced condensation $&  
'()*! +,,-.+/(! (+*! 01)2)345! *06*1-+14! 7-.0,*! ,.**4**)87! +! -42+1)942:! +/)5)/! ,-.1.8!
+5;+/481!1.!1(4!8)1-.748!<37=!i.e>!?@AB"CD>!ABCD>!AE>!.-!F(G!H!9+-)41:!.I!C!7-.0,*!
(+94! 6448! -4,.-145>! J.*1! 1:,)/+22:! K>! .-! AB"C">! L()24! CD+85! C"! +-4! +2),(+1)/! .-!






Scheme 8 Base induced cyclization 
 







Pathway a: - 
!
     





Scheme 9 Two suggested mechanisms for based induced cyclization 
         towards the synthesis of  N-oxybenzimidazole 
 
1.5   Nucleic acids and benzimidazoles 
1.5.1 Background: general structure of nucleic acids  
 
$%&'()*+&,-./%*.! 0.*1! 2$345! 6&)78! &-)! 9%,%8:! 0,1! .&,;0*,8! 0//! ;<%! 9%,%;*.!
*,6&)70;*&,! 6&)! /*6%! ;&! 1%=%/&>! 0,1! %=&/=%! 6)&7! 8*7>/%! +0.;%)*0! ;&! .&7>/%'!7-/;*?




$%&'&! ('&! )*+'! ,-))&'&./! %&/&'*0102-0! 3(4&4! -.! 5678! 7,&.-.&! 940:;! <+(.-.&! 941:;!
01/*4-.&! 942:! (.,! $%1=-.&! 943:! 9Figure 6:>! ?67! 9?-3*.+02&-0! (0-,:! -4! (! 4-.@2&!
4/'(.,&,!/'(.40'-A/!)'*=!567>!B.!?67!$%1=-.&!-4!'&A2(0&,!31!C'(0-2> D.!/%&!*/%&'!
%(.,;! /%&! ,&*E1'-3*4&! 4+@('! *)! 567! -4! '&A2(0&,! 31! (! '-3*4&! 4+@('>! $%&! 3+-2,-.@!
32*0F!*)!4+@('!(.,!3(4&!-4!/&'=&,!(!.+02&*4-,&;!(.,!G%&.!(!HIJA%*4A%(/&!-4!(//(0%&,;!
-/!-4!(!.+02&*/-,&!9Figure 7:>!!!
$%&! ,*+32&! %&2-0(2! 4/'+0/+'&! *)! 567! G(4! )-'4/! ,-40*K&'&,! 31! L(=&4! M(/4*.! (.,!
N'(.0-4!O'-0F! -.!#PH">"Q M%&.! /%&! /G*!4/'(.,4!0*=&! /*@&/%&';! /%&1!*.21!3*.,! -.!(!
0&'/(-.! G(1!G-/%! 7,&.-.&! 3*.,-.@! /*! $%1=-.&! /%'*+@%! /G*! %1,'*@&.! 3*.,4;! (.,!
O1/*4-.&!/*!<+(.-.&!/%'*+@%!/%'&&!%1,'*@&.!3*.,4!9Figure 8:>!$%&!RJ567!)*'=!-4!
/%&! A%14-*2*@-0(2! )*'=! *)! /%&! 567! ,*+32&! %&2-E>! $%&! 4A&0-)-0! 0*.)*'=(/-*.(2!
0*.4/'(-./4!=(,&! -/!02&('! /%(/! /%&!4&S+&.0&!*)! /%&!3(4&4! -.! /%&!A*21=&'!&.0*,&4! /%&!
@&.&/-0! -.)*'=(/-*.! )*'! /%&! 41./%&4-4! *)! A'*/&-.4>!$%&! 0*.)*'=(/-*.! *)! T'&(2T! 567;!
%*G&K&';!,&K-(/&4!42-@%/21!)'*=!/%&!RJ)*'=!-.!(!4&S+&.0&J,&A&.,&./!=(..&'!(4!G&22!
(4!,&A&.,-.@!*.!/%&!-./&'(0/-*.!G-/%!567J3-.,-.@!A'*/&-.4>!!
$%&! /G*! 4/'(.,4! -.! 567! '+.! A('(22&2! /*! &(0%! */%&'! /%'*+@%! -./&'J4/'(.,! %1,'*@&.!
3*.,4;! HIJ&.,!*.!*.&! 4-,&! (.,! /%&!"I!*.! /%&!*/%&'>!5+'-.@! /'(.40'-A/-*.! 90*,-.@!*)!
567!/*!?67:!.+02&-0!(0-,4!0(.!*.21!3&!'&(,!31!/%&!?67!A*21=&'(4&!&.U1=&!-.!/%&!
,*G.4/'&(=!,-'&0/-*.!HI!/*!/%&!"I 9Figure 9:> !
O%&=-0(2! -.4/'+0/-*.4! )*'! A'*/&-.! 41./%&4-4! -.! *+'! 3*,1! ('&! &.0*,&,! 31! /%&! 2-.&('!
(''(.@&=&./!*)!/%&!3(4&4!-.!*+'!@&.&4>!V(.1!,-4&(4&4!('&!/%&!'&4+2/!*)!(3&''(./!@&.&!










Figure 7 General structures for nucleosides and nucleotides 
!
!
1.5.2 Major and minor grooves of DNA 
 
$%! &'(!)*+,-(!'(-./!*0!1234! &'(5(!65(!7.%*5!6%)!768*5!95**:(;!<.%).%9!6-*%9! &'(!
'(-./!;+506=(>!?'(!@'*;@'6&(!,6=A,*%(!.%!&'(!)*+,-(!'(-./!.;!=-*;(5!&*9(&'(5!*%!*%(!
;.)(!*0!&'(!'(-./!&'6%!&'(!*&'(5>!3;!;'*<%!.%!0.9+5(!B!6%)!CD4!&'(!;76--(5!96@!.;!=6--()!
&'(!7.%*5! 95**:(! 6%)! &'(!768*5! 95**:(! .;! &'(! ,.99(5! 96@4! <.&'! &'(!768*5! 95**:(!
,(.%9! 6@@5*/.76&(-E! FDG! ,.99(5! &'6%! &'(!7.%*5! 95**:(>! ?'(! 95**:(;! 65(! )(0.%()!
;&5+=&+56--E!,E! &'(!*5.(%&6&.*%!*0! &'(!,6;(!@6.5;4! ;+='!6;! &'(!2H!6&*7!*0! &'(!@+5.%(!
5.%9! 6%)! IF! 6&*7! *0! &'(! @E5.7.).%(! 5.%9! 06=.%9! *+&! .%&*! &'(! 768*5! 95**:(>! J*&'!
95**:(;! 65(! -.%()! <.&'! 'E)5*9(%! )*%*5! K655*<;! *+&L! 6%)! 'E)5*9(%! 6==(@&*5! ;.&(;!
K655*<;!.%L!KFigure!ML>"H!
 
Figure 8 major and minor groove among the nucleic acid bases 




!!!!!!!!!!!!!!!!!!!!!!!!!!!!(a)                                                                  (b) 
 
Figure 9  DNA Watson-Crick base-pairing and free H-bond sites  
  
!
1.5.3 DNA-drugs interactions 
 
#!$%&'()!*+!,)%-.!/012!34)0*%.!'0*5*-0645!(++(61.7!(8()1!12(0)!4610*$.!*$!(012()!9:#!
*)!;:#!via! 34)0*%.!&(624$0.&.<!=2(.(! 0$65%,(!&4$>! 4$10?$(*@54.106! A4$10?1%&*)B7!
4$10+%$-45! ,)%-.7! $%&()*%.! 4$10?@4)4.0106! 4-($1.7! 4$1030)45! 6*&@*%$,.7! 4$,! .*&(!
4$10'0*106.<!
9:#!0.!12(!'4.0.!+*)!50+(<!C1!0.!*$(!*+!12(!12)((!&40$!!654..(.!*+!'0*@*5>&()!!A@)*1(0$7!
@*5>.46624)0,(! 4$,! $%65(06! 460,B<! 9:#7! 4.! 12(! 64))0()! *+! -($(106! 0$+*)&410*$! 0.! 4!
&4D*)! 14)-(1! +*)! .*&(!,)%-.!/2062! 0$1()+()(!/012!9:#!)(@506410*$7!4!&4D*)! .1(@! 0$!
6(55! ,030.0*$! 4$,! -)*/127! /2062! 0.! 6($1)45! +*)! 1%&*%)0-($(.0.! 4$,! @412*-($(.0.! *+!
,0.(4.(.<! E*&(! *12()! ,)%-.! 45.*! 0$1()+()(! /012! 1)4$.6)0@10*$! A-($(! (8@)(..0*$! 4$,!
@)*1(0$!.>$12(.0.B<"F  G84&@5(.!*+!9:#-,)%-.!0$1()4610*$.!4)(!4.!+*55*/.H? 
!
1.5.3.1 Intercalation: 
C$1()645410*$! 0$1*!9:#!A0$.()10*$!'(1/(($!4!@40)!*+!'4.(!@40).B! 0.!4!3()>! 0&@*)14$1!





$%&'()*+*&,-%! ('./+&.! 0(-1! ,%.'(&,-%! -0! *! 2+*%*(! *(-1*&,)! ./3.&,&/'%&! 3'&4''%!567!
3*.'!2*,(.8!4,&9!)-%)-1,&*%&!/%4,%:,%;!*%:!+'%;&9'%,%;!-0!&9'!567!9'+,<=">!
 567! ,%&'()*+*&,-%! -0! 9'&'(-)?)+,)! *(-1*&,)! )-12-/%:.! 9*.! 3''%! *%! ,%&'('.&,%;!
./3@')&! :/'! &-! &9',(! 2-&'%&,*+! *.! )?&-.&*&,)! ('*;'%&.! *%:! *.! 2(-3'.! ,%! 1-+')/+*(!
3,-+-;?=#A $%&'()*+*&,-%! -0! 567! 4*.! -(,;,%*++?! '<2+*,%':! 3?! B'(1*%8#C! *.! &9'!




Figure 10 Drugs intercalation into DNA  
!!
I9'.'!,%&'()*+*&,%;!:(/;.!*('!)*2*3+'!-0!.+,22,%;!3'&4''%!&9'!+*?'(.!-0!%/)+',)!*),:!







Figure11 Some of intercalating drugs  
!





1.5.3.2 Alkylating drugs 












Scheme 10 Nitrogen mustard as an example of cross linking alkylating agent   
 
1.5.3.3 Chain cleavage drugs !
73-+,5%!+245!-;!.,5@*./0!*3+5%/.+*-3!*3.0&85(!+,5!.,/*3!.05/</'5!8%&'(?!A,5(5!8%&'(!
/%5! /B05! +-! .&+! +,5! (+%/38(!-;!$67!B2! %/8*./0! /B(+%/.+*-3!-;! ,28%-'53! /+-@(! ;%-@!
$67C! +,53! 4%5<53+*3'! +,5! 53D2@5! $67! 0*'/(5! ;%-@! %54/*%*3'! +,5! 8/@/'5?! A,5!
%5(&0+/3+! %/8*./0(! %5/.+!)*+,! -E2'53! +-! ;-%@! 45%-E2! (45.*5(C!),*.,! +,53! ;%/'@53+?!
F05-@2.*3:G5=HH>! IJ! *(! /! @5+/0:B*38*3'! 8%&'! ),*.,! /.+(! /(! %/8*./0! K! /B(+%/.+-%! ?!
L+%/38! .05/</'5! -..&%!)*+,! -%!)*+,-&+! /88*+*-3/0! -E2'53! (*3'05! (+%/38! .05/</'5! IM!
=Scheme 11>?!!
!





1.5.4  DNA groove binders 
$%&'!()*+,'!-./!012+)3!4'!&+2%&5!4+3*+36!2)!2%&!(07)5!65))8&9!)5!4'!4+3*+36!2)!2%&!
(+3)5!65))8&:!;+3*+36!2)!)3&!),! 2%&!65))8&<!=<=0>>'!0>2&5<! 2%&!1)3,)5(02+)3!),! 2%&!





Figure 13 Drugs that are groove binders 
 
1.5.4.1 Major groove binders-oligonucleotides 
G>+6)3=1>&)2+*&<!05&!0()36!2%&!1)(A)=3*<!*&<+63&*!,)5!052+,+1+0>!5&6=>02+)3!),!6&3&!
&?A5&<<+)3:! /! *&)?'5+4)3=1>&+1! 01+*! E-./F! )5! 5+4)3=1>&+1! 01+*! EH./F! <&@=&31&!
1)(A)<&*!),!<&8&50>!1)80>&32>'!>+3I&*!3=1>&)2+*&<:!G>+6)3=1>&)2+*&<!05&!1>0<<+,+&*!0<!
*&)?'5+4))>+6)3=1>&)2+*&<! )5! 5+4))>+6)3=1>&)2+*&<:! J506(&32<! 1)320+3+36! =A! 2)! KL!
3=1>&)2+*&<! 05&! 6&3&50>>'! 2&5(&*! )>+6)3=1>&)2+*&<B! 03*! >)36&5! ,506(&32<! 05&! 10>>&*!







Figure 14!An oligonucleotide fragment containing the four nitrogen bases 




$4!-$)0%+!2+%&*/%!:;<!05! 4$67&('!=$$'.,++(! ,53+!0$(-.! >/.!.2$1(! &(! ,2+!Figure 





Figure 15 Formation of Hoogsteen type bond for triple helix!
!
Figure 16 The formation of triple helix   
 
$%&%!%'()%**+,&!-.&!/%!.)0+1+-+.223!-,&0),22%4!/3!*3&05%0+-!,2+6,&7-2%,0+4%*!05.0!/+&4!
%+05%)! 0,! 05%! 6%&%! +0*%21! ,)! 0,! +0*! 8%**%&6%)! 9:;<! =+&4+&6! ,1! .&! .&0+6%&%!
,2+6,&7-2%,0+4%!0,!05%!8.>,)!6),,?%!,1!@:;!+&?,2?%*!05%!1,)8.0+,&!,1!.!0)+(2%!5%2+'<!







$%&'! ()! *+(! ,(-*.(/01! (/'! 2./&0! *(! *3'! *%-4'*! 0'56'/7'! 28! )(-$./4!9%*0(/:;-.7<!
2%0'!,%.-0!(0'' Figure 8)=!*3'!0'7(/&!(/'!2./&0!*(!*3.0!&(62>':3'>.7%>!-'4.(/!*(!)(-$!
%!*-.,>':3'>.7%>!7($,>'?!(Figure 15)@!A3'0'!7>%$,!(>.4(/67>'(*.&'0!%-'!%2>'!*(!%--'0*!
-',>.7%*.(/! ()! %! 0./4>':0*-%/&'&!BCD!(-! -'E'-0'! *-%/07-.,*.(/! ()! %! E.-%>!FCD@!A3'!
%/*.4'/'!%/&!7>%$,!0*-%*'4.'0!7%/!2'!%&%,*'&!*(!%!4'/'!*3'-%,8!,-(*(7(>@GH!
A-.,>'! 3'>.?! )(-$%*.(/! ./E(>E'0! *3'! -'7(4/.*.(/! ()! 9%*0(/:;-.7<! 2%0'! ,%.-0! 28!




*((>@GP!A3'8!2./&! *(! *3'!$%I(-!4-((E'!()!&6,>'?!BCD!%/&! ./3.2.*!4'/'!'?,-'00.(/@!
A3'.-! 60'! ./7>6&'0! *(! ,(0.*.(/! BCD! -'%7*.E'! %4'/*0! *(! 0,'7.).7! >(7%*.(/0! ./! *3'!
4'/($'@! ANJ0! %-'! 03(+/! *(! ./3.2.*! 4'/'! '?,-'00.(/! ,-(E.&./4! %! ,(00.2>'! -(>'! )(-!
*3'0'! 7($,(6/&0! ./! 7%/7'-! *3'-%,8@! A3'! )(-$%*.(/! ()! ./*'-$(>'76>%-! BCD! *-.,>'!
3'>.7'0! 7-'%*'&! *3'! ,(00.2.>.*8! ()! &'0.4/./4! 7($,(6/&0! +.*3! '?*'/0.E'! 0'56'/7'!
-'7(4/.*.(/!,-(,'-*.'0@!A3'8!$%8!2'!60')6>!%0!%/*.:4'/'!%4'/*0!(-!*((>0!./!$(>'76>%-!





  Antisense oligonucleotides !
















Figure 17  Antisense drug to DNA  
 
$%&'()%()!*+$!'(!/6,,)%&0B!-%!-@@,1A).! &5),-@B! 91,!/B&13)>-01A',6(! '%9)/&'1%(!19!
&5)! )B)8! 6%.),! &5)! &,-.)! %-3)! C'&,-A)%);! C'&,-A)%)! &-,>)&(! &=1! .'99),)%&! A',-0!
@,1&)'%(;!$%&'()%()!*+$!'(!-0(1!2)'%>!)7@01,).! 91,! &5),-@B!19!DEC8!(13)!/-%/),(8!
-%.!1&5),!.'()-()(;!F%)!.'99'/60&B!'%!-@@0B'%>!&5'(!&5),-@B!'(!(6//)((9600B!.)0'A),'%>!
&5)! -%&'()%()! *+$! 1,! ?+$! &1! -00! &-,>)&! &'((6)(! 491,! '%(&-%/)8! 3-G'%>! (6,)! &5)!
-%&'()%()!(&,-%.(!,)-/5!'%9)/&).!2011.!/)00(!91,!DEC:;HI8!HJ!
!
Modification of oligonucleotides !
*6,'%>! &5)! 0-(&! .)/-.)! &5),)! 5-(! 2))%! -%! 6@(6,>)! 19! '%&),)(&! '%! &5)! /5)3'(&,B! -%.!
2'101>B!19!%6/0)'/!-/'.!-%-01>6)(;!K5'(!5-(!3-'%0B!2))%!.6)! &1! &5)!,)-0'L-&'1%! &5-&!
31.'9').! 10'>6%6/0)1&'.)(8!='&5! '3@,1A).! @,1@),&')(8! /-%! 2)! 6().! '%! &5)! ()M6)%/)!
(@)/'9'/!/1%&,10!19!>)%)!)7@,)(('1%;!
N5)3'/-0! 31.'9'/-&'1%! 19! 10'>1%6/0)1&'.)! /-3)! &1! @,13'%)%/)! '%! &5)! )-,0B! #JJO(!
='&5!&5)!-.A)%&!19!&5)!-%&'()%()!-@@,1-/5!&1!/1%&,10!>)%)!)7@,)(('1%;IO!K5)!-%&'()%()!
9')0.!5-(! (699),).! &1! (13)!)7&)%&! 9,13!6%,)-0'(&'/-00B!5'>5!)7@)/&-&'1%(! 91,!/0'%'/-0!




$%&'&! %('! )%**'+! ,-.+/0/'+! .*/1.23)*'.4/+'&56! 7%28! &8249'&/&! &4(%4'1/'&! 0.(!
-.+/0/)%4/.2&! 9%:'! $''2! +':'*.;'+! 4.! %/+! +'*/:'(8<! *.)%*/=%4/.2! %2+! /-%1/21! .0!
-.+/0/'+!.*/1.23)*'.4/+'&6!>9'!-%/2!+':'*.;-'24!/&!/2!49'!)9'-/&4(8!%2+!$/.*.18!.0!
-.+/0/'+!.*/1.23)*'.4/+'&<!/2)*3+/21!(')'24!'?%-;*'&!.0!)9'-/)%*!-.+/0/)%4/.2&6!
>9'&'! -.+/0/)%4/.2&! )%2! $'! /2! 49'! $%)@$.2'<! &31%(! %2+A.(! 23)*'.$%&'! %&! B'**! %&!
+'(/:%4/&%4/.2! .(! ).2C31%4/.2! .0! 49'! -.+/0/'+! .*/1.23)*'.4/+'6! >9/&! )%2! /-;(.:'!
&':'(%*! *.21&4%2+/21! ;(.$*'-&! %&&.)/%4'+! B/49! 3&/21! 2%4/:'! 23)*'/)! %)/+<! &3)9! %&!
23)*'%&'! ('&/&4%2)'<! &;')/0/)/48<! %00/2/48<! $/.%:%/*%$/*/48<! $/.+/&4(/$34/.2<! )'**!
4%(1'4/21!/--32'!('&;.2&'!DE!FFigure 18G6!
!
Figure 18 Chemical modification of oligonucleotides including 
The backbone, sugar and/or nucleobase of the nucleotide 
!
H3)*'/)! %)/+&! 9%:'! $''2! '?4'2&/:'*8! -.+/0/'+! $8! (';*%)/21! 49'! ;9.&;9.+/'&4'(!
1(.3;<! B/49! %*4'(2%4/:'! %2/.2/)<! 2'34(%*! %2+! )%4/.2/)! &4(3)43('&6! I':'(%*! .0! 49'&'!
-.+/0/'+! .*/1.23)*'.4/+'&! '?9/$/4! /-;(.:'+! ;(.;'(4/'&! /2)*3+/21! '29%2)'+!
(').12/4/.2!%2+!$/2+/21!4.!JHK<!+3;*'?!LHK!%2+!;(.4'/2&6!>9/&!9%&!('&3*4'+!/2!49'!
+':'*.;-'24! .0! 2'B! %2+!-.('! ;.4'24! %24/&'2&'! %2+! %24/1'2'! %1'24&6! M3(49'(-.('<!
$%)@$.2'! -.+/0/'+! .*/1.23)*'.4/+'&! 9%:'! %*&.! $''2! 3&'+! /2! 49'! +':'*.;-'24! .0!
&':'(%*!%*4'(2%4/:'!&4(%4'1/'&6DN!
!!!
Modification of the backbone  
K-.21!49'!:'(8!0/(&4!-.+/0/)%4/.2&!-%+'!4.!.*/1.23)*'.4/+'&!B'('!%*4'(%4/.2&!.0!49'!
;9.&;9.+/'&4'(! $%)@! $.2'! 4.! &4%$/*/='! 49'! .*/1.23)*'.4/+'&! 4.B%(+&! '2=8-%4/)!
! "#





Figure 19 The natural Structure of phosphodiester and backbone modification  by either 
phosphonoacetate, phosphonoformate  and thiophosphonoacetate <= 
 
 
>! ,?65%'! +7! 1)?$*%1! .(@%! 7+/?1%$! +,! 6+$*7*/()*+,! +7! ).%! ,()*@%! 9.+19.+$*%1)%'!
0*,4(&%! *,! ).%! 5(/45+,%! +7! +0*&+,?/0%+)*$%12! A+'! %8(690%B! 9.+19.+,+(/%)()%B!
9.+19.+,+7+'6()%! (,$! ).*+9.+19.+,+(/%)()% ('%! 9.+19.+$*%1)%' 6+$*7*/()*+,1 
:Figure 19;2<= 
C,%!+7!).%!6+1)!%8)%,1*@%!/+,)'*5?)*+,1!*,!).*1!('%(!.(1!/+6%!7'+6!D%!E%16(%4%'!
(,$! /+F-+'4%'1! -.+! .(@%! 1G,).%1*H%$! ,%?)'(0! $*,?/0%+)*$%! (,(0+&?%1! -*).! 6(,G!
$*77%'%,)!0*,4%'!&'+?91!*,/0?$*,&!/+690%)%!'%90(/%6%,)!+7!9.+19.+$*%1)%'!0*,4(&%!+7!
+0*&+,?/0%+)*$%2!E(,G! 6+*%)*%1! ).()! ('%! ,+)! /.%6*/(00G! 1*6*0('! )+! 9.+19.+$*%1)%'B!
1?/.!(1! (6*$%!.(1!5%%,!?1%$! )+! '%90(/%! ).%!9.+19.+$*%1)%'! 0*,4(&%2!  I,! ($$*)*+,! )+!
(6*$%! +).%'! ,%?)'(0! 6+$*7*/()*+,1! ).()! ('%! -%00! (//+66+$()%$! -*).! ,?/0%*/! (/*$!
$?90%8%1!*,/0?$%!(/%)(0!&'+?92!C,0G!(!7%-!6+$*7*%$!+0*&+1!.(@%!5%%,!'%9+')%$!-*).!
9+1*)*@%0G! /.('&%$! 5(/45+,%1! '%90(/*,&! ).%! ,()*@%! 5(/45+,%! -.%'%! ).%!
9.+19.+$*%1)%'! &'+?9! *1! '%90(/%$! 5G! (! 9+1*)*@%0G! /.('&%$! &?(,*$*,*?6! &'+?9!!
:Figure 20;2<J  
! ""
!
Figure 20 Replacement of  phosphodiester linkage of oligonucleotides  
by either amide, guanidine or acetal linkers #$! 
 
 
Modification of the ribose unit!
%&'()(*+,(&-! &)! ,./! 0(1&2/! 3-(,! (-!456!+-'!756!80&)&3-'9:! (-)93/-*/! 1(&9&;(*+9!
80&8/0,(/2!&)!,./!-3*9/(*!+*('!<!
=&-)&0>+,(&-+9! 0/2,0(*,(&-! &)! ,./! 0(1&2/! 3-(,2?! +2! (-! @56! A@&*B/'!53*9/(*!6*('2C!
A56C!!!+-'!,0(*:*9&D456!A57C?!.+2!1//-!('/-,()(/'!+2!+!8&E/0)39!,&&9!,&!(-*0/+2/!456!
+-'!756!+))(-(,:!+2!E/99!+2!1(&9&;(*+9!2,+1(9(,:!+-'!+-,(2/-2/!80&8/0,(/2<!68+0,!)0&>!
,.+,! 23;+0! >&'()(/'! 456! +-+9&;3/2?! +2! .&>&! 456! A58C?! .+F/! 2.&E-! ,&! 1/!
&0,.&;&-+9! 1+2/D8+(0(-;! 2:2,/>2<! G.(2! 80&8/0,:! *+-! 1/! 32/'! ,&! 80&'3*/! 456! &0!
756D'(+;-&2,(*!,&&92!E(,.!.(;./0!2/9/*,(F(,:!AFigure 21C<#HD#I!!
!
Figure 21 Chemical structures of selected oligonucleotide analogues 
with sugar modification #HD#I 
 
Modification of the nucleobases!
%&'()(*+,(&-2! ,&! ,./! -3*9/&1+2/2! .+F/! 1//-! /J89&0/'! ,&! (-*0/+2/! ,./! 2,+1(9(,:! &)!




0$(!+%9*3-07! *.! 0$(! )%0-:(! )1/2(*'%&(&! $%:(! '(()! %20(3(,;! <*3! (=%+>2(?!@**2! et al!




Figure 22  Chemical structures of base modifications by extended dxA and dxT 
 
1.5.4.2 Minor groove binders 
C$(!+-)*3!D3**:(!*.!0$(!,*1'2(!$(2-=!-&!0$(!&-0(!*.!)*)F/*:%2()0!&(G1()/(!&(2(/0-:(!





JF'*),-)D! *.! 0$(! '()K-+-,%K*2(! .1)/0-*)%2-07! '(08(()! 0$(! )-03*D()&! *.!6?! %),! 0$(!
*=7D()&!*.!C;!C$(!,7(!J*(/$&0!LLM#N!A63B!-&!%)!(=%+>2(!*.!%!&7)0$(0-/!$(0(3*/7/2(!
8$-/$! '-),&! -)! 0$(! 456! +-)*3! D3**:(;! O0! -&! %! '-&A'()K-+-,%K*2(B! 8$-/$! -&!
/$%3%/0(3-K(,! '7! /%0-*)-/! /$%3D(?! )%33*8!+*2(/12%3! /3*&&! &(/0-*)?! %),! -0&! /*)/%:(!
&$%>(! EE! AFigure 23B;! C$(! '-),-)D! >3(.(3()/(! .*3! 0$(!6FC! '%&(! >%-3&! -&! ,1(! 0*! 0$(!
/2*&()(&&!*.!0$(!%3*+%0-/!J!%0*+&!*.!0$(!J*(/$&0!+*2(/12(!%),!0$(!.2**3!*.!0$(!+-)*3!




Figure 23  Representatives of minor groove binding drugs #$%!
      and interaction of Hoechst 33258 with DNA douplex #$&'!#$(!
 
)*+,*-(*! ./*(010(!2345&0-60-7! %8*! .9%::!9;:*(,:*.! <=%<! (%-!/*89*%<*! (*::.! (;,:6!
/;<*-<0%::>! 8*7,:%<*! <8%-.(80/<0;-! ;1! ./*(010(! 7*-*.?! @=*! :*%6.! 0-! Figure 23! %8*!
.*+,*-(*!.*:*(<0A*!&,<!-;<!./*(010(!1;8!/%8<0(,:%8!.*+,*-(*.!@=0.!=%.!./,88*6!*11;8<.!
0-! <=*! 6*A*:;/9*-<! ;1! -*B! 90-;8! 78;;A*! &0-60-7! %7*-<.! <=%<! (;,:6! (;-<8;:!




&**-!6*.07-*6! %.! .*:*(<0A*!234!90-;8! 78;;A*!&0-6*8.?!@=*! %-%:>.0.! (;-1089.! <=%<!
<=*!/8*60(<*6!;/<09%:!.0<*!1;8!<=*!(;8*!&0.G&*-F0906%F;:*H!9;<010-7!;1!I;*(=.<!JJKLM 
0.!<=*!1;,8!&%.*!.*+,*-(*!L544@@?!@=0.!.*+,*-(*!.*:*(<0A0<>!8*.,:<.!0-!0-=0&0<0;-!;1!
<8%-.(80/<0;-! %<!4N@! 80(=! .0<*.! %-6!9%>! &*! 8*./;-.0&:*! 1;8! (><;<;C0(! %-6! %-<0<,9;8!
*11*(<.!.=;B-!&>!<=0.!=*%65<;5=*%6!&0.G&*-F0906%F;:*H?J#'#M 
 
1.5.4.3 Amide-linked benzimidazoles  
4906*.! /:%>! %! O*>! 8;:*! 1;8! 9*60(0-%:! (=*90.<.'! %.! <=*! %906*! 1,-(<0;-%:0<>! 0.! %!
(;99;-! 1*%<,8*! 0-! 9%->! .9%::! ;8! (;9/:*C! .>-<=*<0(! %-6! -%<,8%:! 9;:*(,:*.?! @=0.!
! "#
$%&'(! &)!*+! !,*-.)(! /0(!,*.(! 1&23$4(! &2!5.*/(&2)6!$2'!2($.17!$11!32*82!(297%()!$.(!
5.*/(&2)6! $11! $2/&:*'&()! $.(! 5.*/(&2)6! 5.*/(&2)! 5.*;&'(! %(,0$2&,$1! )-55*./! (<4!
=,*11$4(2><! ?0(! ,$.:*@$%&'(! 4.*-5! $55($.)! &2! $! )&42&+&,$2/! 5(.,(2/$4(! *+! 32*82!




5*17$%&'()640! 80&,0! 0$;(! )((2! ,*2)&'(.$:1(! &2/(.()/! $)! )(I-(2,(! )(1(,/&;(! HJK!
%&2*.!4.**;(!:&2'&24!$4(2/)!&2!.(,(2/!7($.)!(Figure 24)<!!
!
Figure 24  Two of Dervan’s oligopyrrole molecules 
 
H(.;$2! et al! 0$;(! )-,,(('('! &2! )72/0()&9&24! $1/(.2$/&;(! 0(/(.*,7,1()! +*.! HJK!
.(,*42&/&*2! /0$/! &2,1-'(! $! :(29&%&'$9*1(L&%&'$9*1(! 5$&.<! ?0()(! ,*%5*-2')!
&2,*.5*.$/('!&2/*!HJKA!:&2'&24!5*17$%&'()!,*%5.&)('!*+!57..*1(L&%&'$9*1(!5$&.)!&2!
80&,0! /0(7! 2*/! *217! &2,.($)(! /0(! :&2'&24! )&/(! )&9(! :-/! )&42&+&,$2/17! &2,.($)(! /0(!
:&2'&24! $++&2&/7! *+! /0(! 1&4$2')! $)! 8(11<! ?0&)! :(29&%&'$9*1(A&%&'$9*1(! 5*17$%&'(!
.(5.()(2/)!$!2*;(1!,1$))!*+!HJK!:&2'&24!1&4$2')<!!
?0(! (@5(.&%(2/$1! .()-1/)! &2'&,$/('! /0$/! /0(! :(29&%&'$9*1(M0(/(.*,7,1(! :-&1'&24!
:1*,3)! ,$2! .(51$,(! 57..*1(A57..*1(6! 57..*1(A&%&'$9*1(6! $2'! 57..*1(A07'.*@757..*1(!
,*2)/.-,/)<40!






Figure 25 Hairpin structure binding two anti parallel dimers 
to base pairs in the minor groove. "$ 
!
!
1.6  Chemistry of dimeric and oligomeric benzimidazoles 
 
%&'! (')'*+,! -.)/&'-0-! 12! 31)13'*04! 5')60307+61,'-! 4+)! 5'! +4&0'8'7! 5.! '0/&'*!
41)7')-+/01)!12!+*.,')'70+30)'!+)7!+*.,!4+*519.,04!+407-!+)7!/&'0*!7'*08+/08'-!0)!/&'!
:*'-')4'!12!-/*1)(!+407!-;4&!+-!30)'*+,!+407-<!1*!41)7')-+/01)!12!o=+*.,')'70+30)'!
+)7!+,7'&.7'! 0)! /&'!:*'-')4'!12!1907+)/! -;4&!+-!3'/+50-;,20/'!1*!)0/*15')6')'! >-'' 
Section 1.4?@!%&'!,'+7!413:1;)7!21*!+,,!50->5')60307+61,'-?!0-!/&'!&'+7=/1=/+0,!703'*!
A1'4&-/! BBCD#<! E&04&! &+-! 5'')! ;-'7! +-! /&'! 5+-0-! 21*! /&'! :*':+*+/01)! 12! 3+).!
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L = aliphatic or aromatic linker
6669
!
Figure 26 Some selective benzimidazole containing bioactive features  
!
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1.7 Amide formation 
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Scheme 12 General equation for amide synthesis using activating agent!
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Figure 27 Different novel benzimidazoles with carboxy or amino functionality 
!
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1.9.2 Amide-linked tris(benzimidazoles) 
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Figure 29 Generic structures of amide- 
linked tris(benzimidazoles)!
!
1.9.3 Symmetrical amide-linked tetra(benzimidazoles)!
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Figure 30 Generic structures of amide-linked 
tetra(benzimidazoles)!
!
1.9.4  Symmetrical  bis(benzimidazole) piperidine derivatives 
$%&'()! *)&+,)+&(*! %&(! -..+*)&%)(/! -0! Figure 311! 2-2(&-/-0(! /(&-3%)-3(*! ,%0! %.*4! 5(!
,4+2.(/! )4! 5-*6,%&54785(09-:-/%94.(;! 167! )4! <4&:! *8::()&-,%.! %:-/(=.-0>(/!
5-*65(09-:-/%94.(*;!6Sections 3.3;1!
 
Figure 31 Generic structures of symmetrical   
amide-linked bis(benzimidazoles) with piperidine derivatives 
!



























2.1 Synthesis of amino and carboxy1-H benzimidazoles 
This section discusses  the synthesis of benzimidazole building blocks bearing a 5-NH2 
(via the nitro), 5-CO2H, or a group at C2 bearing an CO2H or NH2 as the precursors for 
dimerization and oligomerization (Figure 32). Preparation of these derivatives involved 
condensation of o-phenylenediamines with either aldehydes or carboxylic acids to afford 
the corresponding amino or carboxybenzimidazoles (except 2-carboxy benzimidazole, 
which was prepared by condensation of o-phenylenediamines with trichloroacetimidate 
followed by hydrolysis). 
 
Figure 32 Generic structures of 2- or 5- amino or carboxybenzimidazole 
 
2.1.1 Condensation of o-phenylenediamine with aldehyde 
Aldehydes can be condensed with o-phenylenediamines to afford a benzimidazole 
product. In this project, two different methods were used employing (i) a sodium 
metabisulfite 31 promoted reaction and (ii) heating in nitrobenzene. 32 
The synthesis of N-H benzimidazoles bearing a 5-amino group as precursors to 
dimerization and oligomerization. For that purpose a phenylenediamine (in this case 5-
nitro) was condensed with aldehyde or affording the corresponding nitrobenzimidazole, 
which was then reduced to the corresponding aminobenzimidazole. 
Specifically, aldehydes 90 can be condensed with o-phenylenediamines to afford the 
corresponding benzimidazole, and the method employed here used sodium metabisulfite 
promoted reaction. These reactions rely on pre-forming the bisulfite adduct of the aryl 




Scheme 13  5-Nitrobenzimidazole synthesis using sodium metabisulfite  
 
A proposed mechanism of the reaction is shown in Scheme 14. The bisulfite adduct 




Scheme 14 Reaction mechanism for the synthesis of 5-nitro benzimidazole 
using sodium metabisulfite.  
 
This type of reaction was used to prepare benzimidazoles 94 and 96, in which an 
ethanolic solution of  4-methoxybenzaldehyde (93) or 2,4-dimethoxybenzaldehyde (95) 
were added seperately to an aqueous solution of sodium metabisulphite; the adduct 
formed precipitated from the reaction was filtered and dried. The o-phenylenediamine 
(92) in DMF was then added to each adduct and the mixture was heated at 130oC for 
(16-48 h) affording 2-(4'-methoxyphenyl)-5-nitrobenzimidazole (94) and 2(2’,4’-di 
methoxyphenyl)-5-nitrobenzimidazole (96). 
The structures of 94 and 96 were confirmed by spectral data. The 1H NMR for 94 
showed the methoxy protons as a singlet at 3.92 ppm and the NH proton appeared as a 
broad peak in the range of 13.4-13.6 ppm. The MH+ peak appeared as expected at m/z 
270.  
In the 1H NMR for compound 96 the six protons of the two methoxy groups appeared as 
singlets at 3.99 and 4.18 ppm, respectively, (Figure 33), whilst MS showed the MH+ 








Figure 33 1H NMR (400 MHz) of 96 in CDCl3 .   
 
                          
With successful reactions demonstrated using aryl aldehydes, similar reactions were 
evaluated  with a pyridine system. 
Thus, an ethanolic solution of 2-formylpyridine (97) was added to an aqueous solution 
of sodium metabisulphite, the adduct formed was filtered and dried. The o-
phenylenediamine (92) in DMF was then added and the mixture was heated at 130 °C 
for 13 hours affording 5-nitropyridylbenzimidazole (98). 
 
2.1.2 Reduction of 5-nitrobenzimidazoles 
This step was crucial in the project, because preparing the amines is a key requirement 
for using amide coupling to link the benzimidazole with different compounds having 
carboxylic acids (e.g. at position 2). Reduction of  2-(p-methoxyphenyl-) or 2-(2,4-di-
methoxyphenyl-) or 5-nitropyridyl-) benzimidazoles was carried out using either (H2/ 
Pd) or SnCl2 /HCl. TLC showed complete disappearance of the starting materials and 
gave high yields of the amine products (Scheme 15). 
                                                 






























































Scheme 15 Reduction of 5-nitrobenzimidazoles to the corresponding amines 
 
Thus, reduction of 2-(4'-methoxyphenyl)-5-nitrobenzimidazole (94) by SnCl2/HCl and  
H2(Pd/C) afforded 100 with 67 % or 68 % yield respectively. The 1H NMR for 100 
showed a singlet peak at 3.91 ppm arising from the methoxy group. The MS showed 
MH+ peak at m/z 240, consistent with the structure shown. 
Another attempt to reduce compound 94 to the corresponding amine 100 using H2(Pd/C) 
was successful. The structure of amine 100 was confirmed by 1H NMR, which showed a 
singlet peak at 3.86 ppm, from the three protons of the methoxy group (Figure 34). The 
13C NMR showed a methoxy peak at 55.7 ppm, consistent with the structure. 
2-(2',4'-dimethoxyphenyl)-5-nitrobenzimidazole (96) was reduced using SnCl2 / HCl 
affording 5-amino-2-(2',4'-dimethoxyphenyl) benzimidazole (101) in 78 % yield. The 1H 
NMR for 101 showed singlet peaks for the two methoxy protons at 3.91 and 4.08 ppm. 
The NH2 proton appeared as a broad peak in the range of 3.43-3.47 ppm, and NH proton 
appeared as a broad peak at 10.18-10.70 ppm, whilst the 13C NMR showed the two 
methoxy peaks at 56.5 and 57.1 ppm. The MS was consistent with the appearance of the 









Figure 34 1H NMR (400 MHz) of 100 in CDCl3  
 
Reduction of 5-nitropyridylbenzimidazole (98) using SnCl2/HCl afforded the 
corresponding amine 102 (Scheme 15) whose structure was confirmed by all spectral 
data. The 1H NMR for 102, showed benzimidazole protons H6, H4 and H7 at 7.50, 7.84 
and 7.93 ppm respectively, while H5’, H4’, H3’ and H6’ in the pyridine ring appeared at 
7.74, 8.19, 8.44 and 8.89 ppm respectively (Figure 35). The MS showed MH+ ion at m/z 
211.  
                                                 











Figure 35 H NMR (400 MHz) of 102 in d6-DMSO  
 
 
2.1.3 Synthesis of 2-(p-carboxyphenyl)-1H-benzimidazole 31 
 
Scheme 16  Synthesis of 2-(4'-carboxyphenyl benzimidazole 
 
The 2-(4'-carboxyphenyl)-5-nitrobenzimidazoles 105 and 106 were prepared by the 
reaction between 4-carboxy benzaldehyde (104) and 4-nitro-1,2-phenylenediamine (92) 
or 3,4-diaminobenzoic acid (103), respectively. In the presence of sodium metabisulfite 
under conditions analogous to those used for preparation of the 2-aryl alkoxy derivatives 
(using DMF as a solvent and heating at 140 °C for 3 days) (Scheme 16). 
NMR and MS confirmed the formation of benzimidazoles 105 and 106 using this 
method. 
The 1H NMR for 105 showed a broad singlet of 13.22-13.23 ppm, related to NH or 
COOH groups, the 13C NMR showed a C=O at 166.9 ppm and the MH+ peak was 
                                                 
















observed at m/z 284. Whilst for 106, the IR showed C=O peaks at 1685, 1700 cm-1 for 
the two carboyxlates and an NH stretch at 3305cm-1, fully consistent with the structure 
shown. The 1H NMR showed a broad peak in the range of 13.07-13.62 ppm related to 
the two COOHs (Figure 36). The structure was further confirmed by 13C NMR which 









Figure 36 1H NMR (400 MHz) of 106 in d6-DMSO  
 
 
2.1.4 Phenylenediamine condensation with aldehydes in nitrobenzene 32 
 
This method is used to synthesize benzimidazoles via condensation of aromatic 
aldehydes and phenylenediamines by high temperature reaction in nitrobenzene. In this 
case, the nitrobenzene acts as a solvent and oxidant at the same time. On the other hand 
some aromatic aldehydes (e.g. p-nitrobenzaldehyde) failed to condense with phenylene 
diamine in sodium metabisulphite reaction. However, 5-nitro-2-(4-nitrophenyl) 
benzimidazole (107) was successfully prepared using the nitrobenzene method.  
                                                 




Scheme 17 Synthesis of 2,5-diaminobenzimidazole by using PhNO2 
 
1H NMR, 13C-NMR and MS confirmed the structure of the above products. 
The 1H NMR for 107 showed a singlet peak at 13.93 ppm related to NH. The MS 
showed MH+ peak at m/z 285, consistent with the structure shown. 
Reduction of 107 using Pd/C in MeOH and DMF afforded the corresponding diamino 
benzimidazole 108 in 78 % yield (Scheme 17) whose structure was confirmed by all 
spectral data. The 1H NMR for 108, showed a broad peak in the range of 6.06-6.38 ppm 









Figure 37 1H NMR (400 MHz) of 108 in d6-DMSO   
                                                 
  This assignment has been confirmed by using 2D NMR (COSY) 
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2.2 Condensation of o-phenylenediamine with carboxylic acids 
2.2.1 Condensation with aliphatic carboxylic acid (Phillip’s method) 27 
Aliphatic carboxylic acids can condense with o-phenylenediamines affording 
benzimidazoles. This method involves condensation of phenylenediamine with 
carboxylic acid in refluxing HCl, affording the benzimidazole. 
 A series of 2-aminobenzimidazoles 110 and 112 (Scheme 18) and 5-carboxy 
benzimidazoles 115 and 116 (Scheme 19) were prepared using this type of chemistry.  
All spectroscopic data (NMR and MS) were consistent with the formation of target 
benzimidazoles. 
  
Scheme 18 Condensation of phenylene diamine with carboxylic acid  
according to Phillip’s method 
 
2-Aminomethyl benzimidazole 110 was formed by condensation of o-phenylene 
diamine 14 with glycine 109 in refluxing HCl (6N) for 24 hours.  
1H NMR for 110 showed the two methylene protons as a singlet peak at 4.56 ppm, the 
two doublet of doublets for aromatic protons at 7.36 and 7.67 ppm respectively, and a 
broad peak in the range of 4.74-6.78 ppm related to NH2 protons. The imidazole NH 
proton appears clearly as a broad singlet peak at 9.15-9.18 ppm (Figure 38). 13C NMR 
showed the methylene carbon at 35 ppm (Figure 39) and the MS showed the expected 








Figure 38 1H NMR (400 MHz) of 110 in d6-DMSO ,  the inset 




Figure 39 13C NMR (300 MHz) of 110 in d6-DMSO 
                                                 
  This assignment has been confirmed by using 2D NMR (COSY) 
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4-(1-H-Benzimidazol-2-yl)-cyclohexyl) methanamine (112) has been synthesized from 
condensation of 1,2-phenylenediamine 14 with trans-4-aminomethyl cyclohexane 
carboxylic acid 111 in refluxing HCl (4N) for 6 hours. 
The 1H NMR for 112, showed a broad singlet peak for the NH2 in the range of  3.36-
3.64 ppm, two doublet of doublets at 6.87 and 7.23 ppm for the four aromatic protons, 
whilst the two methylene protons appear clearly as a doublet at 2.29 ppm. The 13C NMR 
showed the signal for the methylene carbon at 44.4 ppm, and cyclohexyl carbons in the 
range of 29-35.9 ppm. The expected MH+ peak was observed at m/z 230.  
 
2.2.2 Synthesis of 5-carboxybenzimidazoles 
5-Carboxybenzimidazoles 115 and 116 were prepared using this type of chemistry 
(Scheme 19). All spectroscopic data (MS and NMR) were consistent with the formation 
of benzimidazoles 115 and 116. 
 
Scheme 19 Some 5-carboxybenzimidazole 
synthesized via Phillip’s method 27 
 
Condensation of 3,4-diaminobenzoic acid 104 with trifluoro acetic acid 113 in refluxing 
HCl (4N) for 4 hours, gave 5-carboxy-2-trifluoromethyl benzimidazole (115) (Scheme 
19). 
The 13C NMR for 115 showed the C=O peak at 168.2 ppm, and CF3 carbon at 143ppm, 
which appears as quarter with coupling constant JCF = 40.0 Hz.  (Figure 40)  and MS 
showed the expected MH+ peak at m/z 231, and the 1H NMR showed a broad peak for 
the COOH group in the range of 14.25-14.62 ppm, while the imidazole NH appears as a 
broad peak in the range of 12.86-13.27 ppm (Figure 41) and all other spectral data was 












Figure 41 1H NMR (400 MHz) of 115 in d6-DMSO ,  the inset 
 shows  LR mass spectrum 
 
                                                 
















5-carboxybenzimidazole (116) was synthesized from condensation of 3,4-diamino 
benzoic acid 104 with formic acid 114 in refluxing HCl (4N) for 4 hours. The 1H NMR 
for 116, showed a broad singlet at 12.53-13.22 ppm for the COOH group, while the 
imidazole NH appears as a broad singlet peak in the range of 7.21-7.49 ppm. The 13C 
NMR showed a C=O at 166.7 ppm and the MH+ peak was observed at m/z 163.  
 
2.3 Synthesis of 2-carboxy benzimidazoles (123,124,125)  by 
using  trichloroacetonitrile 
 
To introduce a 2-carboxyl group, the use of a precursor 2-trichloroacetimidate was 
employed. This route uses the condensation of o-phenylenediamine and trichloro 
acetimidate  17 75  prepared from the reaction of trichloroacetonitrile 117 and methanol 
in the presence of potassium carbonate affording 2-trichloromethyl benzimidazoles 18, 
118 and 119 (Scheme 20). 
 
Scheme 20 Synthesis of 2-trichloromethyl benzimidazole 
 
The 2-trichloro methyl benzimidazoles 18, 118 and 119 were stirred with NaOH (1M) in 
an ice bath giving the carboxylate salts 76 120, 121 and 122. Once TLC indicated no 
starting material remained (after 2-6 hours) the reaction was neutralized with HCl (2M), 
yielding 123-125 in 77-83 % yields  (Scheme 21). 
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Scheme 21 Synthesis of 2-carboxybenzimidazole via alkaline hydrolysis of  2-trichloromethyl 
benzimidazole  
 










































Scheme 22 Reaction mechanism for the synthesis of 2-carboxy benzimidazole via alkaline  
hydrolysis of 2-trichloromethyl benzimidazole 
 
The structure of the products 123, 124 and 125 were confirmed by 1H NMR, 13C NMR.                         
The 1H NMR for 123 showed two doublet of doublets at 7.16 and 7.45 ppm respectively, 
related to the four aromatic protons. The MS showed the expected MH+ peak at m/z 163 
and the 13C NMR showed a C=O resonance at 159.3 ppm.  
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The MS for 124 showed the MH+ peak at m/z 206, and the 1H NMR showed a broad 
peak for the NH in the range of 3.98-4.83 ppm (Figure 42).  The 13C NMR showed the 
peak C=O at 160.4 ppm. 
Whilst the 13C NMR for 125 showed C=O at 160.4 ppm. The 1H NMR showed a singlet 
peak at 8.30 ppm, related to the imidazole NH or COOH groups. The expected MH+ 
peak was observed at m/z 196. The structure was further confirmed by IR which showed 
C=O at 1638 cm-1 and NH stretch at 3378 cm-1. 







Figure 42 1H NMR (400 MHz) of 124 in d6-DMSO  
 
 
                                                 




The synthesis of monomeric benzimidazoles is a clearly pre-requisite towards 
dimerization and oligomerization. 
Different directions of linkages were suggested (/(0,&-.$ 1"2"1) to target either 




This sort of dimeric system can be obtained via coupling of aminobenzimidazoles and 2-
carboxy or 5-carboxy monomeric benzimidazoles. Examples include the syntheses using 
2-carboxy benzimidazoles and 5-carboxy-2-trifluoro methyl benzimidazole$ and 2-(4'-
carboxyphenyl)-5-nitrobenzimidazole that afford two different orientations of head-to-





Conversion of   carboxylic acid to an amide requires the transformation of the acid into a 
more reactive intermediate. For that purpose, the coupling reagent used was ethyl-3-
dimethylaminopropyl carbodiimide (A%B). The acid and the coupling reagent 
EDC/HOBt were dissolved in DMF on ice bath for 30 minutes followed by adding 
amino benzimidazole. The reaction was left stirring, and once the TLC showed 
completion of the reaction, the key step for purification was the addition of water to the 
reaction mixture. The product precipitated, while the urea side product is water-soluble. 
Finally, compounds were purified either by column chromatography or recrystallization. 






The use of HOBt minimizes the formation of unreactive N-acylurea B'C, which is 
formed from O-acylisourea B'D. This compound B'D reacts with HOBt which is a fast 
step and gives a carbonylbenzotriazole intermediate B'E, which reacts with amine to 
give the amide B'F&(!"#$%$&'(). 
&
'GHG(&I,81*13&-0&"*18-938$.:,%,2*:-6$s  
Synthesis of 2- and 5-carboxybenzimidazoles is the precursor step for introducing amide 
linkage for dimeric or oligomeric systems. Coupling of B'( to BJJ or&BJ' was achieved 












































The 1H NMR for <=> showed a signal for the methoxy group as a singlet at 3.92 ppm,, 
while the characteristic signal for the amide proton appeared at 11.0 ppm, and the 
imidazole NH proton appears clearly as a broad singlet peak in the range of  13.45-13.63 
ppm (?/@A.%!(=). The 13C NMR showed the characteristic signal for carbonyl at 161.6 
ppm, and the methoxy group at 55.8 ppm, whilst the MS showed MH+ ion at m/z 384. 
The IR showed a stretching at 3387 cm-1, for the NH bond. Thus, all data were 














Figure 43 1H NMR (400 MHz) of 130 in d6-DMSO #,  the inset
 shows  LR mass spectrum 
The dimer 131 is the expected product of the coupling between 1-H-
benzimidazole-2-carboxylic acid 123 and 5-amino pyridylbenzimidazole 102 using 
EDC/HOBt (Scheme 24). After 12 days TLC showed no starting material remaining 
and the desired amide 131 was isolated in 69% yield.   
The 1H NMR for 131 showed an amide proton at 10.94 ppm, and the iminol OH 
proton as a singlet peak at  10.99 ppm. The two imidazole NHs, appear as singlets at 
13.15 and 13.49 ppm, respectively, and the iminol NH appears as a singlet at 13.46 
ppm. The 13C NMR showed the characteristic signal for the carbonyl at 157.6 ppm. 
The expected MH+ peak at m/z 355, was also observed, moreover, the IR showed the 
NH stretch at 3355 cm-1.
2.4.3.1 Synthesis of (2-amino-benzimidazol-1-yl)-(1H-benzimidazol-2-        
            yl)methanone (133)
In couplings between 2-amino benzimidazole and 2-carboxylate benzimidazoles the  
amidine-like reactivity affects the site of amide formation. Consequently, coupling 1-H-
benzimidazole-2-carboxylic acid 123 and 2-amino-1H-benzimidazole 132 with EDC/ 
#  This assignment has been confirmed by using 2D NMR (COSY)
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HOBt leads to (2-amino-benzoimidazol-1-yl)-(1H-benzoimidazol-2-yl) methanone (!"") 





The 1H NMR for !"" showed four doublet of doublets at 7.08, 7.24, 7.43 and 7.63 ppm, 
respectively, which arise from the eight aromatic protons. A broad singlet at 3.65-4.68 
ppm is observed for the NH2 (;,75-&(<<). 13C NMR showed C=O at 163.1 ppm, the IR 
showed a stretching at 3350 cm-1 for the amine NH bond and MS showed MH+ peak at 









                                                 






Whilst EDC/HOBt was used for 2-carboxy benzimidazoles (>)/-'0,$!"#"!), the coupling 
reagent N,N-carbonyl diimidazole (;<=)$ was used for 5-carboxy-2-trifluoromethyl 
benzimidazoles. The acid was dissolved in DMF then the solution was treated with CDI 
at room temperature and after 1 h the amino benzimidazole was added. 
The coupling reagent CDI is a useful coupling reagent that allows one-pot amide 
formation.  Acyl carboxyl imidazole and imidazole are initially formed but readily react 
together to yield the activated species as the acylimidazole. Practically, the acyl 
imidazole is normally preformed then the amine is added. 
$
!"#"#"?$;0123',4$05$@A/67809+8),:'&'(6:03)*$-0$4),)76-)$@B@A('&)7*"$
A small range of unsymmetrical head-to-tail and tail to tail amide bis (benzimidazoles) 
were prepared by coupling 5-carboxy-2-trifluoromethyl benzimidazole with 2- and 5-


























































Synthesis of dimer ?G# was initially attempted by coupling 2-(trifluoromethyl)-1H-
benzimidazole-5-carboxylic acid (??@) and 5-amino-2-(4'-methoxyphenyl) 
benzimidazole (?HH) with EDC/HOBt. However, no product could be isolated. Coupling 
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with CDI instead, the reaction went to completion after 10 days affording the desired 
amide in 55% isolated yield (!"#$%$&'().  
The IR for )*+, showed an NH stretch at 3458 cm-1, and the 1H NMR showed the 
methoxy proton as a singlet at 3.98 ppm, and the amide proton as a singlet peak at 10.65 
ppm (,-./0$& +1).  The 13C NMR showed the C=O peak at 163.6 ppm, the methoxy 
group at 54.9 ppm and CF3 carbon at 138.2 ppm which appears as a quartet with 

















An attempt to prepare dimer )*1 involved coupling 2-(trifluoromethyl)-1H-
benzimidazole-5-carboxylic acid ())1)& and 5-amino-2-(2',4'-dimethoxyphenyl) 
benzimidazole ()7)) with EDC/ HOBt, but this was unsuccessful. Using CDI, however, 
)*1 was isolated in 65% yield after 6 days (!"#$%$&'(). 
The MS for )*1 showed the MH+ peak at m/z 482. The IR showed NH stretch at 3416 
cm-1, and the 1H NMR showed the six protons of the two methoxy groups as singlets at 
                                                 
  This assignment has been confirmed by using 2D NMR (COSY) 
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3.94 and 4.11 ppm. A singlet peak at 10.75 ppm, was seen for NH amide, while the 
imidazole NH proton appears as a broad peak in the range of 13.99-14.46 ppm. The 13C 
NMR showed two methoxy groups at 55.9 and 56.4 ppm, C=O peak at 166.1 ppm and 
CF3 carbon at 142.4 ppm appears as a quartet with coupling constant JCF = 39.4 Hz. 
Dimer!"#$ was also prepared in 54% isolated yield by coupling 2-(trifluoromethyl)-1H-
benzimidazole-5-carboxylic acid (""%)! and 2-pyridin-2-yl-1H-benzimidazol-5-ylamine 
("&') using CDI over 8 days ( no product could be isolated using EDC/HOBt ) (()*+,+!
'$).  
The 13C NMR for "#$, showed the C=O, peak at 166.1 ppm, while CF3 carbon at 142.1 
ppm appears as a quartet with coupling constant JCF = 39.5 Hz. The 1H NMR showed the 
amide NH proton as a singlet peak at 10.72 ppm. The structure was confirmed by IR 
which showed NH stretch at 3420 cm-1, while the MS showed MH+ peak at m/z 423, 








Synthesis of dimer "#? involved coupling 2-(trifluoromethyl)-1H-benzimidazole-5-
carboxylic acid! (""%)! and 2-aminomethyl benzimidazole (""&) using EDC/HOBt. 
However, no product could be isolated from these conditions. Switching to use of 
CDI/DMF for 6 days, led to the desired amide in 65% yield (()*+,+!'?).!
The IR for "#? showed NH stretch at 3470 cm-1, and the 1H NMR showed the two 
methylene protons as a broad singlet at 4.76 ppm, and a singlet peak at 9.36 ppm was 
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seen for NH amide, while the imidazole NH proton appears as a broad peak in the range 
of 11.79-13.0 ppm (!"#$%&' ()). The 13C NMR showed the methylene carbon at 38.3 
ppm, and the C=O was observed at 166.9 ppm whilst the CF3 carbon resonates at 142.2 
ppm as a quartet with coupling constant JCF = 39.1 Hz. The MS showed the MH+ ion at 












A second type of extended C2-linked dimer *5G was also prepared by coupling 2-
(trifluoromethyl)-1H-benzimidazole-5-carboxylic acid' (**H) and 4-(1-H-benzimidazol-
2-cyclohexyl)methanamine (**I) using EDC/HOBt (:F>&C&' I6). After 2 days TLC 
showed no starting material remaining and the desired amide *5G was isolated in 68% 
yield. Spectroscopic data (NMR and M.S) confirmed the formation of this dimer.'
The 1H NMR for *5G showed the amide proton as a singlet proton at 8.65 ppm, while the 
two imidazole NH protons appeared as a broad peak in the range of 11.85-12.55 and 
13.90-14.60 ppm respectively, whilst two methylene protons appear clearly as triplet at 
3.23 ppm. The 13C NMR showed methyelene carbon at 45.9 ppm, and cyclohexyl 
                                                 
  This assignment has been confirmed by using 2D NMR (COSY) 
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carbons in the range of 30.5-38.2 ppm, while CF3 carbon at 142.3 ppm appears as a 
quartet with coupling constant JCF = 39.2 Hz. The IR showed NH stretch at 3401 cm-1. 
The MH+ ion appeared in the MS as a base peak at m/z 442. 
 
!"#"$%&'()*+%,*-(%2./#0.12*3-456%78)95:%;5+<)(+%
Several of unsymmetrical head-to-head and head to tail amide bis(benzimidazoles) were 
prepared by coupling of 2-(4'-carboxyphenyl)-5-nitrobenzimidazole (=>$) with 2- and 5-
aminobenzimidazoles. This sort of coupling  was achieved by dissolving the acid and 
EDC/HOBt in DMF at 0 ºC for 30 minutes followed by adding the amine, and  stirring 




Dimer =?@ is the expected product of the coupling between 2-(4'-carboxyphenyl)-5-
nitrobenzimidazole (=>$) and 2-amino-1H-benzimidazole (=?!) using EDC/HOBt. After 
8 days TLC showed no starting material remaining and the desired amide =!F was 
isolated in 65% yield (;A8)()%!B). The 1H NMR for =?@ showed the imidazole NH as a 
broad peak in the range of 12.28-12.51 ppm. A broad peak in the range 8.30-8.47 ppm 
was observed for the NH2. The 13C NMR showed a C=O peak at 169.4 ppm. The 
structure was confirmed by IR which showed NH stretch at 3366 cm-1, while mass 
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spectroscopy showed MH+ peak at m/z 399, which is consistent with the structure 
shown. 
Dimer !"# was also prepared in 68% isolated yield by coupling 2-(4'-carboxyphenyl)-5-
nitrobenzimidazole (!#$) and 2-pyridin-2-yl-1H-benzimidazol-5-ylamine (!#%) using 
EDC/HOBt. After 8 days no starting material remaining (&'()*)+ %,). Spectroscopic 
data (NMR and MS) confirmed the formation of this dimer.+
The IR for !"# showed an NH stretch at 3400 cm-1, and the 1H NMR showed  NH amide 
as a singlet peak at 10.29 ppm and the imidazole NH as a broad singlet peak in the range 
of 8.49-8.51 ppm.  Whilst the MH+ ion appeared in MS as the base peak at m/z 476. 
The extended dimer !"! was also prepared by coupling 2-(4'-carboxyphenyl)-5-
nitrobenzimidazole (!#$)+ and+ 4-(1-H-benzimidazol-2-yl)cyclohexyl)methanamine  
(!!%), however !"! was isolated after 6 days reaction in 70% yield (&'()*)+%,).  
This was confirmed by 1H NMR of !"! which showed a triplet peak at 8.62 ppm for the 
NH amide, while the imidazole NH appears as a broad peak in the range of 11.96-12.39 
ppm, and the two methylene protons appear as triplets at 3.23 ppm. The 13C NMR 
showed methylene carbon at 45.8 ppm, and cyclohexyl carbons in the range of 30.5-38.3 





Synthesis of dimeric systems can be achieved by two different methods. Firstly, 
coupling one equivalent of a diamine with two equivalents of 2- or 5-carboxy 
benzimidazoles or secondly, coupling one equivalent of a dicarboxylic acid with two 
equivalents of 2-aminobenzimidazoles. These methods afford two different types of 









For the synthesis of such bis(benzimidazoles), p-xylenediamine (D,1&7&' <E) and 
ethylenediamine (D,1&7&' FG)' were selected as the bis(amines). These were coupled 
with three 2- and 5-carboxybenzimidazoles ?<FH' ?<( and ??> affording novel 
symmetrical bis(benzimidazoles) ?(I4?(J. 
'
<=>=?=?'@0$A5"+#'0/'p4C65&+&3"27"+&'B".1'<4'0%'>4,2%80C68&+:"7"32:05&='''''''''''
In these syntheses, coupling of 2-carboxybenzimidazole ?<F' or 2-carboxy-5-nitro 
benzimidazole ?<( with p-xylenediamine ?(> was achieved using 1:1 EDC/HOBt at 0 
°C. The reactions went to completion after 8-14 days affording the desired amides ?(I'
and ?() in 60 and 58% yield, respectively. However, the reagent system did not work 
using 5-carboxy-2-trifluromethylbenzimidazole (??>)'and no product could be isolated 
from these conditions. Employing CDI facilitated this coupling affording dimer ?(J in 





Spectroscopic data supported the structures of these dimers in all cases. The 1H NMR of 
compounds :;<=!:;> and!:;? showed benzylic methylene groups at 4.48 and 4.49 ppm 
while the characteristic signals of amide protons were seen at 9.53, 9.77 and 9.16 ppm 
respectively (see @,AB+%!;? for 1H NMR of!:;<). The mass spectra showed the MH+  ion 
for all dimers as the base peak at m/z 425, 515 and 561 respectively. The 13C NMR 
showed the characteristic signals for the amide carbonyl at 159.2 and 166.5 ppm 









                                                 



































In these syntheses coupling of 2-carboxy-5-chlorobenzimidazole (*HJ) or 5-
carboxybenzimidazole (**7) with ethylenediamine *() was achieved using 1:1 
EDC/HOBt at 0 °C. The reactions went to completion after 5-6 days affording the 

























































Similarly, the 1H NMR of the compounds *J1 and!*J* showed methylene groups at 3.55 
and 3.50 ppm respectively, while the characteristic signals of amide protons were seen at 
9.22 , 8.61 and 8.65 ppm respectively. The dimer *J1 showed the base peaks m/z at 417 
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and dimer !"! showed MH+ peak at m/z 349. The 13C NMR showed the characteristic 
signals for the amide carbonyl at 159.0 and 167.7 ppm respectively for !"#$!"! . 
 
%&"&%'()*+,-./')0'12.3-4-563),2'64-.2'7-89'5-:6;1)<=,-:'6:-5'
For the synthesis of such symmetrical bis(benzimidazoles), terephthalic acid was 
coupled with two different aminobenzimidazoles !>% and' !!% affording the novel 






Dimer !"% was formed in 60% yield using 2-aminobenzimidazole (!>%) and terephthalic 
acid coupled by using EDC/HOBt in DMF for 14 days. This product was confirmed by 
MS which showed m/z as the base peak at 397. The 1H NMR showed the two NH2 
protons as a broad peak in the range of 3.25-3.69 ppm and the eight aromatic protons as 
two doublet of doublets at 7.32 and 7.62 ppm (C-/*;2'"#). 13C NMR showed C=O at 
165.6 ppm. 
The dimeric amide !"> was formed in 65 % yield using the same method, with 4-(1-H-
benzimidazol-2-yl)cyclohexyl)methan amine (!!%) and terephthalic acid. This product 
was confirmed by 1H NMR through the appearance of amide protons at 8.66 ppm as a 
triplet peak and the eight aromatic protons as two doublet of doublets at 7.53 and 7.78 
ppm. 13C NMR showed C=O at 165.7 ppm (C-/*;2'"!), the MS showed m/z for doubly 
















                                                 











A number of  unsymmetrical and symmetrical bis(benzimidazoles) were prepared with  
different directions of  amide linked C2-C2 (head-to-head), C2-C5 (head-to-tail) and C5-
C5 (tail-to-tail) linkages, these dimers differ in having a 2-CO2H or 5-CO2H directly on 
the benzimidazole ring, or a aryl spacer at C2. These were coupled with amines by using 
two different coupling reagents (EDC/HOBt) for the 2-carboxybenzimidazole and (CDI) 
with the 5-carboxybenzimidazoles.  
In parallel, a series of dimers were also prepared from amines (2-NH2 or 5-NH2), thus in 

























Synthesis of trimeric and tetrameric benzimidazoles  













3.1 Synthesis of amide linkage trimeric benzimidazole 





























Figure 53 Starting materials used in synthesis of trimeric benzimidazole  
 
3.1.1 Bifunctionality of 2,5-dicarboxybenzimidazole: - 
Several novel tris(benzimidazoles) were synthesized via the utilization of the 
bifunctionality of 2,5-dicarboxy benzimidazole 106 in which one equivalent of the 
diacid was coupled with two equivalents of different 2- or 5-aminobenzimidazoles.  









































































































Scheme 32 Tris(benzimidazole) synthesis from coupling of 2,5-dicarboxybenzimidazole  
and  2- or 5-aminobenzimidazoles 
 
The four trimers were prepared by using EDC/ HOBt (Scheme 32). Trimers 158 and 159 
were obtained after 14 days, whilst 156 was a 12 days reaction and 157 was obtained 
after 13 days when TLC showed no starting material remaining and the desired trimer 
157 was isolated in 75 % yield (Scheme 32).   
The 1H NMR for trimer 156 showed N-H amide protons as triplet at 8.47 and 8.64 ppm, 
whilst four methylene protons appear clearly as triplet at 3.23 ppm.  The 13C NMR 
showed the characteristic signals for two amide carbonyls at 164.7 and 165.8 ppm, and 
methyelene carbons at 44.4 ppm, the MS showed MH+ ion at m/z 705. The IR showed 
the C=O at 1622 and 1636 cm-1 and the NH stretch in the range 3245-3395 cm-1. 
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The IR for 157 showed an NH stretch at 3364-3534 cm-1 and C=O at 1653 and 1664 cm-
1, and the 1H NMR showed NH amide as a singlet peaks at 8.41 and 8.58 ppm 
respectively, while the 13C NMR showed two amide C=O peaks at 152.7 and 153.6 ppm 
respectively. The mass spectra showed MH+ ion as a base peak at m/z  513.  
The 1H NMR for trimer 158 showed N-H amide protons as singlet peaks at 10.69 and 
10.79 ppm. The protons of the methoxy groups as singlets at 3.94 and 4.11 ppm (Figure 
54). The 13C NMR showed the characteristic signals for two amide carbonyls at 163.9 
and 164.9, whilst the MS showed MH+ peak at m/z 785. The IR showed the C=O at 1640 
and 1653 cm-1 and the NH stretch at 3282-3507 cm-1. 
The mass spectra for 159 showed MH+ ion as a base peak at m/z 541, whilst 1H NMR 
showed N-H amide protons as triplet at 9.19 and 9.34 ppm respectively, while the four 
methylene protons appear clearly as doublet at 4.73 ppm. The structure was confirmed 
by IR which showed NH stretch at 3204-3555 cm-1 and the two C=O at 1640 and 1647 
cm-1. The 13C NMR showed methylene carbons at 37.9 ppm, and two amide C=O peaks 












Figure 54 1H NMR (400 MHz) of 158 in d6-DMSO , the inset 
 shows expansion for the aromatic part 
 
                                                 


















































3.1.2 Bifunctionality of 2,5-diaminobenzimidazole. 
With 2,5-diaminobenzimidazole 108 in hand, novel tris(benzimidazoles) were 
synthesized via utilization of the bifunctionality of this diaminobenzimidazole in which 
one equivalent of the diamine was coupled with two equivalents of 2- or 5- 
carboxybenzimidazoles 124 and 115. 
Attempts to prepare trimer 160, using EDC/HOBt with 5-carboxy-2-trifluro 
methylbenzimidazole (115) failed and the starting material was recovered in near-
quantitative amount. However, pleasingly, employing CDI facilitated this coupling 
affording trimer 160 in 64 % yield after 12 days (Scheme 33). 
 
Scheme 33 Synthesis of tris(benzimidazole) via coupling of  diaminobenzimidazole 108 and 
carboxybenzimidazole 115 
 
The 1H NMR of this trimer showed two different amide protons appearing at 10.65 and 
10.79 ppm. The MS showed the MH+ peak at m/z 649. 13C NMR showed two amide 
carbonyls at 165.9 and 166.2 ppm and two CF3 carbons which are coincident at 142.9 
ppm appearing as a quarter with coupling constant (JCF = 39.6 Hz). The IR showed the 
C=O at 1633 and 1653 cm-1 and the NH stretch in the range 3114-3420 cm-1  
For attempted coupling with 2-carboxy-5-nitrobenzimidazole (124) and 5-amino-2-(4-
aminophenyl) benzimidazole (108), using EDC/HOBt in DMF or CDI in DMF, but this 
was unsuccessful, No trimer 161 could be isolated from these conditions (Scheme 34). 
The dimeric amide 162 was formed in 58 % yield after 17 days. 









































 Scheme 34 Synthesis of dimeric benzimidazole via coupling of diaminobenzimidazole 108 and 
carboxybenzimidazole 124 
 
The structure was confirmed by 1H NMR which showed the amide proton as a singlet 
proton at 11.43 ppm, while the NH2 protons appear as a broad peak in the range of 6.04-
6.56 ppm. The MH+ ion appeared in the MS as a base peak at m/z 414. The 13C NMR 




Figure 55 13C NMR (100 MHz) of 162 d6-DMSO, the inset 
 shows  LR mass spectrum 
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The dimeric amide 162 was converted to the trimer 163 in 53 % yield via its coupling 
with 5-carboxybenzimidazole (116) over 12 days (Scheme 35). The 1H NMR of the 
trimer 163 showed two amide protons at 10.66 and 11.43 ppm. The MS showed the 
MH+ peak at m/z 558. The IR showed the C=O at 1622 and 1659 cm-1. 
 
 
 Scheme 35 Tris(benzimidazole) synthesis from coupling of dimeric amide 162 and 5-
carboxybenzimidazole 
 
3.1.3 Extendability feature of nitro bis(benzimidazole) 
Bis(benzimidazoles) bearing a nitro group can be utilized for further coupling, in which 
the nitro group can be reduced to the corresponding amine which can be used as an 
amine for coupling with other carboxybenzimidazoles. Two examples of this type of 
trimer 164 and 165 were synthesized in this way.  
 
3.1.3.1 Synthesis of trimer 164 
The nitrobis(benzimidazole) 141 was reduced by using H2/Pd(C) for 5 days affording 
the desired amine 154 in 60 % yield. 
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Scheme 36  Tris(benzimidazole) synthesis from coupling of aminobis(benzimidazole) and 
carboxybenzimidazole 
 
The 1H NMR of 154 showed a change in chemical shift of the amide proton from 8.62 
ppm in the nitrobis(benzimidazole) 141 to 8.63 ppm. Moreover, the 13C NMR appeared 
C=O at 166.7 ppm compared with that in the nitro compound at 169.7 ppm. The amine 




C28H28ON6    
464.23
 
Figure 56 LRMS of 154 
 
This aminobis(benzimidazole) 154 was then converted to the trimer 164 in 65 % via  
coupling with 2-carboxybenzimidazole (123) (Scheme 36). The 1H NMR of the trimer 
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164 showed the appearance of two amide protons as triplet at 8.73 and a single peak 
11.03 ppm. Mass spectral data was also consistent with a base peak at m/z 609 (Figure 








Figure 57 LRMS of  164 
 
3.1.3.2 Synthesis of trimer 165 
The nitrobis(benzimidazole) 140 was reduced by using H2/Pd(C) for 6 days affording 
the desired amine 155 in 70 % yield. 1H NMR spectrum of this amino dimer showed a 
change in chemical shift for the amide NH from 10.29 ppm in nitro dimer 140 to 10.42 
ppm, and IR which showed the C=O at 1638 cm-1 (compared with the nitro compound 
140 at 1654 cm-1). The compound 155 showed the base peak at m/z 446.  
Aminobis(benzimidazole) 155 was converted to the trimer 165 in 68 % yield via its 
coupling with 2-carboxybenzimidazole (123) over 7 days (Scheme 37). The 1H NMR of 
the trimer 165 showed two amide protons at 8.43 and 10.48 ppm. The 13C NMR showed 
C=O signals at 164.5 and 166.6 for the two different carbonyls whilst mass spectral data 
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4.1 Sequence-specific minor groove binding of novel             
        oligo(benzimidazoles) 
 
4.1.1 Surface plasmon resonance technique 
The interaction of nucleic acids with small molecules has been a primary area of 
interest for therapeutic development for over half a century. Surface plasmon 
resonance (SPR)-biosensor techniques directly provide essential information for the 
study and characterization of small molecule –nucleic acid interactions, and the use 
of these methods is steadily increasing.79 The method is label-free and monitors the 
interactions in real time. Both dynamic and steady-state information can be obtained 
for a wide range of reaction rates and binding affinities. 
Biosensor-SPR methods, particularly as implemented in the Biacore technology, 
offer significant advantages in many measurements of nucleic acid interactions. For 
small molecules, which frequently have large binding constants with weak 
spectroscopic signals and low interaction enthalpies, SPR approaches may provide 
the only practical method for accurate determination of the binding and rate 
constants. 
The Biacore sensor chip is the most versatile chip available and the first choice for 
immobilization is via covalent attachment to -NH2, -SH, -CHO, -OH or -COOH 
groups (eg Figure 72). A common non-covalent attachment involves streptavidin 
/biotin, with these attached to chip surface and ligand respectively. It supports a wide 
range of immobilization levels and permits attachment of proteins, nucleic acids, 
carbohydrates and small molecules.79  
 
Matrix: carboxymethylated dextran covalently attached to a chip surface, 
molecules are covalently coupled to the sensor surface 
via carboxyl group 
Figure 72 Immobilization of chip by carboxyl group    
                                                 
 Taken from www.biacore.com/…/guide/cm5/index.html 
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Covalent attachment by amino or thiol coupling requires that the immobilized 
molecule has a free amino or thiol group that is not involved in the interaction. 
Although other immobilization techniques are available, the biotin-streptavidin 
coupling is popular in Biacore SPR experiments and it is particularly useful for 
nucleic acids immobilization. 
The large affinity constant for the biotin-streptavidin complex results in a stable 
surface for binding studies. An important step in sensor chip immobilization is to 
decide how much biomolecule to immobilize. It is usually best to immobilize the 
smallest amount of materials. 
The response represented by the sensorgarm is the difference between the response 
in the cell with immobilized DNA minus the response of blank flow cell without 
DNA, due to modification of the refractive index/mass at the surface and a resulting 
change in the SPR angle. The angle change is reported in Biacore technology as 
response units (RU) where a 1000 RU response is equivalent to a change in surface 
concentration of about 1ng/mm2 of DNA (the relationship between RU and ng of 
material bound will vary with the refractive index of the bound molecule). The 
experiments thus measure changes in refractive index when the mass of material on 
the surface changes due to ligand binding to DNA. 
Additionally, the ‘‘off’’ response is determined as related to the drop in mass as 
ligand dissociates from DNA when the solvent system consists of pure buffer, and 
the ligand is washed from the DNA.    
The true responses obtained were used to get Kd by plotting it against the drug 
concentration and fitting it with a steady- state affinity fit .  
 
4.1.2 Buffers, DNA and oligonucleotides 
For our studies we used three different DNA oligonucleotides with a 5'- biotin 
attached to, then immobilize on a streptavidin-coated chip (Figure 73 and 74). All 
experiments were conducted in PBS buffer, filtered and degassed, was purchased 
from Sigma-Aldrich (dissolve 1 tablet in 200 mL of water). The three different 5'- 
labeled hairpins (Eurofins MWG Operon.;HPLC purified) used in SPR studies were 
:d(biotin-CGAAATTTCGTCTCCGAAATTTCG);d(biotin-CGAATTCGTCTCCGA 
ATTCG);d(biotin-CGAAAATTTTCGTCTCCGAAAATTTTCG) (HPSF purified). 
































Figure 73 Biotin -conjugated DNA oligonucleotides 
 
 
Figure 74 Attachment of streptavidin/biotin with chip surface  
and oligonucleotides respectively 
 
4.1.3 Determination of binding constant by SPR 79 
SPR measurements were performed with a four-channel BIAcore 3000 optical 
biosensor system and streptavidin-coated sensor chips (SA). Three consecutive 1 min 
injections of 1M NaCl in 50 mM NaOH followed by extensive washing with buffer 
were used to prepare the sensor chips. Nearly the same amounts of 5’-biotinylated 
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oligomers (25 nM) in PBS buffer were immobilized on the surface by non-covalent 
capture, leaving one of the flow cells blank as a control. Manual injection was used 
with a flow rate of 2 PL/min to achieve long contact times with the surface and to 
control the amount of the DNA bound to the surface.  Solutions of compound with 
known concentrations were prepared in filtered and degassed buffer by serial 
dilutions from stock solution  and passed over the immobilized DNA surfaces for a 
predetermined time period (typically 5 min) at a flow rate of 20-30 PL/min and 25 
qC. Buffer flow alone during 10 min was generally sufficient to dissociate the drug 
from DNA for surface regeneration. 
Average fitting of the sensorgrams at the steady-state level was performed with the 
BIAevaluation 4.1 and Origin 7 programs.  
  
 4.1.4 DNA binding assays  
DNA oligonucleotides containing A2T2, or A3T3 or A4T4 sequences were 
immobilized and SPR used to evaluate the binding affinities of a library of different 
oligomeric ligands (Table 2). 
 
                                                 
 See Section 4.1.5 for details. 
Linkage 
Type 
 Structure A2T2  
Kd(PM) 








































































































































































































 Symmetrical with central linker 
 





























































































































 Symmetrical biphenyl core dimers 
 










































































































































































































































 Symmetrical biphenyl core tetramers 
 







































































































Kd = Dissociation constant  (micro molar)                 X = no binding 
 
Table 2 Affinities for (AT)n targets 
 
Data presented in Table 2 showing our ligands binding to DNA are related to the 
well-known minor groove agent Hoechst 33258. 
Hoechst binds very strongly to the three DNA sequences (A2T2, A3T3 and A4T4), 
as can be seen from comparing the binding of our ligands to DNA to Hoechst 
binding. 
Some ligands 155, 171, 174 and 184 bind strongly to the three DNA sequences 
(A2T2, A3T3 and A4T4) others 137, 152 and 160 are very weak binding to the three 
DNA sequences (A2T2, A3T3 and A4T4), other ligands show no binding to DNA 
sequence.  
The best four  (from a screen of 40) are 2L2552L2 tetramers  171 and  174, and 2L5 
dimer 155 and dimeric 5,5-system 184 without terminal additional benzimidazoles   









































































































































Figure 75 Four highest affinity ligands identified from SPR screens 
 
This screen subset identifies three new ligands with micromolar or lower affinities 
for one or more of the three DNA sequences (A2T2, A3T3 and A4T4). The two 
tetrameric benzimidazole-amides 171 and 174, evidence higher affinities for the 
longer target sequences, with 171 showing the best affinity of 60 nM for the longer 
A4T4 oligonucleotide target. 
The compound 184 binds more strongly to the A2T2 DNA duplex (Figure 76) than 
compound 155, 171, and 174 which have slower binding affinities. The sensorgram 
results were fit in the steady-state region as described in the Materials and Methods 






















































Figure 76 BIAcore SPR sensorgrams for interaction  
of compound 184 with the A2T2 sequence DNA 
hairpins in PBS buffer at 25 °C 






Table 3 The concentrations of compound 184 from 0 
(reference line, green) to 137 µM at each RU value 
 
Visual observation of the binding sensorgrams for the 171 compound interacting 
with the A3T3 DNA sequence indicated that it binds strongly (Figure 77). The 
sensorgrams for compound 184 decrease slightly with time at the highest 
concentrations used in the experiments. The binding of compounds 155 and 174 to 






x 137 23.6 
x 137 30.3 
x 68.5 54.7 
x 68.5 59.8 
x 34.3 57.5 
x 34.3 57.4 
x 17.1 67 
x 17.1 56.3 
x 8.56 59.5 
x 8.56 57.1 
x 4.28 44.5 
x 4.28 40.9 
x 2.14 33.6 
x 2.14 37.1 
x 1.07 25.3 
x 1.07 25.2 
x 0.535 24.2 
x 0.535 17.8 







Figure 77 BIAcore SPR sensorgrams for compound 171  
with the A3T3 DNA minor groove in PBS buffer at 25  





Table 4 The RU values at the concentration range 
                                                                                           of compound 171, 0-67.5 µM. 
 
With the A4T4 sequence, quite significant binding of compound 171 is observed, 
(Figure 78) due to the very strong binding of compound 171 to the A4T4 DNA as 
can be seen from the results in Table 1, while the binding of compound 155 to the 
A4T4 sequence (Figure 79) is weaker than compound 171, however, no binding of 


















x 67.5 73.1 
x 67.5 78.6 
x 33.8 79.3 
x 33.8 80 
x 16.9 77.5 
x 16.9 77.9 
x 8.44 79.2 
x 8.44 79.1 
x 4.22 74.9 
x 4.22 74.3 
x 2.11 68.7 
x 2.11 68.8 
x 1.05 62.9 
x 1.05 64.8 
x 0.527 55.5 
x 0.527 58.8 
x 0 0 
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       Figure 78  SPR sensorgrams for binding of      
compound 171 to A4T4 sequence DNA  
               hairpins at 25 °C in PBS buffer 
 
 
Table 5 The concentration ranges of compound 171 
                                                                             are 0 (reference line, blue) to 16.9 µM 









Figure 79 BIAcore SPR sensorgrams for interaction of 
compound 155 with the A4T4 sequence DNA hairpins 
in PBS buffer at 25 °C, the compound 155 bind  





Table 6 The concentrations of compound 155 from 0 









x 16.9 49 
x 16.9 50 
x 8.44 53.7 
x 8.44 52.2 
x 4.22 52 
x 4.22 50.9 
x 2.11 49.4 
x 2.11 49.2 
x 1.05 46.9 
x 1.05 49.1 
x 0.527 42 
x 0.527 45.4 






x 187 129 
x 187 126 
x 94 106 
x 94 109 
x 47 66.2 
x 47 74.4 
x 23.5 69.8 
x 23.5 75.6 
x 11.8 52.6 
x 11.8 51.7 
x 5.88 37.3 
x 5.88 35.9 
x 2.93 21.2 
x 2.93 18.3 
x 1.47 8 
x 1.47 5.31 
x 0.734 7.83 




4.1.5 Dilution of benzimidazoles 
 
Benzimidazoles were dissolved first in DMSO: solution A of a compound was 
prepared using the following as an example calculation:  
 Mw = 896 
n = 5.58 µmole 
V= 1 mL 
).(
)(. 1 molgMwt
gmassnmolesofno                         
                           molemole P58.51058.5
896














u   
P
  
A 20 µL  aliquot of this solution A was mixed with 380 µL of 1.05x PBS buffer to 
prepare solution B with total volume of 400 µL calculated as follows: 











mMCB 279.0  
This dilution of 20 µL into 400 µL results in a twenty-fold dilution to give a final 
concentration of 0.279 mM. 
Further dilution provided solution C with  
CC = 0.139 M, VC =200 µL 
This solution was generated by taking 100 µL of solution B and adding 100 µL of 
1.05x PBS buffer,  generating solution C with total volume of 200 µL. The final 
molarity of sample C was calculated as follows: 











MmMCC P139139.0    
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Table 7 Dilution of benzimidazoles soluble in DMSO 
 
 V   = Volume of DMSO used to dissolve sample  
n   = Number of moles of sample 
CA = Molarity of solution A 
VA = Volume that was taken from V  
VA= Volume of 1.05x PBS buffer that was added to VA 
V1   = VA+VA 
VB  = Volume that was taken from V1  
VB= Volume of 1.05x PBS buffer that was added to VB 
VC  = VB+VB 












































171 1 5.58 5.58 20 380 400 100 100 200 139 
174 1 6.83 6.83 20 380 400 100 100 200 170 
155 1 11.23 11.23 20 380 400 25 50 75 187 
184 1 8.22 8.22 20 380 400 25 50 75 137 
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4.2 Analysis and conclusion 
The SPR studies reveal two types of binding motif. The symmetrical biaryl core of 
171, 174 and 184 and the unsymmetrical dimeric backbone of 155. The efficacy of 
binding is higher for the symmetrical (and larger) systems. Interestingly, the dimer 
155 binds about 4-5 fold better to the longer A3T3 and A4T4 sequences. This is a 
good new compound which leads for future work. However, the symmetrical systems 
show significantly tighter binding, with examples in the low micromolar to 
nanomolar ranges. There is some evidence of a trend to binding better to the longer 
sequence for the tetrameric systems, where binding to the A4T4 sequences is an 
order of magnitude better than to A3T3.  
Recently, a series of symmetric head-to-head bis-benzimidazoles have been reported 
in the literature 72 (see Section 1.6) (186 and 187) and been evaluated for their 
binding affinities to four consecutive AT base pairs in the minor groove of the 
duplex d(CGCGAATTCGCG)2 (Figure 80).  
 
Figure 80  Structures of symmetric head-to-head bis-benzimidazoles  
have been reported in the literature 72 
 
The structural studies of the two reported symmetric head-to-head bis-
benzimidazoles (186 and 187) provide us with the basis to identify factors 
controlling AATT DNA sequence recognition. The majority of reported compounds 
are symmetrical and possess a 2,2'-diphenyl-5,5'-bis benzimidazole core (Figure 81).  
 
 
Figure 81 Common structure of the core of comparable ligands 
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This thesis reports that benzimidazole systems 155, 171, 174 and 184  provide a very 
favourable and flexible DNA recognition.  
This information can be of use in guiding the design of effective DNA-binding 
molecules and binding affinity for AATT sequences. A key binding feature is due to 
the presence of NH atom, which acts as hydrogen donors (Figure 82). 
 
 
Figure 82 Generic structure showing hydrogen bonding formation 
 
Binding of Hoechst 33258 to AT-rich regions is well known to involve NH protons 
of 33258 interacting with adenine N3 and/ or thymine O2, which are capable of 
acting as hydrogen acceptor through specific hydrogen bonding (Figure 83). 
 
 
Figure 83 The structure of adenine and thymine acting as hydrogen acceptors. 
 
Our novel compounds 155, 171, 174 and 184 (Figure 84) bind to the minor groove 
of a 2-6 bp long AT-tract oligonucleotide and from precedents, it is likely that this 
also involves  the NH atom in the benzimidazole rings of these compounds and the 




Figure 84 Generic structures showing the ligand-DNA interface on left side compared to 
our binding examples on right side 
 
For the novel ligands in this thesis. The affinity of binding is higher for the 
symmetrical systems, and encourages the future design of analogues better ablity to 
target specific  sites in DNA.  
These structural studies provide a basis to identify factors controlling DNA 
recognition and design DNA molecules that could ultimately be used as tools or 
agents to control gene expression in cells and that would guide the synthesis of 
possible targets and employ extensive simulation methods to produce a set of 
structures. 
It is now well established that design of low molecular organic compounds such as 
benzimidazoles that can site-specifically recognize sequences in double stranded 
DNA is important for creating tools for studying molecular biology, on the other 
hand design of these compounds is an important pharmacological task, since 
chemotherapeutic efficacy of most of the currently used anti cancer drug depends on 
selectivity and efficiency of their interaction with DNA.    
In the future, we will compare the sequence recognition properties of our compounds 
by means of NMR and other methods, to obtain more information for DNA 
properties and may be used in guiding the design of future effective DNA-binding 
molecules. 
 142
However the pharmacokinetics, bioavailability and toxicity of benzimidazoles  
remain to be established.  
Considering the increasing contribution of cancer to the overall mortality rate, a more 
rational design and application of novel DNA binding compounds, with both higher 






4.3 Future work:- 
It is now established that benzimidazole systems can provide favourable and flexible 
DNA recognition modules. Benzimidazoles, for example, form the core of Hoechst 
33258 (H258), one of the most extensively studied minor groove binding agents, as 
well as of a variety of other related DNA-binding compounds (see Section 1.6). 
To probe these interaction differences further, we have synthesized several new types 
of benzimidazole derivatives, which can be related to the well-known minor groove 
agent, Hoechst 33258.  
The work has developed chemistry enabling synthesis of several different types of 
di-, tri- and tetra-benzimdiazoles with different sorts of linker units. In the future, this 
should enable the synthesis of a range of differently functionalized systems as the 
synthesis is designed to be modular.  In this thesis a diversity of dimeric, trimeric and 
tetrameric ligands have been prepared. 
These agents have to date been evaluated for their ability to bind to DNA using 
Surface Plasmon Resonance (SPR), which provides a practical method for 
determination of the binding affinity and rate constants. In this thesis the affinity of 
binding is higher for the our novel symmetrical ligands, and encourages the future 
design of analogues with better ability to target specific sites in DNA. Our new 
unsymmetrical dimeric structure 155 binds about 4-5 fold better to the longer A3T3 
and A4T4 sequences. However, the symmetrical biaryl core of 171, 174 and 184 
show significantly tighter binding, with examples in the low micromolar to 
nanomolar ranges. There is some evidence of a trend of binding being tighter to the 
longer DNA sequence for the tetrameric systems, where binding to the A4T4 
sequences is an order of magnitude better than to A3T3. These are good new 
compounds which can form the basis for future work.  
 The aims of future work are to identify features leading to DNA binding and to 
determine and prove the type of binding. They will require the use of other 
techniques including 2D-NMR, CD spectroscopy, Tm studies, gel chromatography, 
foot printing and fluorescence.  Future collaborative work can aim to determine more 
details of sequence preferences, with the aim of guiding the design of future specific 
DNA-binding molecules.  
The work in this thesis shows that with initial leads identified, future work is needed 
to further define structure-activity features, including the effects of physico-chemical 
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5.1 General experimental 
 
1H NMR spectra were recorded at 300 and 400 MHz on a Bruker DPX 300 and 400 
spectrometer and 13C NMR and DEPT spectra at 75 MHz and 100 MHz on a Bruker 
DPX300 and DPX 400 spectrometer. In addition to 1D NMR (1H NMR, 13C NMR and 
DEPT), 2D NMR such as (HMQC and COSY) were used in spectra interpretation. 
Chemical shifts are denoted in ppm (į) relative to internal solvent standard (TMS in the 
case of 1H). The splitting patterns for NMR-spectra are designated as follows: s (singlet), 
d (doublet), dd (doublet of doublets), t (triplet), tt (triplet of triplets), dt (doublet of 
triplets), q quartet, dq (doublet of quartets), qd (quartet of doublets), and m (multiplet). 
Coupling constants (J) are designated in Hz. Mass spectra were recorded on a VG 70/70 
Hybrid or a Kratos MS-50 mass spectrometer by ES. Melting points were determined 
with an electrothermal melting point apparatus. IR spectra were obtained using a Perkin 
Elmer 1605 FTIR spectrometer (KBr disc). Analytical TLC was performed on Merck 60 
F254 aluminium backed plate and were developed using an UV lamp. Column 
chromatography employed Prolabo Silica Gel 60 (70-230 Mesh), using pre-distilled 
hexane and AnalaR (AR) ethyl acetate. THF was dried by distillation from sodium 
benzophenone ketyl. All reactions were conducted in dry glassware under an nitrogen 
atmosphere, unless otherwise stated. All chemicals were used directly from suppliers 
vessel without further purification, unless otherwise stated. 
 
5.2 Condensation of aldehyde or carboxylic acid with      
phenylenediamine. 
 
5.2.1 General method for condensation in the presence of Na2S2O5. 
 
An appropriate substituted benzaldehyde (15 mmol) was dissolved in EtOH (50 mL). 
Sodium bisulfite (1.6 g) in water (10 mL) was added to the cooled solution in portions 
and stirred vigorously. The precipitate which formed was filtered off and dried in vacuo. 
The mixture of this adduct (2 mmol) and substituted o-phenylene diamine (2 mmol) in 
DMF (5 mL) were heated at 140 oC for defined time after which the reaction mixture 
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was cooled, poured into water, and the solid was filtered off and purified by 
recrystallization from an appropriate solvent. 
 
5.2.1.1 2-(4'-Methoxyphenyl)-5-nitrobenzimidazole (94) 80, 81 
 
The title compound was synthesized by condensation of 4-nitro-1,2-phenylenediamine 
and p-anisaldehyde bisulfite adduct for 16 h according to procedure 5.2.1 and purified 
by recrystallization from water: ethanol (1:1 v/v) affording 94 as a yellow solid (1.49 g,  
37%);  Mp 239 °C,  (Lit. 80, 81 238 °C). 
1H NMR (400 MHz, DMSO) 3.92 (s, 3H), 7.21 (d, J = 7.4 Hz, 2H), 7.77 (s, 1H),  8.16 
(d, J = 7.2 Hz, 1H), 8.22 (d, J = 7.6 Hz, 2H), 8.40-8.59 (bs, 1H), 13.40-13.60 (br, NH). 
13C NMR (100 MHz, DMSO) 55.8 (CH3), 114.9 (2CH), 115.7 (C), 118.1 (CH), 121.8 
(C), 127.2 (CH), 129.0 (2CH), 129.1 (CH), 142.6 (C), 142.8 (C), 156.2 (C), 161.8 (C). 
LRMS: (ES) m/z (MH)+ 270.8 for C14H12N3O3. 
 
5.2.1.2 2-(2',4'-Dimethoxyphenyl)-5-nitrobenzimidazole (96) 81 
 
The title compound was synthesized by condensation of 4-nitro-1,2-phenylenediamine 
and 2,4-dimethoxybenzaldehyde bisulfite adduct for 48 h according to procedure  5.2.1  
and purified by recrystallization from water: ethanol (1:3 v/v)  affording 96 as a yellow 
solid (0.46 g,  77%); Mp 201 °C,  (201 °C 81). 
1H NMR (400 MHz, CDCl3) 3.99 (s, 3H), 4.18 (s, 3H), 6.73 (s, 1H), 6.86 (d, J = 8.4 Hz, 
1H), 7.86 (d, J = 8.8 Hz, 1H), 8.09 (d, J = 8.4 Hz, 1H), 8.42 (d, J = 8.8 Hz, 1H),  8.61 
(s,1H). 13C NMR (75 MHz, CDCl3) 56.6 (CH3), 57.1 (CH3), 99.9 (CH), 101.6 (CH), 
108.5 (CH), 109.2 (CH), 114.5 (CH), 122.3 (C), 130.1 (C), 131.9 (C), 132.0 (CH), 134.4 




5.2.1.3 2-(4'-Carboxyphenyl)-5-nitro-1H-benzimidazole (105) 81 
 
The title compound was synthesized by condensation of 4-nitro-1,2-phenylenediamine 
and 4-carboxybenzaldehyde bisulfite adduct  for 72 h according to procedure 5.2.1 and 
purified by recrystallization from acetic acid affording 105 as a brown solid (0.41 g,  
73%); Mp > 300 °C,  (> 300 °C 81). 
1H NMR (400 MHz, DMSO)  7.96 (d, J = 7.6 Hz, 1H), 8.07 (d, J = 7.6 Hz, 2H), 8.11 (s, 
1H), 8.21 (d, J = 7.2 Hz, 2H), 8.95 (s, 1H), 13.22-13.23 (bs, 1H, NH or COOH). 13C 
NMR (100 MHz, DMSO) 113.9 (2CH), 115.4 (2CH), 126.5 (2CH), 128.1 (CH), 131.3 
(C), 134.2 (C), 153.8 (2C), 166.9 (C=O). LRMS: (ES) m/z (MH)+ 284.0 for C14H9N3O4. 
 
5.2.1.4 2-(4'-Carboxyphenyl)-5-carboxy-1H-benzimidazole (106)  
 
The title compound was synthesized by condensation of 3,4-diamino benzoic acid and 4-
carboxybenzaldehyde salt for 24 h according to procedure 5.2.1 and purified by 
recrystallization from water: ethanol (1:1 v/v) affording 106 as a beige solid (044 g, 
78%); Mp > 300 °C.  
1H NMR (300 MHz, DMSO)  7.68 (d, J = 7.5 Hz, 1H, H7), 7.85 (d, J = 7.5 Hz, 1H, H6), 
8.11 (d, J = 7.8 Hz, 2H, H2'+H6'), 8.19 (s, 1H, H4), 8.29 (d, J =7.8 Hz, 2H, H3'+H5'), 
13.07-13.62 (br, 2H, 2COOH). 13C NMR (75 MHz, DMSO) 124.2 (CH), 124.4 (CH), 
125.3 (CH), 127.1 (2CH), 130.3 (2CH), 132.5 (C), 132.7 (C), 133.7 (C), 134.0 (C), 
152.8 (C), 152.9 (C), 167.2 (C=O), 168.1 (C=O). IR ȣ max cm –1 1279 (C-N), 1060 (C-O), 
1460 (C=C), 1654 (C=N), 1685 (C=O), 1700 (C=O), 3120 (C-H, aromatic), 3343 (N-H, 






5.2.2 General method for condensation in the presence of nitro benzene 
 
A mixture of unsubstituted or substituted phenylenediamine (10 mmol) and appropriate 
aldehyde (10 mmol) in nitrobenzene (50 mL) was heated at 140 °C. Once tlc showed 
there was no starting material, the mixture was cooled and filtered after adding (50 mL) 
of water. The crude preciptate was purified by recrystallization or column 
chromatography. 
 
5.2.2.1 5-Nitro-2(4-nitrophenyl)-1H-benzimidazole (107) 82,81 
 
The title compound was synthesized by condensation of 5-nitro-1,2-phenylenediamine 
and p-nitrobenzaldehyde sulfite adduct for 48 h according to procedure 5.2.2 and 
purified by column chromatography using DCM:MeOH (10:1) affording 107 as a yellow 
solid  (1.70 g, 69 %); Mp > 300 °C (Lit. 82 356 °C, 81 > 300 °C ).  
1H NMR (300 MHz, DMSO) į 7.81 (d,  J = 8.4 Hz, 1H,), 8.15 (d, J = 8.4 Hz, 1H,), 8.43 
(s, 4H), 8.51 (s, 1H), 13.93 (s, 1H, NH). 13C NMR (75 MHz, DMSO)  118.9 (CH), 124.3 
(CH), 124.4 (2CH), 124.7 (CH), 127.9 (C) 128.4 (2CH), 131.0 (CH), 135.1 (C), 143.5 
(C), 148.8 (CH), 153.8 (C). LRMS: (ES) m/z (MH)+ 285.0 for C13H9N4O4. 
 
 5.3 General procedure for reducing nitrobenzimidazoles via 
       SnCl2/HCl. 
 
A solution of nitrobenzimidazole (2 mmol) in conc. HCl (10 mL) was treated 
portionwise with SnCl2 (12 mmol, 2.28 g) and the resulting solution was stirred at room 
temperature for several hours. The reaction mixture was poured into ice-water and 
neutralized with NaOH 10% solution, extracted with ethyl acetate (5 x 25 mL) washed 
with water (3 x 15 mL), dried over anhydrous Na2SO4, and then solvent removed in 
vacuo leaving an oily material. The residue was crystallized from acetone:hexane (1:10 
v/v) and  purified either by recrystallization or column chromatography. 
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5.3.1 5-Amino-2-(4'-methoxyphenyl) benzimidazole (100) 83,81 
 
The title compound was synthesized according to method 5.3 by reaction over 24 hour 
and purified by recrystallization from ethanol affording 100 as a pale brown solid (0.32 
g, 67 %); Mp 201-203 °C.  
1H NMR (400 MHz, DMSO) 3.91 (s, 3H), 7.32 (d, J = 9.0 Hz, 2H), 7.48 (dd, J1 = 8.5, J2 
= 1.5 Hz, 1H), 7.81 (d, J = 1.5 Hz, 1H), 7.91 (d, J = 8.5 Hz, 1H), 8.20 (d, J = 9.0 Hz, 
2H) . LRMS: (ES) m/z (MH)+ 240.9 for C14H14N3O1, (13C NMR see 5.4.1). 
 
5.3.2 5-Amino-2-(2',4'-dimethoxyphenyl) benzimidazole (101) 81 
 
The title compound was synthesized according to method 5.3 by reaction over 24 h and 
purification by column chromatography DCM:MeOH (10:1 v/v) will afford 101 as a 
brown solid (0.42 g, 78 %); Mp 187 °C,  (187 °C 81). 
1H NMR (400 MHz, CDCl3) 3.43-3.74 (br, 2H, NH2), 3.91 (s, 3H), 4.08 (s, 3H), 6.62 (s, 
1H), 6.70 (d, J = 8.4 Hz, 2H), 6.90-6.94 (bs, 1H), 7.44-7.50 (bs, 1H), 8.49 (d, J = 8.4 Hz, 
1H), 10.18-10.70 (br, NH) 13C NMR (75 MHz, CDCl3)  56.5 (CH3), 57.1 (CH3), 100.1 
(CH), 101.4 (CH), 108.5 (CH), 110.1 (CH), 115.6 (CH), 121.9 (C), 127.8 (C), 130.9 
(CH), 131.2 (C), 131.6 (C), 149.9 (C), 160.3 (C), 167.8 (C). LRMS: (ES) m/z (MH)+  
270.1 for C15H16N3O2. 
 
5.3.3 2-Pyridin-2-yl-1H-benzimidazol-5-ylamine (102) 84, 81 
 
                                                 
  This compound is known, but there is no data regarding its melting point. 
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The title compound was synthesized according to method 5.3 by reaction over 7 h and 
purified by recrystallization from ethanol affording 102 as a brown solid (0.28 g, 66 %); 
Mp 215 °C (Lit. 84, 81  217 °C)  
1H NMR (400 MHz, DMSO) 7.50 (dd, J1 = 8.8, J2 = 1.6 Hz, 1H), 7.74 (dd, J1 = 8.0, J2 = 
4.8 Hz, 1H), 7.84 (d, J = 1.6 Hz, 1H), 7.93 (d, J = 8.8 Hz, 1H), 8.19 (t, J = 8.0 Hz, 1H), 
8.45 (d, J = 8.0 Hz, 1H), 8.89 (d, J = 4.8 Hz, 1H). 13C NMR (75 MHz, DMSO) 108.8 
(CH), 116.2 (CH), 121.3 (CH), 123.7 (CH), 126.2 (CH), 127.8 (CH), 131.9 (C), 
133.2(C), 138.8 (C), 142.6 (C), 149.4 (CH), 150.6 (C). LRMS: (ES) m/z (M+2H)+ 212.1 
for C12H11N4. 
 
5.4 General procedure for reducing nitrobenzimidazoles  
      via H2/Pd(C) 
 
A solution of nitrobenzimidazole (3.5 mmol) in DMF/MeOH (10 mL:10 mL) was 
hydrogenated over 10% Pd/C (0.15 g), under an atmospheric pressure of H2. TLC 
showed the reduction went to a completion after 24-48 h, the catalyst was removed by 
filtration through Celite®, and then water was added and the ppt was purified by either 
recrystallization or column chromatography.  
 
5.4.1 5-Amino-2-(4'-methoxyphenyl) benzimidazole (100) 83,81 
 
The title compound was synthesized from reduction of 2-(4'-methoxyphenyl)-5-
nitrobenzimidazole (3.5 mmol, 0.941 g) according to method 5.4 with the reaction time 
extended for 24 h. The crude product was purified by recrystallization from ethanol 
affording 100 as a pale brown solid (0.57 g, 68 %); Mp  201-203 °C.   
1H NMR (400 MHz, CDCl3)  3.86 (s, 3H), 6.68 (d, J = 8.5 Hz, 1H), 6.85 (s, 1H), 6.97 
(d, J = 9.1 Hz, 2H), 7.45 (d, J = 8.4 Hz, 1H), 7.96 (d, J = 9.0 Hz, 2H). 13C NMR (75 
                                                 




MHz, CDCl3) 55.7 (CH3), 99.0 (CH), 113.0 (2CH), 114.7 (CH), 116.8 (C), 122.6 (C), 
128.1(2CH), 134.3 (CH), 138.8(C), 143.0 (C), 150.9 (C), 161.2(C). LRMS: (ES) m/z 
(MH)+ 240.7 for C14H14N3O1. 
 
5.4.2 2 (4-Amino-phenyl)-3H-benzimidazol-5-ylamine (108) 85, 81 
 
The title compound was synthesized by reduction of 5-nitro-2(4-nitro 
phenyl)benzimidazole (3.5 mmol, 0.994 g) according to method 5.4, with the reaction 
extended to 48 h. The crude product was purified by recrystallization from ethanol 
affording 108 as a brown solid (0.61 g, 78 %); Mp 247 °C.  
1H NMR (400 MHz, DMSO) 6.06-6.38 (br, 4H, NH amine), 6.76 (dd, J1 = 8.4, J2 = 2.0 
Hz, 1H), 6.77 (d, J = 8.8 Hz, 2H),  6.85 (d, J = 1.8 Hz, 1H), 7.39 (d, J = 8.4 Hz, 1H), 
7.96 (d, J = 8.8 Hz, 2H). 13C NMR (100 MHz, DMSO) 96.9 (C), 111.2 (C), 114.4 
(2CH), 114.6 (CH), 120.0 (C), 125.8 (CH), 129.6 (2CH), 134.9(C), 146.9 (CH), 148.8 
(C), 153.6 (C). LRMS: (ES) m/z (MH)+ 225.1 for C13H13N4. 
 
5.5 General method for condensation with aliphatic carboxylic    
acid (Phillip’s method) 
 
A solution of unsubstituted or substituted o-phenylene diamine (10 mmol) and 4N HCl 
(15 mL) was treated with appropriate aliphatic carboxylic acid (15 mmol) and heated 
under reflux for 3-24 h. The solution was cooled and allowed to stand overnight. The 
mixture was neutralized with 2 N NaOH, the solid was filtered, washed with water and 
purified by recrystalization from suitable solvent. 
 
5.5.1 2-(Aminomethyl)-1H-benzimidazole (110) 86, 81 
 
                                                 
  This compound is known, but there is no data regarding its melting point. 
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The title compound was synthesized by condensation of o-phenylenediamine (1.08 g) 
with glycine (1.12 g) for 24 h according to procedure 5.5 and purified by 
recrystallization from diethyl ether affording 110 as a pale green crystals (0.65g, 44 %); 
Mp 252 °C (Lit. 86, 81 252 °C ) 
1H NMR (400 MHz, DMSO) 4.56 (s, 2H, CH2), 4.74-6.78 (br, 2H, NH2), 7.36 (dd, J1 = 
6.2, J2 = 3.2 Hz, 2H), 7.67 (dd, J1 = 6.1, J2 = 3.2 Hz, 2H), 9.15-9.18 (bs, 1H NH). 13C 
NMR (75 MHz, DMSO) 35.0 (CH2), 114.8 (2CH), 125.8 (2CH), 132.6 (2C), 147.4 (C). 
LRMS: (ES) m/z (MH)+148.1 for C8H10N3. 
 
5.5.2 4-(1-H-Benzimidazol-2-yl)cyclohexyl)methanamine (112) 87,81 
 
The title compound was synthesized by condensation of o-phenylenediamine (1.08 g) 
with trans 4-aminomethylcyclohexane carboxylic acid (2.32 g) for 9 h according to 
procedure 5.5 and purified by recrystalisation from ethanol afforded 112 as a beige 
powder (1.12g, 49%); Mp 238 °C.       
1H NMR (300 MHz, DMSO)  0.83 (qd, J1 = 12.5, J2 = 2.8 Hz, 2H, Hc), 1.16-1.21 (m, 
1H, Ha), 1.36 (qd, J1 = 12.5, J2 = 2.8 Hz, 2H, He), 1.68 (dq, J1 = 12.0, J2 = 0.8 Hz, 2H, 
Hb), 1.85 (dq, J1 = 12.0, J2 = 0.8 Hz, 2H, Hd), 2.29 (d, J = 7.5 Hz, 2H, CH2), 2.55 (tt, J1 
= 12.0, J2 = 0.8 Hz, 1H, Hf), 3.36-3.64 (br, 2H, NH2), 6.87 (dd, J1 = 6.0, J2 = 3.0 Hz, 
2H), 7.23 (dd, J1 = 6.0, J2 = 3.0 Hz, 2H). 13C NMR (75 MHz, DMSO) 29.0 (2CH2), 29.5 
(2CH2), 34.9 (CH), 35.9 (CH), 44.4 (CH2), 114.2 (2CH), 125.8 (2CH), 131.2 (2C), 157.4 
(C). LRMS: (ES) m/z (MH)+ 230.2 for C14H20N3. 
 
                                                 





5.5.3 2-(Trifluoromethyl)-1H-benzimidazole-5-carboxylic acid (115) 88,81  
 
The title compound was synthesized by condensation of 3,4-diaminobenzoic acid (1.52 
g) with trifluoroacetic acid (1.71 g) for 3 h according to procedure 5.5 and purified by 
recrystallization from ether affording  115 as a white powder (1.68 g, 73 %); Mp 286 °C 
(Lit. 88, 81 285 °C ) . 
1H NMR (400 MHz, DMSO)  7.83-7.89 (bs, 1H), 8.05 (d, J = 8.5 Hz, 1H), 8.37 (s, 1H), 
12.86-13.27 (br, 1H, NH), 14.25-14.62 (br, 1H, COOH). 13C NMR (100 MHz, DMSO) 
115.6 (CH), 118.3 (CH), 120.9 (CH), 123.6 (C), 126.0 (C), 127.4 (C), 143.0 (C, CF3, JCF 
= 40.0 Hz), 168.2 (C=O). LRMS: (ES) m/z (MH)+ 231.9 for C9H5F3N2O2. 
 
5.5.4 1H-Benzimidazole-5-carboxylic acid (116) 89,81 
 
The title compound was synthesized by condensation of 3,4-diaminobenzoic acid with 
formic acid for 4 h according to procedure 5.5 and purified by recrystallization from 
ethanol affording 116 as a white solid (1.34 g, 83 %); Mp 243 °C . 
1H NMR (400 MHz, DMSO) į 7.21-7.49 (bs, 1H, N-H Imidazole), 7.62-7.69 (bs, 1H), 
7.83 (d, J = 8.4 Hz, 1H), 8.20 (s, 1H), 8.39 (s, 1H), 12.53-13.22 (br, 1H, COOH). 13C 
NMR (100 MHz, DMSO) 116.9 (CH), 121.9 (C), 122.5 (C), 122.8 (CH), 123.2 (C), 
124.1 (CH), 143.2 (CH), 166.7 (C=O). LRMS: (ES) m/z (MH)+163.0 for C8H7N2O2. 
 
5.6 General procedure for the synthesis of unsubstituted and     
substituted  2-carboxybenzimidazole 
 
Fresh methyltrichloroacetimidate (5 mmol, 0.88 g) was added dropwise to a cooled 
solution of unsubstituted or substituted o-phenylenediamine (4 mmol) in acetic acid (20 
mL). At the end of the addition (30 minutes), the reaction was kept at room temperature 
                                                 
  This compound is known, but there is no data regarding its melting point. 
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for 1 h and the resulting precipitate was filtered, washed with acetic acid (10 mL) and 
dried in vacuo to give unsubstituted or substituted 2-(trichloromethyl) benzimidazole as 
a white solid which was added to a cooled solution of sodium hydroxide (100 ml; 1N). 
The resulting solution was filtered and the filtrate was acidified with hydrochloric acid 
(1N) to pH 4. The precipitate was filtered off, washed twice with a solution of water and 
acetonitrile 3:1 v/v ( 30 mL) and ether (2 x 30 mL). 
 
5.6.1 1-H-Benzimidazole-2-carboxylic acid (123) 90,81 
 
The title compound was synthesized according to method 5.6 in which o-
phenylendiamine condensed with methyltrichloroacetimidate affording 2-trichloro 
methylbenzimidazole 17, that was then hydrolysed affording the corresponding 2-
carboxy benzimidazole 123 as an off-white solid (0.67 g, 83 %); Mp 65 °C  (65 °C 81).  
1H NMR (400 MHz, DMSO) 7.16 (dd, J1 = 8.0, J2 = 3.8 Hz, 2H), 7.45 (dd, J1 = 8.0, J2 = 
3.6 Hz, 2H), 8.18-8.96 (br, 2H, NH+COOH). 13C NMR (100 MHz, DMSO) 116.3 
(2CH), 124.8 (2CH), 136.6 (2C), 144.9 (C), 159.3 (C=O). LRMS: (ES) m/z (MH)+ 163.0 
for C8H5N2O2. 
 
5.6.2 5-Nitro-1H-benzimidazole-2-carboxylic acid (124) 90,81 
 
The title compound was synthesized according to method 5.6 in which 5-nitro-o-
phenylenediamine condensed with methyltrichloroacetimidate affording 5-nitro-2-
trichloromethylbenzimidazole 118, that was then hydrolysed affording the 
corresponding 5-nitro-2-carboxy-1H-benzimidazole 124 as a pale yellow solid  (0.64 g, 
77 %); Mp 46 C  (46 °C 81).  
                                                 
 




1H NMR (400 MHz, DMSO) 3.98-4.83 (br, 1H, N-H), 7.72 (d, J = 6.9 Hz, 1H), 8.13 (d, 
J = 6.9 Hz, 1H), 8.49 (s, 1H), 13C NMR (75 MHz, DMSO) 114.7 (CH), 116.2 (CH),  
17.9 (C), 119.5 (C), 126.6 (CH), 143.9 (C), 147.9(C), 160.4 (C=O). LRMS: (ES) m/z 
(MH)+ 206.0 for C8H4N3O4. 
 
5.6.3 5-Chloro-1H-benzimidazole-2-carboxylic acid (125) 90 
 
The title compound was synthesized according to method 5.6 in which 5-chloro-o-
phenylenediamine condensed with methyltrichloroacetimidate affording 5-chloro-2-
trichloromethylbenzimidazole 119 that was then hydrolysed affording the corresponding 
5-chloro-2-carboxy-1H-benzimidazole 124 as a pale yellow solid  (0.79 g, 80 %); Mp 
155 °C. 
1H NMR (400 MHz, DMSO) 7.22 (dd, J1 = 8.4, J2 = 2.0 Hz, 1H, H6), 7.61 (d, J = 8.4 
Hz, 1H, H7), 7.67 (d, J = 2.0 Hz, 1H, H4), 8.30 (s, 1H, NH or COOH), 13C NMR (100 
MHz, DMSO) 115.5 (CH), 116.3 (CH), 116.7 (C), 122.4 (C), 124.7 (CH), 126.5 (C), 
143.8 (C), 160.4 (C=O). IR ȣ max cm –1 809 (C-Cl), 1294 (C-N), 1063 (C-O), 1441 
(C=C), 1609 (C=N), 1636 (C=O), 3100 (C-H, aromatic), 3378 (N-H, amine) 3503 (O-
H). HRMS: (ES) m/z (MH)+ obsd. 196.0028, calcd. 196.0034 for C8H5ClO2N2. 
 
5.7 General procedure for synthesis of dimeric and trimeric  
      benzimidazoles by using the coupling reagent  
      EDC/HOBt. 
     
The unsubstituted or substituted 2-carboxybenzimidazole (1.1 mmol) was dissolved in 
dry DMF (10 mL) with HOBt (1.1 mmol) and EDC (1.1 mmol). The reaction was then 
cooled to 0 °C and, after half an hour, the amine or the aminobenzimidazole (1 mmol) 
                                                                                                                                                
  
 
  This compound is known, but there is no data regarding its melting point. 
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was added and the reaction left stirring at room temperature. Once the TLC showed no 
starting material, the solvent was removed in vacuo, then (25 mL) water and ethyl 
acetate (50 mL) were added. The organic layer was washed with HCl 5% (5 mL) then 
with NaHCO3 (10%) (5 mL) and finally with brine (5 mL). The organic layers were 
combined, dried (MgSO4) concentrated and left over night in vacuo. The crude product 



























The title compound was synthesized according to procedure 5.7 via amidation of 2-
carboxybenzimidazole with 5-amino-2-(4'-methoxyphenyl) benzimidazole by reaction 
over 20 h. The product was purified by column chromatography using DCM:MeOH 
(10:l v/v) affording 130 as a brown solid  (0.30 g, 71 %); Mp 301-303 °C. 
1H NMR (400 MHz, DMSO)  3.92 (s, 3H, CH3), 7.16 (d, J = 8.5 Hz, 2H, H3''+H5''), 
7.35-7.45 (bs, 2H, H6'+H7'), 7.62 (d, J = 7.8 Hz, 2H, H5+H6), 7.81  (d, J = 7.8 Hz, 2H, 
H4+H7), 8.21 (d, J = 8.5 Hz, 2H, H2''+H6''), 8.36 (s, 1H, H4'), 11.07 (s, 1H, N-H 
Amide), 13.45-13.63 (bs, 2H, N-H Imidazole). 13C NMR (100 MHz, DMSO)   55.8 
(CH3), 105.9 (CH), 114.9 (2CH), 115.2 (CH), 117.1 (2CH), 120.0 (C), 121.1 (2CH), 
125.2 (C), 128.9 (2CH), 134.2 (CH), 134.4 (C), 135.3 (C), 136.9 (C), 146.1 (2C), 151.3 
(C), 157.5 (C), 161.6 (C=O). IR ȣ max cm -1 1257 (C-N), 1078 (C-O), 1427 (C=C), 1644 
(C=N), 1669 (C=O), 2928 (C-H, aliphatic), 3076 (C-H, aromatic), 3221 (N-H, amide), 







5.7.2 1H-Benzimidazole-2-carboxylica cid(2-pyridin-2-yl-1H-benzimidazol-5- 
yl)-amide (131) 
 
The title compound was synthesized according to procedure 5.7 via amidation of 2-
carboxybenzimidazole with 2-pyridin-2-yl-1H-benzimidazol-5-ylamine by reaction over 
12 days. The product was purified by recrystallization from ethanol affording 131 as a 
pale brown solid (0.27 g, 69%); Mp > 300 °C . 
1H NMR (400 MHz, DMSO)  7.36 (dq, J1 = 7.6, J2 = 7.2 Hz, 2H, H5+H6), 7.53 (dd, J1 = 
9.2, J2 = 2.8 Hz, 1H, H5''), 7.61 (dd, J1 = 7.6, J2 = 3.2 Hz, 1H, H4), 7.69 (s, 1H, H4'), 
7.83 (d, J = 8.0 Hz, 1H, H7'), 8.02 (dd, J1 = 7.6, J2 = 3.2 Hz, 1H, H7), 8.34 (dd, J1 = 8.0, 
J2 = 2.4 Hz, 1H, H6'), 8.31-8.36 (m, 2H, H6'+H4''), 8.39-8.41 (bs, 1H, H3''), 8.75 (d, J = 
2.8, 1H, H6''), 10.94 (s, 0.6 H, N-H Amide), 10.99 (s, 1H, O-H Iminol), 13.15 (s, 1H, N-
H Imidazole), 13.46 (s, 1H, N-H Iminol), 13.49 (s, 0.7 H, N-H Imidazole). 13C NMR (75 
MHz, DMSO) 105.2 (CH), 113.5 (C), 114.7 (CH), 116.6 (2CH), 121.1 (CH), 123.6 
(2CH), 124.4 (CH), 130.7 (CH), 137.3 (CH), 138.3 (2C), 138.8 (C), 140.8 (C), 142.2 
(C), 145.3 (C), 147.9 (CH), 150.8 (C), 157.6 (C=O). IR ȣ max cm -1 1280 (C-N), 1097 (C-
O), 1490 (C=C), 1636 (C=N), 1670 (C=O), 3058 (C-H, aromatic), 3221 (N-H, amide), 
3355 (N-H, amine). HRMS: (ES) m/z (MH)+  obsd. 355.1288, calcd. 355.1302 for 
C20H15N6O. 
 
 5.7.3 (2-Amino-benzimidazol-1-yl)-(1H-benzimidazol-2-yl)methanone (133) 
 
The title compound was synthesized according to procedure 5.7 via amidation of 2-
carboxybenzimidazole with 2-aminobenzimidazole by reaction over 11 days. The 
product was purified by recrystallization from ethanol affording 133 as a pale yellow 
solid (0.20 g, 66%); Mp > 300 °C . 
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1H NMR (400 MHz, DMSO)  3.65-4.68 (br, 2H, NH2), 7.08 (dd, J1 = 6.0, J2 = 3.2 Hz, 
2H, H5+H6), 7.24 (dd, J1 = 6.0, J2 = 2.8 Hz, 2H, H5'+H6'), 7.43 (dd, J1 = 6.0, J2 = 3.2 
Hz, 2H, H4+H7), 7.63 (dd, J1 = 8.8, J2 = 4.4 Hz, 2H, H4'+H7'). 13C NMR (75 MHz, 
DMSO)  113.3 (2CH),  116.6 (2CH), 120.8 (2CH), 122.9 (2CH), 135.9 (2C), 139.6 (C), 
150.5 (C), 154.1 (C), 154.2 (C), 163.1 (C=O). IR ȣ max cm -1 1275 (C-N), 1060 (C-O), 
1472 (C=C), 1628 (C=N), 1670 (C=O), 3056 (C-H, aromatic), 3350 (N-H, amine). 
HRMS: (ES) m/z (MH)+  obsd. 278.1044, calcd. 278.1036  for C15H12N5O. 
 
5.7.4  2-Trifluoromethyl-1H-benzimidazole-5-carboxylic acid [4-(1H-
benzimidazol-2-y1)-cyclohexylmethyl]-amide (138)  
 
The title compound was synthesized according to procedure 5.7 via amidation of 2-
(trifluoromethyl)-1H-benzimidazole-5-carboxylic acid with 4-(1-H-benzimidazol-2-yl) 
cyclohexyl)methanamine by reaction over 2 days. The product was purified by 
recrystallization from ethanol: water (3:1 v/v)  affording 138 as a pale yellow solid (0.33 
g, 68 %); Mp 259-260 °C. 
1H NMR (400 MHz, DMSO) 1.16 (qd, J1 = 10.8, J2 = 2.2 Hz, 2H, Hc), 1.59 (qd, J1 = 
10.8, J2 = 2.2 Hz, 2H, He), 1.67-1.71 (m, 1H, Ha), 1.92 (dq, J1 = 12.0, J2 = 0.7 Hz, 2H, 
Hd), 2.11 (dq, J1 = 12.0, J2 = 0.7 Hz, 2H, Hb), 2.82 (tt, J1 = 10.8, J2 = 0.4 Hz, 1H, Hf), 
3.23 (t, J = 6.4 Hz, 2H, CH2), 7.11 (d, J = 6.0 Hz, 2H, H5'+H6'), 7.43-7.51 (bs, 2H, 
H4'+H7'), 7.78 (d, J = 8.4 Hz, 1H, H7), 7.94 (d, J = 8.4 Hz, 1H, H6), 8.28 (s, 1H, H4), 
8.65 (s, 1H, N-H Amide), 11.85-12.55 (br, 1H, N-H Imidazole), 13.90-14.60 (br, 1H, N-
H Imidazole). 13C NMR (75 MHz, DMSO) 30.5 (2CH2), 31.2 (2CH2), 37.5 (CH), 38.2 
(CH), 45.9 (CH2), 114.7 (2CH), 117.4 (C), 120.6 (C), 121.0 (CH), 121.5 (2CH), 123.9 
(CH), 125.7 (CH), 131.1 (2C), 141.7 (C), 142.3 (C,CF3, JCF = 39.2 Hz), 159.0 (C), 159.1 
(C), 166.5 (C=O). IR ȣ max cm -1 612 (C-F), 1274 (C-N),  1046 (C-O), 1422 (C=C), 1620 
(C=N), 1625 (C=O), 2876 (C-H, aliphatic), 3020 (C-H, aromatic), 3330 (N-H, amide), 
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methanone (139)  
 
The title compound was synthesized according to procedure 5.7 via amidation of 2-(4'-
carboxyphenyl)-5-nitrobenzimidazole with 2-aminobenzimidazole by reaction over 8 
days. The product was purified by column chromatography using DCM:MeOH (15:l 
v/v) affording 139 as a pale yellow solid  (0.28 g, 65 %); Mp > 300 °C . 
1H NMR (400 MHz, DMSO) 7.18 (dd, J1 = 5.6, J2 = 3.2 Hz, 2H, H5'+H6'), 7.48 (dd, J1 
= 5.4, J2 = 2.7 Hz, 2H, H4'+H7'), 7.84 (d, J = 8.9 Hz, 1H, H7), 8.17 (d, J = 9.0 Hz, 1H, 
H6), 8.30-8.47 (br, 2H, NH2), 8.30-8.48 (bs, 4H, H2''+H3''+H5''+H6''), 8.60 (s, 1H, H4), 
12.28-12.51 (br, 1H, N-H Imidazole). 13C NMR (75 MHz, DMSO) 112.4 (CH), 113.2 
(2CH), 115.4 (C), 118.8 (CH), 122.2 (2CH), 122.3 (C), 127.2 (2CH), 129.4 (2CH), 
132.0 (CH), 133.2 (2C), 137.7 (C), 143.2 (2C), 144.6 (C), 150.4 (C), 169.4 (C=O). IR ȣ 
max cm -1 740 (N-O), 1298 (C-N),  1107 (C-O), 1421 (C=C), 1603 (C=N), 1630 (C=O), 
3092 (C-H, aromatic), 3100 (N=O), 3366 (N-H, amine). HRMS: (ES) m/z (MH)+  obsd. 
399.1210, calcd. 399.1200 for C21H15N6O3. 
 
5.7.6 4-(5-Nitro-1H-benzimidazol-2-yl)-N-(2-pyridin-2-yl-1H- 
          benzimidazol-5-yl)-benzamide (140) 
 
The title compound was synthesized according to procedure 5.7 via amidation of 2-(4'-
carboxyphenyl)-5-nitrobenzimidazole with 2-pyridin-2-yl-1H-benzimidazol-5-ylamine 
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by reaction over 8 days. The product was purified by recrystalization from ethanol 
affording 140 as a brown solid (0.38 g, 72%); Mp > 300 °C . 
1H NMR (400 MHz, DMSO)  7.46 (dd, J1 = 8.0, J2 = 5.2 Hz, 1H, H5''), 7.58 (d, J = 8.8 
Hz, 1H, H7'), 7.71 (d, J = 7.8 Hz, 1H, H3''), 7.76 (d, J = 8.8 Hz, 1H, H6'), 7.90 (t, J = 7.8 
Hz, 1H, H4''), 8.13 (d, J = 7.2 Hz, 1H,  H7), 8.16 (d, J = 7.2 Hz, 1H, H6), 8.20 (d, J = 
7.6 Hz, 2H, H3'''+H5'''), 8.24 (d, J = 7.6 Hz, 2H, H2'''+H6'''), 8.41 (s, 1H, H4'), 8.48 (s, 
1H, H4), 8.49-8.51 (bs, 1H, N-H Imidazole), 8.66 (d, J = 5.2 Hz, 1H, H6''), 10.29 (s, 1H, 
N-H Amide). 13C NMR : There were no peaks for 13C on NMR, as the tested sample did 
not dissolve in DMSO. IR ȣ max cm -1 795 (N-O), 1267 (C-N),  1065 (C-O), 1444 (C=C), 
1647 (C=N), 1654 (C=O), 3065 (C-H, aromatic), 3266 (N=O), 3364 (N-H, amide), 3400 




         benzimidazol-2-yl)-benzamide (141) 
 
The title compound was synthesized according to procedure 5.7 via amidation of 2-(4'-
carboxyphenyl)-5-nitrobenzimidazol with 4-(1-H-benzimidazol-2-yl) cyclohexyl)methan 
amine by reaction over 6 days. The product was purified by recrystalization from 
acetone affording 141 as a pale yellow solid (0.38 g, 70%); Mp  >300 °C. 
1H NMR (400 MHz, DMSO)  1.16 (qd, J1 = 11.6, J2 = 1.2 Hz, 2H, Hc), 1.56-1.65 (m, 
1H, Ha), 1.60 (qd, J1 = 11.6, J2 = 1.2 Hz, 2H, He), 1.93 (dq, J1 = 10.8, J2 = 0.3 Hz, 2H, 
Hd ), 2.11 (dq, J1 = 10.8, J2 = 0.3 Hz, 2H, Hb), 2.82 (tt, J1 = 12.0, J2 = 1.0 Hz, 1H, Hf), 
3.23 (t, J = 6.0 Hz, 2H, CH2), 7.11 (d, J = 6.0 Hz, 2H, H5'+H6'), 7.46-7.47 (bs, 2H, 
H4'+H7'), 7.62 (d, J = 8.8 Hz, 1H, H7), 7.95-8.11 (m, 3H, H2''+H6''+H4), 8.25 (d, J = 
8.8 Hz, 1H, H6), 8.41(d, J = 6.0 Hz, 2H, H3''+H5''), 8.5 (s, 1H, N-H Imidazole)  8.62 (t, 
 162
J = 5.6 Hz, 1H, N-H Amide), 11.96-12.39 (br, 1H, N-H Imidazole). 13C NMR (75 MHz, 
DMSO) 30.5 (2CH2), 31.2 (2CH2), 37.5 (CH), 38.3 (CH), 45.8 (CH2), 112.8 (CH), 115.4 
(CH), 116.5 (2CH), 121.4 (2CH), 126.6 (CH), 127.1 (2CH), 127.9 (2CH), 129.9 (C), 
135.4 (2C), 141.2 (C), 143.3 (C), 148.7 (C), 159.1 (C), 160.4 (C), 166.3 (C), 169.7 
(C=O). IR ȣ max cm -1 740 (N-O), 1250 (C-N), 1064 (C-O), 1432 (C=C), 1634 (C=N), 
1636 (C=O), 2925 (C-H, aliphatic), 3064 (C-H, aromatic), 3286 (N=O), 3310 (N-H, 
amide), 3410 (N-H, amine). HRMS: (ES) m/z (MH)+  obsd. 495.2134, calcd. 495.2139 
for C28H27N6O3. 
 
5.7.8 N,N'-Bis(1H-benzimidazole-2-carbonyl)-p-xylylenediamine (146) 
 
The title compound was synthesized according to procedure 5.7 via amidation of 
benzimidazole-2-carboxylic acid by using p-xylenediamine over 8 days. The product 
was purified by column chromatography using DCM: MeOH (15:l) affording 146 as a 
white solid  (1.27 g, 60  % yield); Mp > 300 °C. 
1H NMR (400 MHz, DMSO) į 4.48 (d, J = 6.0 Hz, 4H, 2 CH2), 7.31 (s, 4H, 
H2'+H3'+H5'+H6'), 7.53 (d, J = 7.6 Hz, 4H, H5+H6), 7.72 (d, J = 7.6 Hz, 4H, H4+H7), 
9.53 (t, J = 6.0 Hz, 2H, N-H Amide), 13.27 (s, 2H, N-H Imidazole). 13C NMR (100 
MHz, DMSO) 42.4 (2CH2), 112.9 (2CH), 115.6 (2CH), 120.2 (2CH), 122.9 (2CH), 
124.5 (2CH), 127.7 (2CH), 129.9 (2C), 134.8 (C), 138.2 (C), 142.9 (2C), 145.9 (2C), 
159.2 (2C=O). IR ȣ max cm -1 1281 (C-N), 1114 (C-O), 1446 (C=C), 1622 (C=N), 1661 
(C=O), 2931 (C-H, aliphatic), 3070 (C-H, aromatic), 3222 (N-H, amide), 3391 (N-H, 
amine). HRMS: (ES) m/z (MH)+  obsd. 425.1723, calcd. 425.1726 for C24H21N6O2. 
 




The title compound was synthesized according to procedure 5.7 via amidation of 5-nitro-
1H-benzimidazole-2-carboxylic acid by using p-xylenediamine over 14 days. The 
product was purified by column chromatography using DCM: MeOH (15:l) affording 
147 as a pale brown solid  (1.49 g, 58  % yield); Mp > 300 °C. 
1H NMR (400 MHz, DMSO) į 4.49 (d, J = 6.4 Hz, 4H, 2 CH2), 7.33 (s, 4H, 
H2'+H3'+H5'+H6'), 7.42 (s, 2H, H4), 7.77-7.85 (br, 2H, N-H Imidazole), 8.22 (d, J = 7.8 
Hz, 2H, H7), 8.52-8.61 (m, 2H, H6), 9.77 (t, J = 6.4 Hz, 2H, N-H Amide). 13C NMR : 
There were no peaks for 13C on NMR, as the tested sample did not dissolve in DMSO. 
IR ȣ max cm -1 823 (N-O), 1261 (C-N), 1065 (C-O), 1441 (C=C), 1624 (C=N), 1664 
(C=O), 2851 (C-H, aliphatic), 2918 (C-H, aromatic), 3090 (N=O), 3179 (N-H, amide), 
3381 (N-H, amine). HRMS: (ES) m/z (MH)+  obsd. 515.1439, calcd. 515.1427 for C24H19 
N8O6. 
 
5.7.10 N,N'-Bis(5-chloro-1H-benzimidazole-2-carbonyl) ethylenediamine 
(150) 
 
The title compound was synthesized according to procedure 5.7 via amidation of 5-
chloro-1H-benzimidazole-2-carboxylic acid by using ethylenediamine over 6 days. The 
product was purified by recrystallization from ethanol affording 150 as an off brown 
solid (0.98 g, 47 % yield); Mp 298-300 °C. 
1H NMR (400 MHz, DMSO) į 3.55 (s, 4H, 2 CH2), 7.32 (dd, J1 = 8.4, J2 = 1.6 Hz, 2H, 
H6), 7.54 (d, J = 1.6, 2H, H4), 7.75 (d, J = 8.4 Hz, 2H, H7), 7.96 (s, 2H, N-H 
Imidazole), 9.22 (s, 2H, N-H Amide). 13C NMR (100 MHz, DMSO) 40.5 (2CH2), 112.5 
(2CH), 114.3 (2CH), 119.5 (2CH), 121.6 (2C), 123.4 (2C), 124.7 (2C), 147.0 (2C),  
159.0 (2C=O). IR ȣ max cm -1 803 (C-Cl), 1246 (C-N), 1057 (C-O), 1425 (C=C), 1656 
(C=N), 1659 (C=O), 2961 (C-H, aliphatic), 3183 (C-H, aromatic), 3333 (N-H, amide), 




5.7.11 N,N'-Bis(1H-benzimidazole-5-carbonyl)ethylenediamine (151) 
 
The title compound was synthesized according to procedure 5.7 via amidation of 
benzimidazole-5-carboxylic acid by using ethylenediamine over 5 days. The product 
was purified by recrystallization from ethanol affording 151 as a pale brown solid (0.05 
g, 57 % yield); Mp > 300 °C. 
1H NMR (400 MHz, DMSO) į 3.50 (s, 4H, 2 CH2), 7.57 (d, J = 8.0 Hz, 2H, H6), 7.72 
(d, J = 10.0 Hz, 1H, N-H Imidazole), 7.79 (d, J = 8.0 Hz, 2H, H7), 8.08 (s, 2H, N-H 
Imidazole), 8.25 (s, 2H, H4), 8.34 (d, J = 10.0 Hz, 2H, H2), 8.61 (s, 1H, N-H Amide), 
8.65 (s, 1H, N-H Amide). 13C NMR (100 MHz, DMSO) į 40.2 (2CH2), 111.7 (2CH), 
118.6 (2CH), 121.1 (2CH), 122.4 (2C), 125.9 (2C), 128.4 (2CH), 143.8 (2C), 167.7 
(2C=O). IR ȣ max cm -1 1253 (C-N), 1055 (C-O), 1448 (C=C), 1608 (C=N), 1630 (C=O), 
2945 (C-H, aliphatic), 3229 (C-H, aromatic), 3395 (N-H, amide), 3488 (N-H, amine). 
HRMS: (ES) m/z (MH)+  obsd. 349.1402, calcd. 349.1413 for C18H17N6O2. 
 
5.7.12 [4-(2-Amino-benzimidazole-1-carbonyl)-phenyl]-(2-amino-
benzimidazol-1-yl)-methanone (152)    
 
The title compound was synthesized according to procedure 5.7 via amidation of 2-
aminobenzimidazole by using terephthalic acid over 14 days. The product was purified 
by by column chromatography using DCM: MeOH (10:l) affording 152 as a pale yellow 
solid (0.26 g, 60 % yield); Mp > 300 °C. 
1H NMR (400 MHz, DMSO) į 3.25-3.69 (br, 4H, 2 NH2), 7.32 (dd, J1 = 4.8, J2 = 2.0 
Hz, 4H, H5+H6), 7.62 (dd, J1 = 5.2, J2 = 3.2 Hz, 4H, H4+H7), 8.35 (s, 4H, H2'+H3' 
+H5'+H6'). 13C NMR (100 MHz, DMSO) į 113.4 (4CH), 124.7 (4C), 128.8 (4CH), 
128.9 (4CH), 135.9 (2C), 144.1 (2C), 165.6 (2C=O). IR ȣ max cm -1 1271 (C-N), 1040 
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(C-O), 1428 (C=C), 1635 (C=N), 1664 (C=O), 3030 (C-H, aromatic), 3358 (N-H, 





The title compound was synthesized according to procedure 5.7 via amidation of 4-(1-H-
benzimidazol-2-yl)cyclohexyl)methanamine by using terephthalic acid over 8 days. The 
product was purified by column chromatography using DCM: MeOH (8:l) affording 153 
as a beige solid (0.42 g, 65 % yield); Mp > 300 °C. 
1H NMR (400 MHz, DMSO) į 1.12-1.22 (m, 2H, Ha), 1.17 (qd, J1 = 12.4, J2 = 3.2 Hz, 
4H, Hc), 1.68 (qd, J1 = 12.4, J2 = 3.2 Hz, 4H, He), 1.94 (dq, J1 = 11.2, J2 = 1.2 Hz, 4H, 
Hd ), 2.19 (dq, J1 = 11.2, J2 = 1.2 Hz, 4H, Hb), 3.14-3.22 (m, 6H, Hf+2CH2), 7.53 (dd, J1 
= 6.4, J2 = 3.2 Hz, 4H, H5+H6), 7.78 (dd, J1 = 6.4, J2 = 3.2 Hz, 4H, H4+H7), 7.94 (s, 
4H, H2'+H3'+H5'+H6'), 8.66 (t, J = 6.0 Hz, 2H, N-H Amide),. 13C NMR (100 MHz, 
DMSO) į 29.4 (4CH2), 29.5 (4CH2), 35.9 (2CH), 36.6 (2CH), 45.2 (2CH2), 113.8 
(4CH), 125.4 (4CH), 127.1 (4CH), 130.9 (4C), 136.7 (2C), 157.4 (2C), 165.7 (2C=O). 
IR ȣ max cm -1 1294 (C-N), 1076 (C-O), 1431 (C=C), 1620 (C=N), 1636 (C=O), 2922 (C-
H, aliphatic), 3085 (C-H, aromatic), 3283 (N-H, amide), 3390 (N-H, amine). HRMS: 












The title compound was synthesized according to procedure 5.7 via amidation of 2-(4'-
Carboxyphenyl)-5-carboxybenzimidazole by using 4-(1-H-benzimidazol-2-yl) cyclo 
hexyl)methanamine over 12 days. The product was purified by recrystallization from 
ethanol affording 156 as a pale brown solid (0.54 g, 70 % yield); Mp > 300 °C. 
1H NMR (400 MHz, DMSO)  1.16 (qd, J1 = 12.0, J2 = 2.2 Hz, 4H, Hc+Hc'), 1.55-1.70 
(m, 2H, Ha+Ha'), 1.61 (qd, J1 =12.0, J2 = 2.2 Hz, 4H, He+He'), 1.93 (dq, J1 = 12.2, J2 = 
0.7 Hz, 4H, Hd+Hd' ), 2.11 (dq, J1 = 12.2, J2 = 0.7 Hz, 4H, Hb+Hb'), 2.83 (tt, J1 = 12.0, J2 
= 0.4 Hz, 2H, Hf+Hf'), 3.23 (t, J = 5.6 Hz, 4H, 2CH2), 7.11 (dd, J1 =  6.0, J2 = 3.2 Hz, 
4H, H5'+H6'+H5'''+H6'''), 7.44-7.49 (m, 4H, H4'+H7'+H4'''+H7'''), 7.62 (d, J = 8.0 Hz, 
1H, H6), 7.72 ( d, J = 8.0 Hz, 1H, H7), 8.03 (d, J = 8.4 Hz, 2H, H2''+H6''), 8.15 (s, 1H, 
H4),  8.33 (d, J = 8.4 Hz, 2H, H3''+H5''), 8.47 (t, J = 5.4 Hz, 1H, N-H Amide), 8.64 (t, J 
= 5.4 Hz, 1H, N-H Amide), 12.08-12.33  (br, 3H, N-H Imidazole). 13C NMR (100 MHz, 
DMSO)  29.1 (4CH2), 29.7 (4CH2), 36.1 (2CH), 36.8 (2CH), 44.4 (2CH2), 109.7 (CH), 
116.9 (CH), 119.9 (2CH), 120.3 (2CH), 124.6 (C),  125.1 (2C), 125.3 (2CH), 126.7 
(2CH), 127.4 (2CH), 131.8 (CH), 134.3 (2CH), 138.8 (C), 140.9 (C), 147.2 (C), 149.8 
(C), 152.0 (2C), 154.9 (C), 157.7 (2C) 164.7 (C=O), 165.8 (C=O). IR ȣ max cm -1 1233 
(C-N), 1044 (C-O), 1452 (C=C), 1615 (C=N), 1622 (C=O), 1636 (C=O), 2852 (C-H, 
aliphatic), 2923 (C-H, aromatic), 3330 (N-H, amide), 3395 (N-H, amine). HRMS: (ES) 





carboxylic acid (1H-benzimidazol-2-yl)-amide (157) 
 
The title compound was synthesized according to procedure 5.7 via amidation of 2-(4'-
carboxyphenyl)-5-carboxybenzimidazole by using 2-aminobenzimidazole over 13 days. 
The product was purified by column chromatography using DCM:MeOH (15:l v/v) 
affording 157 as a pale yellow solid (0.42 g, 75 % yield); Mp > 300 °C. 
1H NMR (400 MHz, DMSO) 7.14-7.19 (m, 4H, H5'+H6'+H5'''+H6'''), 7.49 (dd, J1 = 6.0, 
J2 = 2.8 Hz, 4H, H4'+H7'+H4'''+H7'''), 7.70 (d, J = 8.8 Hz, 1H, H2''), 7.82 (d, J = 8.4 Hz, 
1H, H3''), 8.08 (d, J = 8.4 Hz, 1H, H5''), 8.12 (d, J = 8.8 Hz, 1H, H6''), 8.36 (d, J = 7.2 
Hz, 2H, H6+H7), 8.39 (s, 1H, H4), 8.41 (s, 1H, N-H Amide), 8.58 (s, 1H, N-H Amide),  
12.29-12.39 (bs, 3H, N-H Imidazole). 13C NMR (100 MHz, DMSO) 111.7 (CH), 112.7 
(CH), 113.3 (CH), 118.5 (C), 118.9 (2CH), 120.1 (2C), 121.7 (2CH), 122.2 (2CH), 
122.9 (C) 123.9 (C), 126.8 (2CH), 126.9 (2CH), 129.4 (2CH), 132.8 (C), 135.1 (C), 
138.3 (C), 143.8 (2C), 146.9 (2C), 152.7 (C=O), 153.6 (C=O). IR ȣ max cm -1 1227 (C-
N), 1026 (C-O), 1420 (C=C), 1629 (C=N), 1653 (C=O), 1664 (C=O), 3069 (C-H, 
aromatic), 3390 (N-H, amide), 3534 (N-H, amine). HRMS: (ES) m/z (MH)+  obsd. 






The title compound was synthesized according to procedure 5.7 via amidation of 2-(4'-
carboxyphenyl)-5-carboxybenzimidazole by using 5-amino-2-(2',4'-dimethoxyphenyl) 
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benzimidazole over 14 days. The product was purified by recrystallization from ethanol 
affording 158 as a brown solid (0.51 g, 59 %); Mp > 300 °C. 
1H NMR (400 MHz, DMSO) 3.94 (s, 6H, 2CH3), 4.11 (s, 6H, 2CH3),  6.89-6.91 (m, 4H, 
Hx+H4'+H4'''), 7.70-7.89 (m, 6H, H3''+H5''+H6'+H3''''+H5''''+H6'''),  7.98 (d, J = 8.4 Hz, 
2H, H6''+H6''''), 8.25 (q, J = 8.4 Hz, 3H, Hy+H6), 8.39-8.40 (bs, 1H, H4), 8.44 (d, J = 
8.4 Hz, 1H, H7), 8.61 (d, J = 8.2 Hz, 2H, H7'+H7'''), 10.69 (s, 1H, N-H Amide), 10.79 
(s, 1H, N-H Amide), 13.97-14.61 (br, 2H, N-H Imidazole). 13C NMR (100 MHz, 
DMSO) 54.9 (2CH3), 55.3 (2CH3), 97.9 (2CH), 102.9 (C), 103.1 (CH), 103.3 (CH), 
106.2 (2CH), 112.6 (2CH), 112.7 (2CH), 116.9 (2CH), 117.4 (C), 117.8 (CH) 121.5 (C), 
125.5 (2CH), 127.4 (2CH), 130.2 (2CH), 130.7 (C),  131.2 (C), 134.7 (2C), 135.6 (2C), 
136.1 (2C), 145.0 (2C), 145.2 (2C), 151.2 (C), 158.4 (2C), 163.6 (2C), 163.9 (C=O), 
164.9 (C=O). IR ȣ max cm -1 1266 (C-N), 1086 (C-O), 1437 (C=C), 1610 (C=N), 1640 
(C=O), 1653 (C=O), 2851 (C-H, aliphatic), 3043 (C-H, aromatic), 3400 (N-H, amide), 







The title compound was synthesized according to procedure 5.7 via amidation of 2-(4'-
carboxyphenyl)-5-carboxybenzimidazole by using 2-(aminomethyl)-1H-benzimidazole 
over 14 days. The product was purified by column chromatography using DCM:MeOH 
(15:l v/v) affording 159 as a pale brown solid (0.33 g, 55 %); Mp 290-292 °C. 
1H NMR (400 MHz, DMSO) 4.73 (d, J = 5.6 Hz, 4H, 2CH2), 7.14-7.15 (m, 4H, 
H5'+H6'+H5'''+H6'''), 7.50 (dd, J1 = 8.6, J2 = 1.2 Hz, 4H, H4'+H7'+H4'''+H7'''), 7.63 (d, J 
= 1.2 Hz, 1H, H4), 7.77 (d, J = 8.8 Hz, 1H, H7), 7.88 (dd, J1 = 8.8, J2 = 1.2 Hz, 1H, H6), 
8.14 (d, J = 8.0 Hz, 2H, H2''+H6''), 8.17 (s, 1H, N-H Imidazole), 8.31-8.36 (m, 4H, 
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H3''+H5''+N-H Imidazole), 9.19 (t, J = 5.6 Hz, 1H, N-H Amide), 9.34 (t, J = 5.6 Hz, 1H, 
N-H Amide). 13C NMR (100 MHz, DMSO) 37.9 (2CH2), 99.5 (2C), 111.2 (2CH), 118.3 
(2CH), 121.0 (2CH), 121.8 (2CH), 122.5 (C), 122.8 (C), 126.5 (2CH), 128.2 (2CH), 
132.3 (CH), 134.3 (CH), 134.7 (C), 135.1 (C), 143.1 (CH), 143.3 (C),  146.7 (C), 152.2 
(2C), 152.6 (2C), 165.9 (C=O), 166.9 (C=O). IR ȣ max cm -1 1271 (C-N), 1054 (C-O), 
1443 (C=C), 1622 (C=N), 1640 (C=O), 1647 (C=O), 2852 (C-H, aliphatic), 3054 (C-H, 
aromatic), 3379 (N-H, amide), 3555 (N-H, amine). HRMS: (ES) m/z (MH)+  obsd. 





The title compound was synthesized according to procedure 5.7 via amidation of 5-nitro-
1H-benzimidazole-2-carboxylic acid by using 2(4’-aminophenyl)-1H-benzimidazol-5-
ylamine over 17 days. The product was purified by column chromatography using 
DCM: MeOH (15:l) affording 162 as a brown solid  (0.53 g, 58  % yield); Mp > 300 °C. 
1H NMR (300 MHz, DMSO) į 6.04-6.56 (br, 2H, NH2), 6.76 (d, J = 8.7 Hz, 2H, 
H2''+H6''), 7.70 (d, J = 8.7 Hz, 1H, H7), 7.79 (dd, J1 = 8.8, J2 = 0.9 Hz, 1H, H6'), 7.97 
(d, J = 8.7 Hz, 2H, H3''+H5''), 8.25 (dd, J1 = 8.7, J2 = 0.9 Hz, 2H, H6+H7'), 8.43 (d, J = 
0.9 Hz, 1H, H4), 8.63-8.69 (bs, 1H, H4'), 11.43 (s, 1H, N-H Amide), 14.12-14.28 (bs, 
2H, N-H Imidazole). 13C NMR (100 MHz, DMSO) 99.5 (C), 104.6 (2CH), 113.4 (2CH), 
113.6 (2CH), 118.2 (2CH), 120.7 (C), 129.4 (2CH), 129.6 (C), 134.0 (C), 134.9 (C), 
150.5 (2C), 150.6 (2) 153.5 (2C), 156.6 (C=O). IR ȣ max cm -1 736 (N-O), 1232 (C-N), 
1062 (C-O), 1473 (C=C), 1604 (C=N), 1630 (C=O), 3060 (C-H, aromatic), (N=O) 3281, 
3338 (N-H, amide), 3447 (N-H, amine). HRMS: (ES) m/z (MH)+  obsd. 414.1309, calcd. 
414.1309 for C21H16N7O3. 
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5.7.19 5-Nitro-1H-benzimidazole-2-carboxylic acid (2-{4-[(1H-benzimidazol-
5-carbonyl)-amino]-phenyl}-1H-benzimidazol-5-yl)-amide (163) 
 
The title compound was synthesized according to procedure 5.7 via amidation of 5-
Nitro-1H-benzoimidazole-2-carboxylic acid[2-(4-amino- phenyl)-1H-benzoimidazol-5-
yl]-amide 162 by using benzimidazole-5-carboxylic acid over 12 days. The product was 
purified by column chromatography using DCM: MeOH (12:l) affording 163 as a brown 
solid  (0.59 g, 53 % yield); Mp > 300 °C. 
1H NMR (400 MHz, DMSO) į 6.77 (d, J = 8.8 Hz, 1H, H7''), 7.71 (dd, J1 = 8.8, J2 = 2.0 
Hz, 1H, H6''), 7.78 (d, J = 8.4 Hz, 1H, H7), 7.81-8.03 (m, 3H, H4'', H6, H4), 8.09 (d, J = 
8.8 Hz, 1H, H7'), 8.17 (d, J = 9.2 Hz, 1H, H2''), 8.22 (d, J = 8.4 Hz, 2H, H2'''+H6'''), 
8.42 (d, J = 8.4 Hz, 2H, H3'''+H5'''), 8.64 (dd, J1 = 8.8, J2 = 2.0 Hz, 2H, H4'+H6'), 10.66 
(s, 1H, N-H Amide), 11.30 (d, J = 9.2 Hz, 1H, N-H Imidazole), 11.43 (s, 1H, N-H 
Amide), 14.11-14.25 (bs, 1H, N-H Imidazole). 13C NMR : There were no peaks for 13C 
on NMR, as the tested sample did not dissolve in DMSO. A large amount of precipitate 
was observed in the tube. IR ȣ max cm -1 734 (N-O), 1242 (C-N), 1064 (C-O), 1471 
(C=C), 1599 (C=N), 1622 (C=O), 1659 (C=O), 3075 (C-H, aromatic), (N=O) 3185, 
3333 (N-H, amide), 3389 (N-H, amine). HRMS: (ES) m/z (MH)+  obsd. 558.1649, calcd. 
558.1638 for C29H20N9O4. 
 
5.8 4-(5-Amino-1H-benzimidazol-2-yl)-N-[4-(1H-benzimidazol-2-yl)-
cyclohexylmethyl-benzamide (154)    
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The title compound was synthesized from reduction of N-[4-(1H-benzimidazol-2-yl)-
cyclohexylmethyl]-4-(5-nitro-1H-benzimidazol-2-yl)-benzamide 141 according to 
method 5.4 over 5 days. The crude product was purified by column chromatography 
DCM: MeOH (10:1) affording 154 as a brown solid in (0.97 g, 60 %); Mp 298-300 °C. 
1H NMR (400 MHz, DMSO)  1.16 (qd, J1 = 11.6, J2 = 1.2 Hz, 2H, Hc), 1.24-1.29 (m, 
1H, Ha), 1.62 (qd, J1 = 11.6, J2 = 1.2 Hz, 2H, He), 1.93 (dq, J1 = 11.2, J2 = 0.7 Hz, 2H, 
Hd ), 2.13 (dq, J1 = 11.2, J2 = 0.7 Hz, 2H, Hb), 2.87-2.91 (bs, 1H, Hf), 3.22 (t, J = 6.0 Hz, 
2H, CH2),  6.63 (d, J = 8.8 Hz, 1H, H7),  6.77 (s, 1H, H4), 7.18 (dd, J1 =  6.0, J2 = 3.2 
Hz, 2H, H5'+H6'), 7.35 (d, J = 8.8 Hz, 1H, H6),  7.52 ( dd, J1 = 6.0, J2 = 3.2 Hz, 2H, 
H4'+H7'), 8.00 (d, J = 8.4 Hz, 2H, H3''+H5''), 8.17 (d, J = 8.4 Hz, 2H, H2''+H6''), 8.63 
(t, J = 5.6 Hz, 1H, N-H Amide). 13C NMR (100 MHz, DMSO) į 29.9 (2CH2), 30.6 
(2CH2), 35.8 (CH), 37.5 (CH), 45.4 (CH2), 114.3 (CH), 115.8 (CH), 121.8 (2CH), 125.5 
(2CH), 127.3 (2CH), 127.8 (2CH), 129.8 (C), 130.6 (CH), 134.7 (C), 135.9 (C), 137.3 
(C), 138.3 (C), 153.1 (C), 162.3 (C), 165.7 (2C), 166.7 (C=O). IR ȣ max cm –1 1229 (C-
N), 1434 (C=C), 1613 (C=N), 1643 (C=O), 2855 (C-H, aliphatic), 3064 (C-H, aromatic), 
3208 (N-H, amide), 3338 (N-H, amine). HRMS: (ES) m/z (M+2H)2+ obsd 233.1247 
calcd. 233.1241 for C28H28N6O. 
 




The title compound was synthesized according to procedure 5.7 via amidation of 1H-
benzimidazole-2-carboxylic acid by using 4-(5-Amino-1H-benzimidazol-2-yl)-N-[4-
(1H-benzimidazol-2-yl)-cyclohexylmethyl-benzamide 154 over 6 days. The product was 
purified by column chromatography using DCM: MeOH (12:l) affording 164 as a brown 
solid  (0.79 g, 65  % yield); Mp 284-286 °C. 
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1H NMR (400 MHz, DMSO)  1.19 (qd, J1 = 12.0, J2 = 2.2 Hz, 2H, Hc), 1.71 (qd, J1 = 
12.0, J2 = 2.2 Hz, 2H, He), 1.75-1.77 (m, 1H, Ha), 1.97 (dq, J1 = 11.6, J2 = 0.8 Hz, 2H, 
Hd ), 2.21 (dq, J1 = 11.6, J2 = 0.8 Hz, 2H, Hb), 3.16 (tt, J1 = 11.6, J2 = 0.8 Hz, 1H, Hf), 
3.25 (t, J = 6.0 Hz, 2H, CH2), 7.35 (dd, J1 =  5.6, J2 = 2.4 Hz, 1H, H5'), 7.42 (dd, J1 =  
5.6, J2 = 2.4 Hz, 1H, H4'), 7.49 (dd, J1 =  6.0, J2 = 3.2 Hz, 2H, H5''+H6''), 7.55 (dd, J1 =  
8.4, J2 = 2.0 Hz 1H, H6), 7.66 (d, J = 8.4 Hz, 1H, H7), 7.72 (s, 1H, H4), 7.76 (dd, J1 =  
6.0, J2 = 3.2 Hz, 2H, H4''+H7''), 7.82 (dd, J1 = 5.6, J2 = 2.4 Hz, 1H, H6'), 7.99 (d, J = 5.6 
Hz, 1H, H7'), 8.07 (d, J = 8.0 Hz, 2H, H2'''+H6'''), 8.29 (d, J = 8.0 Hz, 2H, H3'''+H5'''), 
8.39 (s, 1H, N-H imidazole), 8.73 (t, J = 6.0 Hz, 1H, N-H Amide), 11.03 (s, 1H, N-H 
Amide), 13.38-13.75 (br, 2H, N-H Imidazole). 13C NMR (100 MHz, DMSO) į 29.5 
(2CH2), 29.7 (2CH2), 36.0 (CH), 36.7 (CH), 43.5 (CH2), 109.6 (CH), 113.8 (2CH), 119.1 
(CH), 119.9 (C), 124.5 (2CH), 125.1 (2CH), 126.2 (2CH), 127.3 (2CH), 127.8 (2CH), 
127.9 (CH), 131.4 (C), 135.5 (2C), 140.7 (C), 143.1 (C), 145.7 (C), 145.9 (C), 154.5 
(2C), 157.4 (C), 157.7 (C), 165.1 (C=O), 165.7 (C=O). IR ȣ max cm –1 1230 (C-N), 1448 
(C=C), 1555 (C=N), 1616 (C=O), 1637 (C=O), 2855 (C-H, aliphatic), 3058 (C-H, 
aromatic), 3214 (N-H, amide), 3361 (N-H, amine). HRMS: (ES) m/z (MH)+  obsd. 
609.2734, calcd. 609.2726 for C36H33N8O2. 
5.10 4-(5-Amino-1H-benzimidazol-2-yl)-N-(2-pyridin-2-yl-1H-benzimidazol-
5-yl)-benzamide (155)  
 
The title compound was synthesized from reduction of 4-(5-nitro-1H-benzimidazol-2-
yl)-N-(2-pyridin-2-yl-1H-benzimidazol-5-yl)-benzamide 140 according to method 5.4 
over 6 days. The crude product was purified by column chromatography DCM: MeOH 
(10:1) affording 155 as a brown solid in (1.09 g, 70 %); Mp > 300 °C. 
1H NMR (400 MHz, DMSO)  6.56 (dd, J1 = 8.8, J2 = 1.6 Hz, 1H, H6), 6.68-6.71 (bs, 
1H, H3''), 7.32 (d, J = 8.8 Hz, 1H, H7), 7.51-7.64 (m, 1H, H5''), 7.96 (s, 1H, H4), 8.04 
(d, J = 8.4 Hz, 2H, H2'''+H6'''), 8.09 (d, J = 8.4 Hz, 1H, H7'), 8.14 (t, J = 8.0 Hz, 1H, 
H4''), 8.17 (d, J = 8.4 Hz, 2H, H3'''+H5'''), 8.22-8.35 (m, 2H, H4'+H6'), 8.74 (dd, J1 = 
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4.8, J2 = 1.2 Hz, 1H, H6''), 10.42 (s, 1H, N-H Amide), 12.42-12.63 (br, 1H, N-H 
Imidazole), 13.07-13.22 (br, 1H, N-H Imidazole). 13C NMR (100 MHz, DMSO) į 105.9 
(CH), 116.9 (CH), 119.0 (CH), 120.8 (CH), 122.4 (C), 124.4 (2CH), 127.8 (CH), 128.6 
(2CH), 129.8 (CH), 130.1 (CH), 133.0 (CH), 135.9 (C), 138.4 (CH), 141.5 (C), 141.7 
(CH), 143.4 (C), 143.5 (C), 147.6 (C), 149.8 (C), 150.4 (C), 155.9 (C), 156.0 (C), 158.7 
(C), 164.4 (C=O). IR ȣ max cm -1  1232 (C-N), 1018 (C-O), 1475 (C=C), 1610 (C=N), 
1638 (C=O), 3058 (C-H, aromatic), 3215 (N-H, amide), 3350 (N-H, amine). HRMS: 
(ES) m/z (MH)+  obsd. 446.1734, calcd. 446.1729 for C26H20N7O. 
 




The title compound was synthesized according to procedure 5.7 via amidation of 1H-
benzimidazole-2-carboxylic acid by using  4-(5-Amino-1H-benzimidazol-2-yl)-N-(2-
pyridin-2-yl-1H-benzimidazol-5-yl)-benzamide 155 over 7 days. The product was 
purified by column chromatography using DCM: MeOH (15:l) affording 165 as a brown 
solid  (0.80 g, 68  % yield); Mp 296-298 °C. 
1H NMR (400 MHz, DMSO)  7.33-7.36 (bs, 2H, H5'''+H6'''), 7.53 (dd, J1 = 7.6, J2 = 4.8 
Hz, 1H, H5''), 7.59 (d, J = 7.6 Hz, 1H, H3''), 7.62-7.68 (m, 2H, H4'''+H7'''), 7.79 (dd, J1 
= 4.8, J2 = 1.6 Hz, 2H, H6''), 8.01 (t, J = 7.6 Hz, 1H, H4''), 8.09 (d, J = 8.4 Hz, 2H, 
H2''''+H6''''), 8.13 (dd, J1 = 8.0, J2 = 1.6 Hz, 1H, H6'), 8.17 (d, J = 8.0 Hz, 1H, H7'), 8.22 
(d, J = 8.4 Hz, 2H, H3''''+H5''''), 8.25-8.29 (bs, 1H, N-H Imidazole), 8.33 (s, 1H, N-H 
Imidazole), 8.34 (d, J = 8.0 Hz, 1H, H7), 8.36 (d, J = 1.6 Hz, 1H, H4'), 8.39 (dd, J1 = 
8.0, J2 = 2.8 Hz, 1H, H6), 8.43 (s, 1H, N-H Amide), 8.75 (d, J = 2.8 Hz, 1H, H4), 10.48 
(s, 1H, N-H Amide). 13C NMR (100 MHz, DMSO) į 106.8 (CH), 113.3 (2CH), 116.3 
(CH), 119.8 (CH), 121.6 (C), 122.3 (C), 123.6 (CH), 123.9 (C), 125.9 (2CH), 126.2 
(CH), 129.8 (2CH), 130.3 (2CH), 133.2 (CH), 133.5 (CH), 135.3 (C), 136.4 (CH), 136.6 
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(CH), 141.6 (C), 142.3 (CH), 145.8 (C), 147.1 (C), 152.0 (C), 154.2 (C), 156.5 (2C), 
157.1 (C), 157.6 (C), 158.9 (C), 164.5 (C=O), 166.6 (C=O). IR ȣ max cm –1 1223 (C-N), 
1071 (C-O), 1447 (C=C), 1611 (C=N), 1650 (C=O), 1664 (C=O), 3068 (C-H, aromatic), 
3203 (N-H, amide), 3372 (N-H, amine). HRMS: (ES) m/z (MH)+  obsd. 590.2065, calcd. 
590.2053 for C34H24N9O2. 
 
5.12 1H,1'H-[5,5']Bibenzimidazolyl-2,2'-diphenyl-4,4'-dicarboxylic acid (167) 
 
The title compound was synthesized by condensation of 3,3'-diaminobenzidine and 4-
carboxybenzaldehyde salt  for 48 h according to procedure 5.2.1 and purified by 
recrystallization from water:ethanol (1:1 v/v) affording 167 as a yellow solid (0.75 g, 79 
%); Mp > 300 °C. 
1H NMR (400 MHz, DMSO) į 7.64 (d, J = 8.4 Hz, 2H, H6), 7.76 (d, J = 8.4 Hz, 2H, 
H7), 7.92 (s, 2H, H4), 8.14 (d, J = 8.0 Hz, 4H, H2'+H6'), 8.34 (d, J = 8.0 Hz, 4H, 
H3'+H5'), 12.48-13.83 (br, 2H, 2COOH). 13C NMR (100 MHz, DMSO) 113.4 (2C), 
116.2 (2CH), 118.9 (2CH), 122.9 (2CH), 126.9 (4CH), 130.4 (4CH), 132.1 (2C), 133.9 
(4C), 136.5 (2C), 151.1 (2C), 167.3 (2 C=O). IR ȣ max cm –1 1292 (C-N), 1050 (C-O), 
1460 (C=C), 1620 (C=N), 1682 (C=O), 3120 (C-H, aromatic), 3360 (N-H, amine) 3450 
(O-H). HRMS: (ES) m/z (MH)+  obsd. 475.1399, calcd. 475.1401 for C28H19N4O4. 
 
5.13 1H,1'H-[5,5']Bibenzimidazolyl-2,2'-diphenyl-4,4'-dicarboxylic acid bis-
{[4-(1H-benzimidazol-2-yl)-cyclohexylmethyl]-amide} (171) 
 
The title compound was synthesized according to procedure 5.7 via amidation of 
1H,1'H-[5,5']bibenzimidazolyl-2,2'-diphenyl-4,4'-dicarboxylic  acid 167 by using 4-(1-
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H-benzimidazol-2-yl)cyclohexyl)methanamine over 14 days. The product was purified 
by recrystallization from ethanol affording 171 as a pale brown solid (0.64 g, 65 % 
yield); Mp > 300 °C. 
1H NMR (400 MHz, DMSO)  1.16 (qd, J1 = 12.0, J2 = 1.2 Hz, 4H, Hc), 1.55-1.68 (m, 
2H, Ha), 1.63 (qd, J1 = 12.0, J2 = 1.2 Hz, 4H, He), 1.93 (dq, J1 = 11.6, J2 = 0.8 Hz, 4H, 
Hd ), 2.11 (dq, J1 = 11.6, J2 = 0.8 Hz, 4H, Hb), 2.83 (tt, J1 = 11.6, J2 = 0.8 Hz, 2H, Hf), 
3.24 (t, J = 6.0 Hz, 4H, 2CH2), 7.10 (dd, J1 =  6.3, J2 = 2.7 Hz, 4H, H5'+H6'), 7.42-7.55 
(m, 4H, H4'+H7'), 7.60 (d, J = 8.1 Hz, 2H, H6), 7.70-7.75 (bs, 2H, H4), 7.86-7.93 (br, 
2H, N-H Imidazole), 8.07 (d, J = 8.4 Hz, 2H, H2''+H6''), 8.18 ( d, J = 8.1 Hz, 2H, H7), 
8.35 (d, J = 8.4 Hz, 2H, H3''+H5''), 8.68 (t, J = 6.0 Hz, 2H, N-H Amide), 12.22 (s, 2H, 
N-H imidazole). 13C NMR (100 MHz, DMSO)  29.0 (4CH2), 29.7 (4CH2), 36.0 (2CH), 
36.8 (2CH), 44.4 (2CH2), 99.5 (2CH), 119.9 (2C), 124.5 (4CH), 125.1 (4CH), 126.8 
(4CH), 128.4 (4CH), 129.3 (2CH), 131.3 (2CH), 134.3 (2C), 140.3 (2C), 149.9 (2C), 
150.9 (2C), 157.7 (4C), 162.3 (2C) 164.6 (2C), 168.2 (2 C=O).  IR ȣ max cm –1 1271 (C-
N), 1070 (C-O), 1460 (C=C), 1616 (C=N), 1635 (C=O), 2852 (C-H, aliphatic), 3033 (C-
H, aromatic), 3193 (N-H, amide), 3405 (N-H, amine). HRMS: (ES) m/z (MH)+  obsd. 






The title compound was synthesized according to procedure 5.7 via amidation of  
1H,1'H-[5,5']bibenzimidazolyl-2,2'-diphenyl-4,4'-dicarboxylic acid 167 by using 2-
aminobenzimidazole over 11 days. The product was purified by column chromatography 
using DCM: MeOH (10:l) affording 172 as a brown solid (0.43 g, 55 % yield); Mp > 
300 °C. 
1H NMR (400 MHz, DMSO) 7.17 (dd, J1 = 6.0, J2 = 2.8 Hz, 4H, H5'+H6'), 7.49 (dd, J1 
= 5.2, J2 = 2.0 Hz, 4H, H4'+H7'), 7.61 (q, J = 8.0 Hz, 2H, H4), 7.71-7.79 (bs, 4H, NH2), 
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7.89-7.97 (bs, 2H, N-H Imidazole), 8.09 (d, J = 8.0 Hz, 2H, H6), 8.19 (d, J = 8.0 Hz, 
2H, H7), 8.34 (d, J = 8.0 Hz, 2H, H2''+H6''), 8.39 (d, J = 8.0 Hz, 2H, H3''+H5''), 12.20-
12.77 (br, 2H, N-H Imidazole) 13C NMR (100 MHz, DMSO) 111.8 (2CH), 116.9 (2C), 
120.5 (4CH), 124.5 (2CH), 125.1 (4CH), 127.9 (4CH), 128.4 (4CH), 129.2 (2CH), 131.8 
(2C), 132.5 (2C), 134.9 (2C), 140.4 (2C), 140.5 (2C), 149.9 (4C), 150.9 (2C), 168.1 (2 
C=O). IR ȣ max cm –1 1270 (C-N), 1015 (C-O), 1470 (C=C), 1620 (C=N), 1630 (C=O), 
3103 (C-H, aromatic), 3378 (N-H, amine). HRMS: (ES) m/z (MH)+  obsd. 705.2546, 
calcd. 705.2542 for C42H29N10O2. 
 
5.15 1H,1'H-[5,5']Bibenzimidazolyl-2,2'-diphenyl-4,4'-dicarboxylic acid bis-
{[2-(2',4'-dimethoxy-phenyl)-1H-benzimidazol-5yl]-amide} (173) 
 
The title compound was synthesized according to procedure 5.7 via amidation of 
1H,1'H-[5,5']bibenzimidazolyl-2,2'-diphenyl-4,4'-dicarboxylic acid 167 by using 5-
amino-2-(2',4'-dimethoxyphenyl) benzimidazole over 11 days. The product was purified 
by recrystallization from ethanol affording 173 as a brown solid (0.75 g, 70 % yield); 
Mp > 300 °C. 
1H NMR (400 MHz, DMSO) 3.88 (s, 6H, 2CH3), 4.05 (s, 6H, 2CH3), 6.73 (dd, J1 = 8.4, 
J2 = 2.0 Hz, 2H, H5''), 6.77 (d, J = 2.0 Hz, 2H, H3''), 7.55 (q, J = 8.4 Hz 6H, 
H4+H6+H7), 7.67 (d, J = 7.6 Hz, 4H, H4'+H7'), 7.87 (s, 2H, N-H Imidazole), 8.04 (d, J 
= 7.8 Hz, 4H, H2'''+H6'''), 8.18 (d, J = 7.8 Hz, 4H, H3'''+H5'''), 8.27(d, J = 8.4 Hz, 2H, 
H6''), 8.43 (dd, J1 = 7.6, J2 = 2.0 Hz, 2H, H6'), 10.39 (s, 2H, N-H Amide), 11.98-12.07 
(br, 2H, N-H Imidazole). 13C NMR (100 MHz, DMSO) 55.9 (2CH3), 56.2 (2CH3), 98.9 
(2CH), 106.6 (2CH), 112.0 (2C), 112.5 (2C), 124.6 (4CH), 126.3 (2CH), 126.7 (2CH), 
128.7 (2CH), 130.1 (4CH), 131.0 (2C), 131.2 (2C), 132.3 (2C), 132.5 (2C), 132.9 
(2CH), 133.8 (2CH), 135.0 (2CH), 136.2 (2C), 136.4 (2CH), 150.9 (2C), 151.4 (2C), 
151.9 (4C), 158.4 (4C), 165.0 (2 C=O). IR ȣ max cm –1 1240 (C-N), 1050 (C-O), 1458 
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(C=C), 1617 (C=N), 1636 (C=O), 2810 (C-H, aliphatic), 3040 (C-H, aromatic), 3235 
(N-H, amide), 3441 (N-H, amine). HRMS: (ES) m/z (MH)+  obsd. 977.3533, calcd. 
977.3524 for C58H45N10O6. 
 
5.16 1H,1'H-[5,5']Bibenzimidazolyl-2,2'-diphenyl-4,4'-dicarboxylic acid bis-
{[(1H-benzimidazol-2-ylmethyl)]-amide} (174) 
 
The title compound was synthesized according to procedure 5.7 via amidation of 
1H,1'H-[5,5']bibenzimidazolyl-2,2'-diphenyl-4,4'-dicarboxylic acid 167 by using 2-
(aminomethyl)-1H-benzimidazole over 20 days. The product was purified by column 
chromatography using DCM: MeOH (15:l) affording 174 as a brown solid (0.42 g, 52 % 
yield); Mp > 300 °C. 
1H NMR (400 MHz, DMSO) 4.77 (t, J = 5.6 Hz, 4H, 2CH2), 7.16 (dd, J1 = 6.0, J2 = 3.2 
Hz, 4H, H5'+H6'), 7.53-7.56 (m, 4H, H4'+H7'), 7.61 (dd, J1 = 8.4, J2 = 2.7 Hz, 2H, H6), 
7.71-7.75 (bs, 2H, N-H Imidazole), 7.89-7.93 (bs, 2H, N-H Imidazole), 8.10 (d, J = 8.4 
Hz, 2H, H7), 8.16 (d, J = 2.7 Hz, 2H, H4), 8.19 (d, J = 8.8 Hz, 4H, H2''+H6''), 8.36 (d, J 
= 8.8 Hz, 4H, H3''+H5''), 9.53 (t, J = 5.6 Hz, 2H, N-H Amide). 13C NMR (100 MHz, 
DMSO) 37.8 (2CH2), 114.9 (2CH), 118.3 (2CH), 125.7 (2CH), 126.2 (4CH), 128.2 
(4CH), 129.6 (4CH), 132.7 (2C), 133.2 (2C), 134.7 (4CH), 137.6 (2C), 138.2 (2C), 
147.1 (2C), 147.4 (2C), 154.4 (2C), 154.7 (4C), 165.9 (2 C=O). IR ȣ max cm –1 1273 (C-
N), 1060 (C-O), 1443 (C=C), 1590 (C=N), 1615 (C=O), 2924 (C-H, aliphatic), 3058 (C-
H, aromatic), 3310 (N-H, amide), 3400 (N-H, amine). HRMS: (ES) m/z (MH)+  obsd. 
733.2776, calcd. 733.2788 for C44H33N10O2. 
 
5.17 1H,1ƍH-[5,5ƍ]Bibenzimidazolyl-2,2ƍ-dicarboxylic acid (166) 81 
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The title compound was synthesized according to method 5.6. One equivalent of 3,3’-
diaminobenzidine was condensed with two equivalents of methyl trichloroacetimidate 
affording 5,5’-bis(2-trichloromethyl-1H-benzimidazole) which was hydrolysed 
affording the corresponding bisbenzimidazolyl-2,2ƍ-dicarboxylic acid 166 as a pale 
yellow  solid (0.82 g, 64 % yield); Mp > 300 °C,  (> 300 °C 81). 
1H NMR (400 MHz, DMSO)  7.79 (dd, 2H, J1 = 8.4, J2 = 1.6 Hz, H6), 7.87 (d, 2H, J = 
8.4 Hz, H7), 8.03 (d, 2H, J = 1.6 Hz, H4), 9.07 (s, 2H, N-H Imidazole), 9.98-10.14 (br, 
2H, 2COOH).  13C NMR (100 MHz, DMSO) į 113.9 (2CH), 115.4 (2CH), 126.5 (2CH), 
128.1 (2C), 131.3 (2C), 134.2 (2C), 153.8 (2C), 166.9 (2 C=O). LRMS: (ES) m/z (MH)+ 
323.3 for C16H21N4O4. 
 
5.18 3H,3ƍH-[5,5ƍ]Bibenzimidazolyl-2,2ƍ-dicarboxylic acid bis-{[4-(1H-  
benzimidazol-2-yl)-cyclohexylmethyl]-amide} (176) 
 
The title compound was synthesized according to procedure 5.7 via amidation of 
3H,3ƍH-[5,5ƍ]bibenzimidazolyl-2,2ƍ-dicarboxylic acid 166 by using 4-(1-H-
benzimidazol-2-yl)cyclohexyl)methanamin over 13 days. The product was purified by 
recrystallization from ethanol affording 176 as a brown solid (0.49 g, 60 % yield); Mp > 
300 °C. 
1H NMR (400 MHz, DMSO)  1.18 (qd, J1 = 12.4, J2 = 2.8 Hz, 4H, Hc), 1.58 (qd, J1 = 
12.4, J2 = 2.8 Hz, 4H, He), 1.69-1.75 (m, 2H, Ha), 1.89 (dq, J1 = 11.6, J2 = 1.2 Hz, 4H, 
Hd ), 2.08 (dq, J1 = 11.6, J2 = 1.2 Hz, 4H, Hb), 2.80 (tt, J1 = 11.6, J2 = 1.2 Hz, 2H, Hf), 
3.25 (t, J = 6.0 Hz, 4H, 2CH2), 7.59 (dd, J1 =  6.0, J2 = 2.8 Hz, 4H, H5'+H6'), 7.76 (dd, 
J1 =  8.4, J1 = 0.8 Hz, 2H, H6), 7.84 (dd, J1 = 6.0, J2 = 2.8 Hz, 4H, H4'+H7'), 7.85 (d, J = 
8.4 Hz, 2H, H7), 7.96 (d, J = 0.8 Hz, 2H, H4), 9.01 (t, J = 6.0 Hz, 2H, N-H Amide), 
12.11 (s, 4H, N-H imidazole). 13C NMR : There were no peaks for 13C on NMR, as the 
tested sample did not dissolve in DMSO.  IR ȣ max cm –1 1273 (C-N), 1037 (C-O), 1450 
(C=C), 1537 (C=N), 1661 (C=O), 2854 (C-H, aliphatic), 3070 (C-H, aromatic), 3221 
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(N-H, amide), 3355 (N-H, amine). HRMS: (ES) m/z (MH)+  obsd. 745.3734, calcd. 
745.3727 for C44H45N10O2. 
 
5.19 {4-[2'-(4’’-Aminomethyl-cyclohexyl)-1H,1'H-[5,5']bibenzimidazolyl            
-2-yl]-cyclohexyl}-methylamine (169) 81 
 
The title compound was synthesized by condensation of 3,3’-diaminobenzidine with 
trans 4-aminomethyl cyclohexane carboxylic acid over 72 h according to procedure 5.5 
and purified by recrystallization from (water:ethanol;  1:3, v/v) affording 169  as a 
brown powder (0.34 g, 75 % yield); Mp > 300 °C,  (> 300 °C 81). 
1H NMR (400 MHz, DMSO)  1.03 (qd, J1 = 12.4, J2 = 3.2 Hz, 4H, Hc), 1.27-1.32 (m, 
2H, Ha), 1.61 (qd, J1 = 12.4, J2 = 3.2 Hz, 4H, He), 1.90 (dq, J1 = 10.8, J2 = 0.7 Hz, 4H, 
Hd ), 2.09 (dq, J1 = 10.8, J2 = 0.7 Hz, 4H, Hb), 2.45 (d, J = 6.4 Hz, 4H, 2CH2), 2.79 (tt, J1 
= 10.8, J2 = 0.7 Hz, 2H, Hf), 7.42 (dd, J1 =  8.4, J2 = 1.6 Hz, 2H, H6), 7.53 (d, J = 8.4 
Hz, 2H, H7), 7.69 (s, 2H, H4). 13C NMR (100 MHz, DMSO) į 30.4 (4CH2), 31.4 
(4CH2), 38.6 (2CH), 40.6 (2CH), 48.6 (2CH2), 113.0 (2CH), 114.7 (2CH), 121.2 (2CH), 
127.7 (2C), 135.5 (2C), 138.8 (2C), 159.9 (2C). LRMS: (ES) m/z (MH)+457.3 for 
C28H37N6. 
 




The title compound was synthesized according to procedure 5.7 via amidation of 5-
chloro-1H-benzimidazole-2-carboxylic acid by using 169 over 5 days. The product was 
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purified by recrystallization from ethanol affording 177 as a beige solid (1.76 g, 72 % 
yield); Mp 238-240 °C. 
1H NMR (400 MHz, DMSO)  1.16 (qd, J1 = 11.6, J2 = 2.2 Hz, 4H, Hc), 1.61 (qd, J1 = 
11.6, J2 = 2.2 Hz, 4H, He), 1.71-1.74 (m, 2H, Ha), 1.98 (dq, J1 = 11.2, J2 =0.7 Hz, 4H, Hd 
), 2.12 (dq, J1 = 11.2, J2 = 0.7 Hz, 4H, Hb), 2.84 (tt, J1 = 11.2, J2 = 0.7 Hz, 2H, Hf), 3.25 
(t, J = 6.4 Hz, 4H, 2CH2), 7.33 (dd, J1 =  8.8, J2 = 2.0 Hz, 2H, H6), 7.42 (d, J = 8.0 Hz, 
2H, H7'), 7.52 (s, 2H, H4'), 7.54 (d, J =  8.0, J = 8.0 Hz, 2H, H6'), 7.68 (s, 2H, H4), 7.76 
(d, J = 8.8 Hz, 2H, H7), 7.79 (s, 2H, N-H imidazole), 9.08 (t, J = 6.4 Hz, 2H, N-H 
Amide), 12.01-12.43 (br, 2H, N-H imidazole). 13C NMR (100 MHz, DMSO) į 28.8 
(4CH2), 29.7 (4CH2), 35.9 (2CH), 36.7 (2CH), 43.8 (2CH2), 110.9 (2CH), 112.8 (2CH), 
116.9 (2C), 117.9 (2C), 120.2 (2CH), 121.9 (2CH), 123.2 (2CH), 125.7 (2CH), 127.2 
(2C), 132.1 (2C), 133.9 (2C), 140.2 (2C), 142.2 (2C) 146.1 (2C), 157.3 (2 C=O).  IR ȣ 
max cm –1 808 (C-Cl), 1235 (C-N), 1058 (C-O), 1423 (C=C), 1560 (C=N), 1663 (C=O), 
2857 (C-H, aliphatic), 3090 (C-H, aromatic), 3400 (N-H). HRMS: (ES) m/z (MH)+  obsd. 






The title compound was synthesized according to procedure 5.7 via amidation of 
benzimidazole-5-carboxylic acid by using 169 over 8 days. The product was purified by 
recrystallization from ethanol affording 178 as a brown solid (1.49 g, 67 % yield); Mp > 
300 °C. 
1H NMR (400 MHz, DMSO)  1.16 (qd, J1 = 11.4, J2 = 1.2 Hz, 4H, Hc), 1.55-1.71 (m, 
2H, Ha), 1.61 (qd, J1 = 11.4, J2 = 1.2 Hz, 4H, He), 1.93 (dq, J1 = 11.4, J2 = 0.4 Hz, 4H, 
Hd), 2.12 (dq, J1 = 11.4, J2 = 0.4 Hz, 4H, Hb), 2.84 (tt, J1 = 11.4, J2 = 0.4 Hz, 2H, Hf), 
3.22 (t, J = 5.7 Hz, 4H, 2CH2), 7.41 (d, J = 8.4 Hz, 2H, H6), 7.52 (d, J = 8.4 Hz, 2H, 
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H7), 7.61 (s, 2H, H4), 7.65 (d, J = 8.1 Hz, 2H, H6'), 7.77 (d, J = 8.1 Hz, 2H, H7'), 8.18 
(s, 2H, H4'), 8.34 (s, 2H, H2'),  8.51 (t, J = 5.7 Hz, 2H, N-H Amide), 11.98-12.44 (br, 
2H, N-H imidazole). 13C NMR (100 MHz, DMSO) į 30.2 (4CH2), 30.9 (4CH2), 37.2 
(2CH), 38.0 (2CH), 45.5 (2CH2), 114.4 (2CH), 115.1 (2CH), 115.3 (2CH), 120.8 (2CH), 
121.4 (2CH), 122.7 (2CH), 128.5 (2C), 135.1 (2C), 138.1 (2C), 138.3 (2C), 139.7 (2C), 
139.8 (2C),  143.9 (2CH), 159.4 (2C), 166.8 (2 C=O).  IR ȣ max cm –1  1281 (C-N), 1042 
(C-O), 1453 (C=C), 1574 (C=N), 1661 (C=O), 2850 (C-H, aliphatic), 3080 (C-H, 
aromatic), 3189 (N-H). HRMS: (ES) m/z (MH)+  obsd. 745.3722, calcd. 745.3721 for 
C44H45N10O2. 
 
5.22 1H,1ƍH-[5,5ƍ]Bisbenzimidazolyl-2,2ƍ-diphenyl-4,4'-diamine (168) 73 
 
The title compound was synthesized from reduction of 1H,1ƍH-[5,5ƍ]bisbenzimidazolyl-
2,2ƍ-diphenyl-4,4'-dinitro 179 according to method 5.4, with the reaction extended to 48 
h. The crude product was purified by recrystallization from ethanol affording 168 as a 
brown solid (1.05 g, 72 %); Mp 242-244  °C (Lit. 73 242-244 °C ). 
1H NMR (400 MHz, DMSO) 5.63 (s, 4H, NH amine), 6.69 (d, J = 8.8 Hz, 4H, H2'+H6'), 
7.45(d, J = 8.4 Hz, 2H, H7), 7.60-7.64 (m, 2H, H6), 7.81 (s, 2H, H4), 7.87 (d, J = 8.8 
Hz, 4H, H3'+H5'), 7.96 (s, 2H, N-H Imidazole). 13C NMR (100 MHz, DMSO) į 79.3 
(2C), 110.8 (2C), 112.8 (2C), 113.5 (4CH), 114.5 (2C), 117.2 (2CH), 118.1 (2C), 127.7 
(4CH), 131.8 (2CH), 150.6 (2CH), 153.1 (2C). IR ȣ max cm –1  1276 (C-N), 1443 (C=C), 
1605 (C=N), 3099 (C-H, aromatic), 3336 (N-H amine). HRMS: (ES) m/z (MH)+  obsd. 








5.23 1H,1'H-[5,5']Bibenzimidazolyl-2,2'-diphenyl-4,4'-diamine bis-    
[benzimidazol-2-yl]-amide (180) 
 
The title compound was synthesized according to procedure 5.7 via amidation of 
1H,1ƍH-[5,5ƍ]bisbenzimidazolyl-2,2ƍ-diphenyl-4,4'-diamine 168 by using benzimidazole-
2-carboxylic acid over 15 days. The product was purified by column chromatography 
using DCM: MeOH (10:l) affording 180 as a brown solid (1.37 g, 65 % yield); Mp > 
300 °C. 
1H NMR (400 MHz, DMSO) 7.33-7.41 (dq, J1 = 6.8, J2 = 6.7 Hz,  4H, H5'+H6'), 7.61 
(dd, J1 = 6.2, J2 = 1.6 Hz, 4H, H4'+H7'), 7.69-7.72 (bs, 2H, H4), 7.84 (d, J = 8.0 Hz, 2H, 
H7), 7.89 (dd, J1 = 8.0, J2 = 2.0 Hz, 2H, H6), 8.16 (d, J = 8.8 Hz, 4H, H2''+H6''), 8.23 (d, 
J = 8.8 Hz, 4H, H3''+H5''), 11.17 (s, 2H, N-H Amide), 12.85-13.09 (br, 2H, N-H 
Imidazole), 13.52 (s, 2H, N-H Imidazole) . 13C NMR (100 MHz, DMSO) 112.7 (2CH), 
115.2 (2C), 120.1 (4CH), 120.5 (4CH), 122.0 (2C), 122.9 (2CH), 125.7 (4CH), 126.9 
(4CH), 132.7 (2C), 134.7 (2C), 134.8 (2C), 139.8 (2C), 142.5 (2CH), 145.4 (4C), 151.6 
(2C), 157.5 (2 C=O). IR ȣ max cm –1 1280 (C-N), 1118 (C-O), 1446 (C=C), 1596 (C=N), 
1662 (C=O), 3053 (C-H, aromatic), 3232 (N-H, amide), 3344 (N-H, amine). HRMS: 
(ES) m/z (MH)+  obsd. 705.2467, calcd. 705.2475 for C42H29N10O2. 
 
5.24 1H,1'H-[5,5']Bibenzimidazolyl-2,2'-diphenyl-4,4'-dicarboxylic acid-
di(piperidin-1-yl)methanone (184)   
 
The title compound was synthesized according to procedure 5.7 via amidation of 
1H,1'H-[5,5']bibenzimidazolyl-2,2'-diphenyl-4,4'-dicarboxylic acid 167 by using 
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piperidine over 6 days. The product was purified by recrystallization from ether 
affording 184 as a pale brown solid (0.40 g, 60 % yield); Mp > 300 °C. 
1H NMR (400 MHz, DMSO) 1.48-1.59 (bs, 4H, 2CH2(3')), 1.61-1.66 (bs, 4H, 2CH2(4')), 
3.30-3.39 (bs, 8H, 4CH2(2'+5')), 3.58-3.66 (bs, 4H, 2CH2(6')), 7.54 (dd, J1 =  8.8, J2 = 
3.2 Hz, 4H, H2''+H6''), 7.65-7.70 (m, 4H, H3''+H5''), 7.82 (s, 2H, N-H imidazole), 8.08 
(dd, J1 =  8.0, J2 = 2.0 Hz, 2H, H6), 8.21 ( d, J = 8.0 Hz, 2H, H7), 8.33 (q, J =  8.0 Hz, 
2H, H4). 13C NMR (100 MHz, DMSO)  24.0 (2CH2), 29.6 (4CH2), 35.3 (4CH2), 116.2 
(2C), 120.6 (2C), 120.8 (2C), 121.8 (2CH), 125.7 (2CH), 126.5 (4CH), 127.3 (4CH), 
129.5 (2CH), 141.9 (2C), 142.2 (2C), 151.9 (2C), 168.4 (2 C=O).  IR ȣ max cm –1 1279 
(C-N), 1020 (C-O), 1445 (C=C), 1549 (C=N), 1593 (C=O), 2851 (C-H, aliphatic), 2935 
(C-H, aromatic), 3288 (N-H, amide), 3417 (N-H, amine). HRMS: (ES) m/z (MH)+  obsd. 
609.2966, calcd. 609.2978 for C38H37N6O2. 
 
5.25 1H,1'H-[5,5']Bibenzimidazolyl-2,2'-diphenyl-4,4'-dicarboxylic acid bis-
{[(piperidin-1-ylethyl)]-amide} (185) 
 
The title compound was synthesized according to procedure 5.7 via amidation of 
1H,1'H-[5,5']bibenzimidazolyl-2,2'-diphenyl-4,4'-dicarboxylic acid 167 by using 1-(2-
amino ethyl)-piperidine over 9 days. The product was purified by recrystallization from 
methanol affording 185 as a pale yellow solid (0.38 g, 50 % yield); Mp > 300 °C. 
1H NMR (300 MHz, DMSO)  1.19-1.24 (m, 4H, 2CH2(4')), 1.33-1.41 (m, 4H, 2CH2(3')), 
1.47-1.54 (m, 4H, 2CH2(5')), 2.37-2.46 (m, 8H, 4CH2(2'+6')), 2.49-2.51 (bs, 4H, 
2CH2(amine)), 3.36-3.53 (bs, 4H, 2CH2(amide)), 7.57 (dd, J1 =  7.8, J2 = 1.6 Hz, 2H, 
H6), 7.68-7.74 (bs, 2H, H4), 7.82-7.90 (bs, 2H, N-H imidazole), 8.01-8.09 (m, 4H, 
H2''+H6''), 8.19 ( d, J = 7.8 Hz, 2H, H7), 8.34 ( d, J = 8.1 Hz, 4H, H3''+H5''), 8.58 ( t, J 
= 5.1 Hz, 2H, N-H Amide). 13C NMR (100 MHz, DMSO) 24.0 (2CH2), 24.4 (2CH2), 
25.6 (2CH2), 36.5 (2CH2), 36.7 (2CH2), 54.1 (2CH2), 57.7 (2CH2), 107.4 (2C), 107.9 
(2C), 119.5 (2C), 120.0 (2CH), 125.6 (2CH), 126.3 (4CH), 127.8 (4CH), 129.6 (2CH), 
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146.3 (2C), 153.8 (2C), 156.4 (2C), 165.3 (2 C=O). IR ȣ max cm –1 1233 (C-N), 1040 (C-
O), 1419 (C=C), 1616 (C=N), 1639 (C=O), 2851 (C-H, aliphatic), 3058 (C-H, aromatic), 
3288 (N-H, amide), 3490 (N-H, amine). HRMS: (ES) m/z (MH)+  obsd. 695.3824, calcd. 
695.3822 for C42H46N8O2. 
 
5.26 General procedure for synthesis of amides that arised 
from coupling of amines with 2-trifluoromethyl 1H-
benzimidazole-5-carboxylic acid by using the CDI.  
 
A solution of 2-trifluoromethyl 1H-benzimidazole-5-carboxylic acid (2 mmol, 0.46 g) in 
DMF (10 mL) was treated with CDI (2 mmol, 0.325 g) at room temperature. The 
mixture was stirred at room temperature for 30 minutes, then treated with appropriate 
aminobenzimidazole (1 mmol) in DMF (5 mL), and the reaction stirred at room 
temperature. After 6-12 days  the TLC showed no starting material left. After removing 
the solvent in vacuo, ethyl acetate (50 mL) was added to the crude, and washed with 
saturated NaHCO3 (20 mL), brine (10 mL) and water (10 mL). The organic layer was 
dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by either 
column chromatography or recrystalization. 
 
5.26.1 2-Trifluoromethyl-1H-benzimidazole-5-carboxylicacid[2-(4'- 
           methoxy-phenyl)-1H-benzimidazol-5-yl]-amide (134) 
 
The title compound was synthesized according to procedure 5.26 via amidation of 2-
(trifluoromethyl)-1H-benzimidazole-5-carboxylic acid with 5-amino-2-(4'-methoxy 
phenyl)benzimidazole, by reaction over 10 days. The product was purified by column 
chromatography using DCM: MeOH (15:1 v/v) affording 134 as a brown solid (0.49 g, 
55 %); Mp > 300 °C. 
1H NMR (400 MHz, DMSO)   3.89 (s, 3H, CH3 ), 7.22 (d, J = 9.2 Hz, 2H, H3''+H5''), 
7.72 (d, J = 8.8 Hz, 1H, H7'), 7.81 (d, J = 8.6 Hz, 1H, H7), 7.90 (d, J = 8.8 Hz, 1H, H6'), 
8.06 (d, J = 8.6 Hz, 1H, H6), 8.18 (d, J = 9.2 Hz, 2H, H2''+H6''), 8.49 (s, 1H, H4'), 8.59 
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(s, 1H, H4), 10.65 (s, 1H, N-H Amide). 13C NMR (75 MHz, DMSO)  54.9 (CH3), 104.2 
(CH), 112.4 (CH), 113.7 (CH), 114.7 (CH), 114.9 (2CH), 115.5 (C), 116.2 (C), 117.4 
(2CH), 119.5 (CH), 121.3 (C), 124.1 (CH), 127.7 (C), 129.6 (C), 130.8 (C), 131.8 (C), 
137.9 (C),  138.2 (C, CF3, JCF = 39.3 Hz), 148.9 (C), 161.8 (C), 163.6 (C=O). IR ȣ max 
cm -1 595 (C-F), 1235 (C-N), 1073 (C-O), 1472 (C=C), 1644 (C=N), 1610 (C=O), 2865 
(C-H, aliphatic), 3088 (C-H, aromatic), 3378 (N-H, amide), 3458 (N-H, amine). HRMS: 
(ES) m/z (MH)+ obsd. 452.1336, calcd. 452.1329 for C23H16F3N5O2 . 
 































The title compound was synthesized according to procedure 5.26 via amidation of 2-
(trifluoromethyl)-1H-benzimidazole-5-carboxylic acid with 2-(2',4'-dimethoxyphenyl)-
5-aminobenzimidazole, by reaction over 6 days. The product was purified by column 
chromatography using DCM: MeOH (12:1 v/v) affording 135 as a brown solid (0.63 g, 
65 %); Mp > 300 °C. 
1H NMR (400 MHz, DMSO) 3.94 (s, 3H, CH3), 4.11 (s, 3H, CH3), 6.91 (d, J = 7.2 Hz, 
1H, H5''), 6.93 (d, J = 1.1 Hz, 1H, H3''), 7.79 (d, J = 8.4 Hz, 1H, H7), 7.83 (d, J = 9.2 
Hz, 1H, H6'), 7.87 (d, J = 7.2 Hz, 1H, H6''),  8.05 (d, J = 9.2 Hz, 1H, H7'), 8.09 (d, J = 
8.4 Hz, 1H, H6),  8.46 (s, 1H, H4'), 8.61 (s, 1H, H4),  10.75 (s, 1H, N-H Amide), 13.99-
14.46 (br, 2H, N-H Imidazole). 13C NMR (100 MHz, DMSO) 55.9 (CH3), 56.4 (CH3), 
99.0 (CH), 103.5 (CH), 104.4 (CH), 107.5 (CH), 115.9 (CH), 117.7 (CH), 120.4 (CH), 
124.3 (C), 127.3(C), 130.8 (CH), 131.2 (CH), 131.5 (C), 137.7 (C), 138.5 (C), 139.6 (C), 
142.2 (C), 142.4 (C, CF3, JCF = 39.4 Hz), 143.0 (C), 146.4 (C), 159.9 (C), 165.4 (C), 
166.1 (C=O). IR ȣ max cm -1 590 (C-F), 1230 (C-N), 1050 (C-O), 1463 (C=C), 1620 
(C=N), 1614 (C=O), 2847 (C-H, aliphatic), 3090 (C-H, aromatic), 3360 (N-H, amide), 
3416 (N-H, amine). HRMS: (ES) m/z (MH)+ obsd. 482.1435, calcd. 482.1435 for C24H19 
F3N5O3. 
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5.26.3 2-Trifluoromethyl-1H-benzimidazole-5-carboxylic acid (2-pyridin-  
           2-yl-1H-benzimidazol-5-yl)-amide (136) 
 
The title compound was synthesized according to procedure 5.26 via amidation of 2-
(trifluoromethyl)-1H-benzimidazole-5-carboxylic acid with 2-pyridin-2-yl-1H-
benzimidazol-5-ylamine by reaction over 6 days. The product was purified by 
recrystalization from ethanol affording 136 as a brown solid (0.46 g, 54 %); Mp > 300 
°C. 
1H NMR (400 MHz, DMSO) 7.71 (dd, J1 = 8.0, J2 = 4.4 Hz, 1H, H5''), 7.81 (d, J = 8.4 
Hz, 1H, H6'), 7.83 (d, J = 8.4 Hz, 1H, H7'), 7.96 (d, J = 8.8 Hz, 1H, H7), 8.03 (d, J = 8.8 
Hz, 1H, H6), 8.18 (t, J = 8.0 Hz, 1H, H4''), 8.39 (d, J = 8.0 Hz, 1H, H3''), 8.40 (s, 1H, N-
H Imidazole), 8.46 (s, 1H, H4'), 8.58 (s, 1H, H4), 8.70 (s, 1H, N-H Imidazole), 8.88 (d, J 
= 4.4 Hz, 1H, H6''), 10.72 (s, 1H, N-H Amide). 13C NMR (75 MHz, DMSO) 104.6 
(CH), 114.6 (CH), 115.9 (CH), 117.2 (CH), 117.8 (CH), 119.3 (C), 120.6 (CH), 120.8 
(CH), 123.4 (CH), 124.3 (CH), 127.6 (C), 128.2(C), 130.6 (C), 132.3 (C), 138.5 (CH), 
139.6 (C), 142.1 (C, CF3, JCF = 39.5 Hz ), 142.7 (C), 147.4 (C), 150.6 (C), 166.1 (C=O). 
IR ȣ max cm -1 610 (C-F), 1240 (C-N), 1050 (C-O), 1447 (C=C), 1630 (C=N), 1647 
(C=O), 3040 (C-H, aromatic), 3360 (N-H, amide), 3420 (N-H, amine). HRMS: (ES) m/z 
(MH)+  obsd. 423.1175, calcd. 423.1176 for C21H14F3N6O.  
 
5.26.4 2-Trifluoromethyl-1H-benzimidazole-5-carboxylic acid(1H-  
           benzimidazol-2-ylmethyl)-amide (137) 
 
The title compound was synthesized according to procedure 5.26 via amidation of 2-
(trifluoromethyl)-1H-benzimidazole-5-carboxylic acid with 2-(aminomethyl)-1H-
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benzimidazole by reaction over 6 days. The product was purified by recrystalization 
from ethanol affording 137 as a brown solid (0.47 g, 65 %); Mp 184-186 °C. 
1H NMR (400 MHz, DMSO)  4.76 (s, 2H, CH2), 7.15 (dd, J1 = 6.0, J2 = 2.8 Hz, 2H, 
H5'+H6'), 7.52 (d, J = 6.0 Hz, 2H, H4'+H7'), 7.82 (d, J = 8.8 Hz, 1H, H7), 8.02 (d, J = 
8.8 Hz, 1H, H6), 8.39 (s, 1H, H4), 9.36 (s, 1H, N-H Amide), 11.79-13.03 (br, 1H, N-H 
Imidazole). 13C NMR (75 MHz, DMSO)  38.3 (CH2), 115.2 (C), 116.3 (CH), 117.4 
(CH), 121.0 (CH), 121.8 (2CH), 124.1 (2CH), 124.6 (C), 130.3 (2C), 138.2 (C), 139.3 
(C), 142.2 (C, CF3, JCF = 39.1 Hz), 152.8 (C) 166.9 (C=O). IR ȣ max cm -1 610 (C-F), 
1273 (C-N), 1100 (C-O), 1443 (C=C), 1622 (C=N), 1646 (C=O), 2840 (C-H, aliphatic), 
3065 (C-H, aromatic), 3320 (N-H, amide), 3470 (N-H, amine). HRMS: (ES) m/z (MH)+  
obsd. 360.1071, calcd. 360.1067 for C17H13F3N5O. 
 
5.26.5 N,N'-Bis(2-Trifluoromethyl-1H-benzimidazole-5-carbonyl)-p-    
xylylenediamine (148) 
 
The title compound was synthesized according to procedure 5.26 via amidation of 2-
(trifluoromethyl)-1H-benzimidazole-5-carboxylic acid by using p-xylenediamine over 9 
days. The product was purified by column chromatography using DCM: MeOH (15:l) 
affording 148 as a white solid  (1.23 g, 73  % yield) ; Mp 290-292 °C. 
1H NMR (400 MHz, DMSO) į 4.49 (d, J = 6.0 Hz, 4H, 2 CH2), 7.32 (s, 4H, H2' 
+H3'+H5'+H6'), 7.77 (d, J = 8.8 Hz, 2H, H7), 7.93 (d, J = 8.8 Hz, 2H, H6), 8.29 (s, 2H, 
H4), 9.16 (t, J = 6.0 Hz, 2H, N-H Amide). 13C NMR (100 MHz, DMSO) į 42.9 (2CH2), 
116.2 (2C), 116.9 (2C), 117.9 (2C), 120.7 (2CH), 123.4 (2C), 123.8 (2CH), 127.6 
(4CH), 130.6 (2CH), 138.6 (2C), 142.4 (2C, 2CF3, JCF = 39.2 Hz), 166.5 (2C=O). IR ȣ 
max cm -1 595 (C-F), 1232 (C-N), 1051 (C-O), 1440 (C=C), 1542 (C=N), 1640 (C=O), 
2851 (C-H, aliphatic), 3064 (C-H, aromatic), 3325 (N-H, amide), 3434 (N-H, amine). 




5.26.6 N-[4-(5(5-Benzimidazolyamino)-2-trifluoromethyl-1H-benzimidazol-         
5-yl)-phenyl]-benzimidazol-5-amide (160) 
 
The title compound was synthesized according to procedure 5.26 via amidation of 2-
(trifluoromethyl)-1H-benzimidazole-5-carboxylic acid with 2(4’-aminophenyl)-1H-
benzimidazol-5-ylamine by reaction over 12 days. The product was purified by column 
chromatography using DCM: MeOH (12:1 v/v) affording 160 as a pale brown solid 
(1.66 g, 64 %); Mp > 300 °C. 
1H NMR (400 MHz, DMSO) 6.79 (d, J = 8.0 Hz, 1H, H7), 7.75 (d, J = 8.8 Hz, 2H, 
H7'+H7''), 7.83 (dd, J1 = 8.8, J2 = 1.6 Hz, 2H, H6'+H6''), 7.96 (d, J = 8.0 Hz, 1H, H6), 
8.04-8.08 (bs, 1H, H4), 8.14 (d, J = 8.4 Hz, 2H, H2'''+H6'''), 8.26 (d, J = 8.4 Hz, 2H, 
H3'''+H5'''), 8.42 (d, J = 1.6 Hz, 2H, H4'+H4''), 8.52-8.59 (br, 1H, N-H Imidazole), 10.65 
(s, 1H, N-H Amide), 10.79 (s, 1H, N-H Amide), 14.32-14.49 (br, 2H, N-H Imidazole). 
13C NMR (100 MHz, DMSO) 105.0 (CH), 113.5 (C), 113.7 (C), 113.9 (CH), 114.9 (C), 
115.1 (C), 117.9 (2CH), 118.5 (2CH), 118.7 (C), 120.5 (CH), 120.6 (2CH), 120.8 
(2CH), 123.2 (2C), 123.3 (C), 128.4 (2CH), 129.9 (2C), 136.6 (2C), 142.9 (2C, 2CF3, 
JCF = 39.6 Hz), 149.9 (2C), 165.9 (C=O) 166.2 (C=O). IR ȣ max cm -1 595 (C-F), 1258 
(C-N), 1060 (C-O), 1471 (C=C), 1620 (C=N), 1633 (C=O), 1653 (C=O), 3050 (C-H, 
aromatic), 3391 (N-H, amide), 3420 (N-H, amine). HRMS: (ES) m/z (MH)+  obsd. 
649.1539, calcd. 649.1530 for C31H19F6N8O2. 
 




The title compound was synthesized according to procedure 5.26 via amidation of 
1H,1ƍH-[5,5ƍ]bisbenzimidazolyl-2,2ƍ-diphenyl-4,4'-diamine 168 by using 2-(trifluoro 
methyl)-1H-benzimidazole-5-carboxylic acid over 18 days. The product was purified by 
column chromatography using DCM: MeOH (10:l)  affording 181 as a brown solid (2.35 
g, 70 % yield); Mp > 300 °C. 
1H NMR (400 MHz, DMSO) 6.55 (dd, J1 = 8.4, J2 = 2.0 Hz, 4H, H2''+H6''), 6.98 (dd, J1 
= 8.0, J2 = 1.6 Hz, 2H, H6), 7.02 (d, J = 1.6 Hz, 2H, H4), 7.24 (d, J = 8.0 Hz, 2H, H7), 
7.51 (d, J = 8.4 Hz, 2H, H7'), 7.58 (dd, J1 = 8.4, J2 = 1.2 Hz, 2H, H6'), 7.95 (dd, J1 = 8.4, 
J2 = 2.0 Hz, 4H, H3''+H5''), 8.06 (d, J = 1.2 Hz, 2H, H4'), 8.22 (s, 2H, N-H Amide). 13C 
NMR (100 MHz, DMSO) 113.4 (4CH), 114.5 (2CH), 117.1 (2CH), 118.7 (2C), 120.8 
(2CH), 121.1 (2CH), 125.3 (2C), 126.5 (2CH), 127.2 (2C), 127.4 (4CH), 132.3 (2C), 
132.9 (2C), 135.5 (2C), 142.3 (2C, 2CF3, JCF = 39.8 Hz ), 146.5 (2CH), 146.9 (2C), 
151.2 (2C), 154.3 (2C), 157.8 (2C), 159.2 (2C), 162.2 (2 C=O). IR ȣ max cm -1 610 (C-F), 
1285 (C-N), 1080 (C-O), 1440 (C=C), 1611 (C=N), 1634 (C=O), 3040 (C-H, aromatic), 
3310 (N-H, amide), 3411 (N-H, amine).  HRMS: (ES) m/z (MH)+  obsd. 841.2233, calcd. 
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Appendix I :SPR binding data for A2T2 
 











The Dissociation constant of Hoechst 33258 was evaluated by fitting the data with BIA 
evaluation 4.1 program 
 
KA(1/M) KD(M) Rmax n Chi2 
7.76 0.129 104 67.9 
Req vs. Conc 1 
 
                                 











Req SE(Req) Conc 
                           hoechst_s Fc=2-1 - 27 116 0.0695 12.5 
                           hoechst_s Fc=2-1 - 28 119 0.0695 12.5 
                           hoechst_s Fc=2-1 - 29 99.9 0.0695 6.25 
                           hoechst_s Fc=2-1 - 30 103 0.0695 6.25 
                           hoechst_s Fc=2-1 - 31 90.5 0.0695 3.13 
                           hoechst_s Fc=2-1 - 32 92.7 0.0695 3.13 
                           hoechst_s Fc=2-1 - 33 90.8 0.0695 1.56 
                           hoechst_s Fc=2-1 - 34 87.8 0.0695 1.56 
                           hoechst_s Fc=2-1 - 35 87.1 0.0695 0.781 
                           hoechst_s Fc=2-1 - 36 87.6 0.0695 0.781 
                           hoechst_s Fc=2-1 - 37 82.2 0.0695 0.391 
                           hoechst_s Fc=2-1 - 38 85.7 0.0695 0.391 
                           hoechst_s Fc=2-1 - 39 0 0.0695 0 
 









































                                                                                             
    The Dissociation constant of compound 171                    Dissociation constant for binding of 
    (Sh61) was evaluated by fitting the data with                   compound 171 (Sh61) to A2T2 DNA  
            BIA evaluation Origin 7 program                                              sequence 
 
                                                                                                  
 
 












Parameter Value Error 
---------------------------------------- 
Vmax 88.2714 10.81577 
k 46.94 17.35142 




Req SE(Req) Conc 
                               Sh61_s Fc=2-1 - 43 48.6 0.0574 67.5 
                               Sh61_s Fc=2-1 - 44 50.3 0.0574 67.5 
                               Sh61_s Fc=2-1 - 45 39.2 0.0574 33.8 
                               Sh61_s Fc=2-1 - 46 39.6 0.0574 33.8 
                               Sh61_s Fc=2-1 - 47 29.3 0.0574 16.9 
                               Sh61_s Fc=2-1 - 48 28.8 0.0574 16.9 
                               Sh61_s Fc=2-1 - 49 23.7 0.0574 8.44 
                               Sh61_s Fc=2-1 - 50 22.2 0.0574 8.44 
                               Sh61_s Fc=2-1 - 51 14.8 0.0574 4.22 
                               Sh61_s Fc=2-1 - 52 13.9 0.0574 4.22 
                               Sh61_s Fc=2-1 - 53 9.24 0.0574 2.11 
                               Sh61_s Fc=2-1 - 54 8.71 0.0574 2.11 
                               Sh61_s Fc=2-1 - 55 6.04 0.0574 1.05 
                               Sh61_s Fc=2-1 - 56 8.1 0.0574 1.05 
                               Sh61_s Fc=2-1 - 57 4.89 0.0574 0.527 
                               Sh61_s Fc=2-1 - 58 4.63 0.0574 0.527 
                               Sh61_s Fc=2-1 - 59 0 0.0574 0 
 










































     The Dissociation constant of compound 174               Dissociation constant for binding of 
    (Sh72) was evaluated by fitting the data with                compound 174 (Sh72) to A2T2 DNA  






















Parameter Value Error 
---------------------------------------- 
Vmax 866929.3321 4707995911 
k 8.5098E+14 1.42E+19 




Req SE(Req) Conc 
                             Sh72_s Fc=2-1 - 62 65.1 0.154 170 
                             Sh72_s Fc=2-1 - 63 51.2 0.154 85 
                             Sh72_s Fc=2-1 - 64 50.9 0.154 85 
                             Sh72_s Fc=2-1 - 65 42.8 0.154 42.5 
                             Sh72_s Fc=2-1 - 66 43 0.154 42.5 
                             Sh72_s Fc=2-1 - 67 35.3 0.154 21.3 
                             Sh72_s Fc=2-1 - 68 34.5 0.154 21.3 
                             Sh72_s Fc=2-1 - 69 27.8 0.154 10.6 
                             Sh72_s Fc=2-1 - 70 23.2 0.154 10.6 
                             Sh72_s Fc=2-1 - 71 21.9 0.154 5.31 
                             Sh72_s Fc=2-1 - 72 12.9 0.154 5.31 
                             Sh72_s Fc=2-1 - 73 15.9 0.154 2.65 
                             Sh72_s Fc=2-1 - 74 18.4 0.154 2.65 
                             Sh72_s Fc=2-1 - 75 13.1 0.154 1.32 
                             Sh72_s Fc=2-1 - 76 12.1 0.154 1.32 
                             Sh72_s Fc=2-1 - 77 16.4 0.154 0.664 
                             Sh72_s Fc=2-1 - 78 11.8 0.154 0.664 
                             Sh72_s Fc=2-1 - 79 0 0.154 0 
 









































 The Dissociation constant of compound 155 (Sh74)            Dissociation constant for binding of 
was evaluated  by fitting the data with BIA evaluation           compound 155 (Sh74) to A2T2                                     
Origin 7 program                                                  DNA sequence 
 
                                                                                                                 
 



















Parameter Value Error 
---------------------------------------- 
Vmax 290.77 57.76255 
k 131.265 67.7698 




Req SE(Req) Conc 
SH74_ Fc=2-1 - 1 178 0.107 188u 
SH74_1 Fc=2-1 - 1 158 0.107 188u 
SH74_1 Fc=2-1 - 2 122 0.107 94u 
SH74_1 Fc=2-1 - 3 121 0.107 94u 
SH74_1 Fc=2-1 - 4 59.7 0.107 47u 
SH74_1 Fc=2-1 - 5 66.7 0.107 47u 
SH74_1 Fc=2-1 - 6 64 0.107 23.5u 
SH74_1 Fc=2-1 - 7 65.4 0.107 23.5u 
SH74_1 Fc=2-1 - 8 36.8 0.107 11.75u 
SH74_1 Fc=2-1 - 9 38.4 0.107 11.75u 
SH74_1 Fc=2-1 - 10 26.1 0.107 5.875u 
SH74_1 Fc=2-1 - 11 24.1 0.107 5.875u 
SH74_1 Fc=2-1 - 12 11.2 0.107 2.93u 
SH74_1 Fc=2-1 - 13 7.96 0.107 2.93u 
SH74_1 Fc=2-1 - 14 3.21 0.107 1.4687u 
SH74_1 Fc=2-1 - 15 3.68E-04 0.0151 1.4687u 
SH74_1 Fc=2-1 - 16 5.36 0.107 0.7343u 
SH74_1 Fc=2-1 - 17 4.16 0.107 0.7343u 
SH74_1 Fc=2-1 - 18 0 0.107 0 
 








































 The Dissociation constant of compound 184 (Sh83) was      Dissociation constant for binding of 
    evaluated  by fitting the data with BIA evaluation             compound 184 (Sh83) to  A2T2    
                             program Origin 7                                                       DNA sequence 
 
 
                   
 
















Parameter Value Error 
---------------------------------------- 
Vmax 62.0535 3.22785 
k 1.40318 0.24918 




Req SE(Req) Conc 
SH83_1 Fc=2-1 - 20 23.6 0.0823 137 
SH83_1 Fc=2-1 - 21 30.3 0.0823 137 
SH83_1 Fc=2-1 - 22 54.7 0.0823 68.5 
SH83_1 Fc=2-1 - 23 59.8 0.0823 68.5 
SH83_1 Fc=2-1 - 24 57.5 0.0823 34.3 
SH83_1 Fc=2-1 - 25 57.4 0.0823 34.3 
SH83_1 Fc=2-1 - 26 67 0.0823 17.1 
SH83_1 Fc=2-1 - 27 56.3 0.0823 17.1 
SH83_1 Fc=2-1 - 28 59.5 0.0823 8.56 
SH83_1 Fc=2-1 - 29 57.1 0.0823 8.56 
SH83_1 Fc=2-1 - 30 44.5 0.0823 4.28 
SH83_1 Fc=2-1 - 31 40.9 0.0823 4.28 
SH83_1 Fc=2-1 - 32 33.6 0.0823 2.14 
SH83_1 Fc=2-1 - 33 37.1 0.0823 2.14 
SH83_1 Fc=2-1 - 34 25.3 0.0823 1.07 
SH83_1 Fc=2-1 - 35 25.2 0.0823 1.07 
SH83_1 Fc=2-1 - 36 24.2 0.0823 0.535 
SH83_1 Fc=2-1 - 37 17.8 0.0823 0.535 
SH83_1 Fc=2-1 - 38 0 0.0823 0 
 
The RU (Response unit )values at the concentration range of compound 184 (Sh83), 0-137 uM 
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Appendix II :SPR binding data for A3T3 
 
II.1 The binding data of Hoechst 33258 to A3T3 DNA sequence 











    The Dissociation constant of Hoechst 33258                       Dissociation constant for binding of                              
     was evaluated by fitting the data with BIA                             Hoechst  33258 to A3T3 DNA  


















Parameter Value Error 
---------------------------------------- 
Vmax 50.05753 1.74717 
k 1.1847E-08 503745424 













Req SE(Req) Conc 
                   hoechst_1 Fc=3-1 - 42 83.3 0.172 10u 
                    hoechst_1 Fc=3-1 - 43 83.7 0.172 10u 
                    hoechst_1 Fc=3-1 - 44 56.2 0.172 5u 
                    hoechst_1 Fc=3-1 - 45 58.7 0.172 5u 
                   hoechst_1 Fc=3-1 - 46 43.1 0.172 2.5u 
                   hoechst_1 Fc=3-1 - 47 49.7 0.172 2.5u 
                   hoechst_1 Fc=3-1 - 48 42.6 0.172 1.25u 
                   hoechst_1 Fc=3-1 - 49 45.3 0.172 1.25u 
                   hoechst_1 Fc=3-1 - 50 47.9 0.172 0.625u 
                   hoechst_1 Fc=3-1 - 51 50.1 0.172 0.625u 
                   hoechst_1 Fc=3-1 - 52 48 0.172 0.3125u 
                   hoechst_1 Fc=3-1 - 53 47.7 0.172 0.3125u 
                   hoechst_1 Fc=3-1 - 54 45.9 0.172 0.156u 
                   hoechst_1 Fc=3-1 - 55 51.5 0.172 0.156u 
                   hoechst_1 Fc=3-1 - 56 52.3 0.172 0.07817u 
                   hoechst_1 Fc=3-1 - 57 54.2 0.172 0.07817u 
                   hoechst_1 Fc=3-1 - 58 0 0.172 0 
 


































II.2 The binding data of compound 171 to A3T3 DNA sequence 




















      
     The Dissociation constant of compound 171                      Dissociation constant for binding of 
          (Sh61) was evaluated by fitting the data                       compound 171 (Sh61) toA3T3 DNA 
           with BIA evaluation Origin 7 program                                                 sequence 
 
                                                                    
                               
 













Parameter Value Error 
---------------------------------------- 
Vmax 82.14521 1.58331 
k 0.16288 0.02634 




Req SE(Req) Conc 
              Sh61_s Fc=3-1 - 43 73.1 0.0782 67.5 
              Sh61_s Fc=3-1 - 44 78.6 0.0782 67.5 
              Sh61_s Fc=3-1 - 45 79.3 0.0782 33.8 
              Sh61_s Fc=3-1 - 46 80 0.0782 33.8 
              Sh61_s Fc=3-1 - 47 77.5 0.0782 16.9 
              Sh61_s Fc=3-1 - 48 77.9 0.0782 16.9 
              Sh61_s Fc=3-1 - 49 79.2 0.0782 8.44 
              Sh61_s Fc=3-1 - 50 79.1 0.0782 8.44 
              Sh61_s Fc=3-1 - 51 74.9 0.0782 4.22 
              Sh61_s Fc=3-1 - 52 74.3 0.0782 4.22 
              Sh61_s Fc=3-1 - 53 68.7 0.0782 2.11 
              Sh61_s Fc=3-1 - 54 68.8 0.0782 2.11 
              Sh61_s Fc=3-1 - 55 62.9 0.0782 1.05 
              Sh61_s Fc=3-1 - 56 64.8 0.0782 1.05 
              Sh61_s Fc=3-1 - 57 55.5 0.0782 0.527 
              Sh61_s Fc=3-1 - 58 58.8 0.0782 0.527 
              Sh61_s Fc=3-1 - 60 0 0.0782 0 
 


































II.3 The binding data of compound 174 to A3T3 DNA sequence 










   
The Dissociation constant of compound 174 (Sh72)           Dissociation constant for binding of  
      was evaluated by fitting the data with BIA                     compound 174 (Sh72) to A3T3 DNA                  




















Parameter Value Error 
---------------------------------------- 
Vmax 133.07468 37.59463 
k 14.19296 34.13182 




Req SE(Req) Conc 
                    Sh72_s Fc=3-1 - 62 85.1 0.172 170 
                    Sh72_s Fc=3-1 - 63 81.6 0.172 85 
                    Sh72_s Fc=3-1 - 64 80.6 0.172 85 
                    Sh72_s Fc=3-1 - 65 75.9 0.172 42.5 
                    Sh72_s Fc=3-1 - 66 75.3 0.172 42.5 
                    Sh72_s Fc=3-1 - 67 70.8 0.172 21.3 
                    Sh72_s Fc=3-1 - 68 71.2 0.172 21.3 
                    Sh72_s Fc=3-1 - 69 66.7 0.172 10.6 
                    Sh72_s Fc=3-1 - 70 61.5 0.172 10.6 
                    Sh72_s Fc=3-1 - 71 60.3 0.172 5.31 
                    Sh72_s Fc=3-1 - 72 52 0.172 5.31 
                    Sh72_s Fc=3-1 - 73 54.1 0.172 2.65 
                    Sh72_s Fc=3-1 - 74 55.4 0.172 2.65 
                    Sh72_s Fc=3-1 - 75 48.4 0.172 1.32 
                    Sh72_s Fc=3-1 - 76 45.3 0.172 1.32 
                    Sh72_s Fc=3-1 - 77 47.4 0.172 0.664 
                    Sh72_s Fc=3-1 - 78 39.5 0.172 0.664 
                    Sh72_s Fc=3-1 - 79 0 0.172 0 
 






























II.4 The binding data of compound 155 to A3T3 DNA sequence  












The Dissociation constant of compound 155 (Sh74)            Dissociation constant for binding of                  
     was evaluated by fitting the data with BIA                     compound 155 (Sh74) to A3T3 DNA  






















Parameter Value Error 
---------------------------------------- 
Vmax 288.64544 15.99197 
k 37.34967 6.16952 




Req SE(Req) Conc 
                          SH74_ Fc=3-1 - 1 244 0.229 188u 
                          SH74_1 Fc=3-1 - 1 232 0.229 188u 
                          SH74_1 Fc=3-1 - 2 196 0.229 94u 
                          SH74_1 Fc=3-1 - 3 195 0.229 94u 
                          SH74_1 Fc=3-1 - 4 117 0.229 47u 
                          SH74_1 Fc=3-1 - 5 125 0.229 47u 
                          SH74_1 Fc=3-1 - 6 112 0.229 23.5u 
                          SH74_1 Fc=3-1 - 7 118 0.229 23.5u 
                          SH74_1 Fc=3-1 - 8 77 0.229 11.75u 
                          SH74_1 Fc=3-1 - 9 78.7 0.229 11.75u 
                          SH74_1 Fc=3-1 - 10 52.4 0.229 5.875u 
                          SH74_1 Fc=3-1 - 11 48.8 0.229 5.875u 
                          SH74_1 Fc=3-1 - 12 26.8 0.229 2.93u 
                          SH74_1 Fc=3-1 - 13 22.6 0.229 2.93u 
                          SH74_1 Fc=3-1 - 14 7.76 0.229 1.4687u 
                          SH74_1 Fc=3-1 - 15 3.47 0.229 1.4687u 
                          SH74_1 Fc=3-1 - 16 5.86 0.229 0.7343u 
                          SH74_1 Fc=3-1 - 17 4.13 0.229 0.7343u 
                          SH74_1 Fc=3-1 - 18 0 0.229 0.0u 
 
































II.5 The binding data of compound 184 to A3T3 DNA sequence 












The Dissociation constant of compound 184 (Sh83)           Dissociation constant for binding of  
       was evaluated by fitting the data with BIA                  compound 184 (Sh83) to  A3T3 DNA  


















Parameter Value Error 
---------------------------------------- 
Vmax 18.64381 1.05615 
k 0.80483 0.20533 





Req SE(Req) Conc 
                     SH83_1 Fc=3-1 - 22 18.2 0.121 68.5 
                     SH83_1 Fc=3-1 - 23 11.1 0.121 68.5 
                     SH83_1 Fc=3-1 - 24 16.6 0.121 34.3 
                     SH83_1 Fc=3-1 - 25 19.2 0.121 34.3 
                     SH83_1 Fc=3-1 - 26 19.9 0.121 17.1 
                     SH83_1 Fc=3-1 - 27 13.8 0.121 17.1 
                     SH83_1 Fc=3-1 - 28 16.8 0.121 8.56 
                     SH83_1 Fc=3-1 - 29 20.5 0.121 8.56 
                     SH83_1 Fc=3-1 - 30 5.85 0.121 4.28 
                     SH83_1 Fc=3-1 - 31 6.48 0.121 4.28 
                     SH83_1 Fc=3-1 - 33 12.5 0.121 2.14 
                     SH83_1 Fc=3-1 - 34 8.65 0.121 1.07 
                     SH83_1 Fc=3-1 - 35 11.3 0.121 1.07 
                     SH83_1 Fc=3-1 - 36 20.6 0.121 0.535 
                     SH83_1 Fc=3-1 - 37 17.9 1.21E-01 0.535 
                     SH83_1 Fc=3-1 - 38 0 0.121 0 
 
The RU (Response unit ) values at the concentration range of compound 184 (Sh83), 0-68.5PM 
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Appendix III :SPR binding data for A4T4 
 
III.1The binding data of Hoechst 33258 to A4T4 DNA sequence 











The Dissociation constant of Hoechst 33258 was evaluated by fitting the data with BIA 
evaluation 4.1 program 
 
 
KA(1/M) KD(M) Rmax n 
8.09E+07 1.24E-08 40.5 
Req vs. Conc 1 
 












Req SE(Req) Conc 
                hoechst_1 Fc=4-1 - 42 96.1 0.0689 10u 
                hoechst_1 Fc=4-1 - 43 96.2 0.0689 10u 
                hoechst_1 Fc=4-1 - 44 62.9 0.0689 5u 
                hoechst_1 Fc=4-1 - 45 64.8 0.0689 5u 
                hoechst_1 Fc=4-1 - 46 42.5 0.0689 2.5u 
                hoechst_1 Fc=4-1 - 47 47.2 0.0689 2.5u 
                hoechst_1 Fc=4-1 - 48 37.1 0.0689 1.25u 
                hoechst_1 Fc=4-1 - 49 40.2 0.0689 1.25u 
                hoechst_1 Fc=4-1 - 50 39.2 0.0689 0.625u 
                hoechst_1 Fc=4-1 - 51 38.4 0.0689 0.625u 
                hoechst_1 Fc=4-1 - 52 36.6 0.0689 0.3125u 
                hoechst_1 Fc=4-1 - 53 36.2 0.0689 0.3125u 
                hoechst_1 Fc=4-1 - 54 35.2 0.0689 0.156u 
                hoechst_1 Fc=4-1 - 55 37 0.0689 0.156u 
                hoechst_1 Fc=4-1 - 56 36.2 0.0689 0.07817u 
                hoechst_1 Fc=4-1 - 57 37 0.0689 0.07817u 
                hoechst_1 Fc=4-1 - 58 0 0.0689 0u 
 


































III.2 The binding data of compound 171 to A4T4 DNA sequence 





















The Dissociation constant of compound 171 (Sh61)           Dissociation constant for binding of   
     was evaluated by fitting the data with BIA                     compound  171 (Sh61) toA4T4 DNA 
              evaluation Origin 7 program                                                        sequence 
 
 
                         
 
















Parameter Value Error 
---------------------------------------- 
Vmax 54.93662 3.31776 
k 0.06215 0.05133 




Req SE(Req) Conc 
                     Sh61_s Fc=4-1 - 47 49 0.0579 16.9 
                    Sh61_s Fc=4-1 - 48 50 0.0579 16.9 
                    Sh61_s Fc=4-1 - 49 53.7 0.0579 8.44 
                    Sh61_s Fc=4-1 - 50 52.2 0.0579 8.44 
                    Sh61_s Fc=4-1 - 51 52 0.0579 4.22 
                    Sh61_s Fc=4-1 - 52 50.9 0.0579 4.22 
                    Sh61_s Fc=4-1 - 53 49.4 0.0579 2.11 
                    Sh61_s Fc=4-1 - 54 49.2 0.0579 2.11 
                    Sh61_s Fc=4-1 - 55 46.9 0.0579 1.05 
                    Sh61_s Fc=4-1 - 56 49.1 0.0579 1.05 
                    Sh61_s Fc=4-1 - 57 42 0.0579 0.527 
                    Sh61_s Fc=4-1 - 58 45.4 0.0579 0.527 
                    Sh61_s Fc=4-1 - 59 0 0.0579 0 
 












































III.3 The binding data of compound 174 to A4T4 DNA sequence 












The Dissociation constant of compound 174 (Sh72)                 Dissociation constant for binding of  
      was evaluated by fitting the data with BIA                         compound 174 (Sh72) to A4T4                    




















Parameter Value Error 
---------------------------------------- 
Vmax 58.82152 8.67438 
k 1.30071 1.0739 




Req SE(Req) Conc 
              Sh72_s Fc=4-1 - 62 48.1 0.12 170 
              Sh72_s Fc=4-1 - 63 48.1 0.12 85 
              Sh72_s Fc=4-1 - 64 47.6 0.12 85 
              Sh72_s Fc=4-1 - 65 45.7 0.12 42.5 
              Sh72_s Fc=4-1 - 66 46.4 0.12 42.5 
              Sh72_s Fc=4-1 - 67 43.6 0.12 21.3 
              Sh72_s Fc=4-1 - 68 46.3 0.12 21.3 
              Sh72_s Fc=4-1 - 69 41.1 0.12 10.6 
              Sh72_s Fc=4-1 - 70 37.6 0.12 10.6 
              Sh72_s Fc=4-1 - 71 36.6 0.12 5.31 
              Sh72_s Fc=4-1 - 72 30 0.12 5.31 
             Sh72_s Fc=4-1 - 73 34.2 0.12 2.65 
             Sh72_s Fc=4-1 - 74 35.1 0.12 2.65 
             Sh72_s Fc=4-1 - 75 30 0.12 1.32 
             Sh72_s Fc=4-1 - 76 28.1 0.12 1.32 
             Sh72_s Fc=4-1 - 77 27.4 0.12 0.664 
             Sh72_s Fc=4-1 - 78 25.6 0.12 0.664 
             Sh72_s Fc=4-1 - 79 0 0.12 0 
 







































III.4 The binding data of compound 155 to A4T4 DNA sequence  










The Dissociation constant of compound 155 (Sh74)               Dissociation constant for binding of             
was evaluated by fitting the data with BIA                     compound 155 (Sh74) to A4T4 DNA  
























Parameter Value Error 
---------------------------------------- 
Vmax 145.03772 6.64896 
k 23.56193 3.50032 




Req SE(Req) Conc 
                       SH74_ Fc=4-1 - 1 129 0.104 187 
                       SH74_1 Fc=4-1 - 1 126 0.104 187 
                       SH74_1 Fc=4-1 - 2 106 0.104 94 
                       SH74_1 Fc=4-1 - 3 109 0.104 94 
                       SH74_1 Fc=4-1 - 4 66.2 0.104 47 
                       SH74_1 Fc=4-1 - 5 74.4 0.104 47 
                       SH74_1 Fc=4-1 - 6 69.8 0.104 23.5 
                       SH74_1 Fc=4-1 - 7 75.6 0.104 23.5 
                       SH74_1 Fc=4-1 - 8 52.6 0.104 11.8 
                       SH74_1 Fc=4-1 - 9 51.7 0.104 11.8 
                       SH74_1 Fc=4-1 - 10 37.3 0.104 5.88 
                       SH74_1 Fc=4-1 - 11 35.9 0.104 5.88 
                       SH74_1 Fc=4-1 - 12 21.2 0.104 2.93 
                      SH74_1 Fc=4-1 - 13 18.3 0.104 2.93 
                      SH74_1 Fc=4-1 - 14 8 0.104 1.47 
                      SH74_1 Fc=4-1 - 15 5.31 0.104 1.47 
                      SH74_1 Fc=4-1 - 16 7.83 0.104 0.734 
                      SH74_1 Fc=4-1 - 17 5.87 0.104 0.734 
                      SH74_1 Fc=4-1 - 18 0 0.104 0 
 
































III.5 The binding data of compound 184 to A4T4 DNA sequence 












No binding of compound 184 (Sh83) to the A4T4 DNA sequence 
 
